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SUMMARY 
 
The ever-increasing demands in education, the workplace, and social life, coupled with 
internal and external pressure to succeed, are assumed to require strategies to enhance 
cognitive function. Nonmedical use of prescription drugs and the use of illegal drugs or 
alcohol for the purpose of cognitive or mood enhancement to improve performance at work or 
while studying is referred to as pharmacological neuroenhancement. Pharmacological 
neuroenhancement as a functional means to improve concentration, attention, and vigilance 
has been increasingly focused throughout the past decade, and has been debated in scientific 
and bioethical literature, media, and politics. The increased stimulant production in recent 
years has been accompanied by a boost in published scientific literature regarding cognitive 
enhancement and neuroenhancement, although both increases may be explained 
independently. Increased stimulant production may indicate that more patients receive 
medical treatment for their mental disorders, which generally represents a positive 
development. The augmented number of publications on nonmedical stimulant use and 
pharmacological neuroenhancement might, on the other hand, suggest that cognitive 
enhancement is on the rise. However, the nonmedical use of prescription stimulants and the 
use of illegal drugs to enhance cognitive performance in healthy individuals are no news. New 
is only that the terms “cognitive enhancement” and “neuroenhancement” have been used to 
describe this phenomenon in the past decade. Moreover, recent studies reporting a high 
prevalence of pharmacological neuroenhancement showed several limitations concerning 
study design and representativeness of the sample, and some of them have been 
misinterpreted by the media.  
At the beginning of this thesis, no data on pharmacological neuroenhancement in 
Switzerland were available. However, findings from a study on stress among Swiss 
employees and expert opinions indicated that psychoactive substance use for enhancement 
purposes might be prevalent in Switzerland. The first Swiss study on pharmacological 
neuroenhancement among Swiss university students revealed that every seventh student had 
used prescription drugs or drugs of abuse at least once in order to achieve better study 
performance. Consistent with studies in Europe and the United States, Ritalin®, containing 
the active ingredient methylphenidate, was the prescription drug most frequently misused to 
improve academic performance. The nonmedical use of methylphenidate and other illicit 
drugs for cognitive and mood enhancement by healthy individuals might cause adverse health 
outcomes. Therefore, the present thesis aimed, amongst others, to investigate the lifetime and 
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12-month prevalence of pharmacological neuroenhancement among the Swiss general 
population, to provide evidence-based knowledge for policy and prevention. 
The first two studies of the present thesis contain findings of the first representative large-
scale online survey on pharmacological neuroenhancement in Europe using a national Internet 
panel. This survey was designed subsequent to a feasibility study on neuroenhancement in 
Switzerland. More than 10,000 people participated in the epidemiological survey, and data 
were weighted for age, sex, and language region. In the first study concerned with these data, 
4.0% of the surveyed sample reported having used prescription drugs or drugs of abuse for 
pharmacological neuroenhancement at least once. However, only half of them (2.1%) 
reported pharmacological neuroenhancement within the past year and regular use was 
uncommon. Pharmacological mood enhancement was more prevalent than pharmacological 
cognitive enhancement, and experience with one or both forms of enhancement was 
associated with being a student, having used illegal drugs, frequent stress, perceived poor 
health, and with having a mental disorder.  
The second study examined the importance of stress, self-efficacy, and self-medication for 
pharmacological neuroenhancement based on measures referring to stress, self-efficacy, 
mental health, and illegal drug use in the past 12 months. Current medical treatment for a 
mental disorder was the strongest predictor of both pharmacological cognitive enhancement 
and pharmacological mood enhancement. Cannabis use, frequent stress, and long-term stress 
at work or in education were further predictors of both enhancement forms. Time pressure and 
negative stressors at work or in education were no predictors of pharmacological 
neuroenhancement in the overall prediction model. Pharmacological mood enhancement was 
positively associated with being female and negatively associated with self-efficacy. Being 
male, being a student, and using illegal drugs other than cannabis, were positively associated 
with pharmacological cognitive enhancement. The findings of this study indicate a big gap 
between pharmacological neuroenhancement by healthy individuals as moderate self-
medication to cope with temporary stress and pharmacological neuroenhancement by 
individuals with a mental disorder as serious self-medication to cope with stress, symptoms, 
and side effects of their medical treatment. 
The third study addressed cognitive, social, and personality differences between healthy 
individuals with regular methylphenidate use for cognitive enhancement and stimulant-naïve 
controls. While previous studies suggested that pharmacological cognitive enhancement aims 
to cope with cognitive deficits, recently abstinent cognitive enhancement users showed no 
cognitive deficits and even superior strategic thinking and decision-making compared to 
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controls. However, the neuropsychological assessment revealed that pharmacological 
cognitive enhancement users shared certain personality features with recreational cocaine 
users. For example, they displayed higher levels of self-reported impulsivity, novelty seeking, 
and Machiavellianism, and lower social reward dependence than controls. Moreover, they 
behaved more self-serving, less empathic, and less prosocial in social interaction tasks 
compared to controls. The highly specific personality structure of healthy individuals who 
engage in pharmacological cognitive enhancement and the difficulties in recruiting healthy 
with regular methylphenidate use for cognitive enhancement give no cause for concern that 
pharmacological cognitive enhancement with prescription stimulants will spread in the near 
future.  
In conclusion, pharmacological neuroenhancement is prevalent but uncommon among the 
Swiss population compared to findings in the United States. Moreover, psychoactive 
substance use for mood enhancement is more common in Switzerland than direct cognitive 
enhancement. However, being a student, high levels of stress, using illegal drugs, and medical 
treatment for a present mental disorder were important predictors for both forms of 
enhancement. Pharmacological neuroenhancement as self-medication to cope with symptoms 
of a mental disorder and associated stress was identified as an important public health issue 
that has up-to-date achieved minor attention. The assumption that cognitive enhancement 
among healthy individuals will widely spread and become a desirable means to improve work 
and study performance was not supported by the present findings. Monitoring the 
development of pharmacological neuroenhancement in Switzerland is essential in order to 
develop effective policy responses. Nevertheless, future research should transfer from first-
world problems with self-optimization of already good functioning to the preservation and 
recovery of health of vulnerable groups in the public. Moreover, while regular prescription 
drug misuse for cognitive and mood enhancement in Switzerland is rare, regular use of 
alcohol and cannabis to relieve stress is more common and affects physical and mental health. 
Future research on pharmacological neuroenhancement considering the complexity of 
psychoactive substance use for improved performance at work and in education is therefore 
recommended. Building on the present findings, future studies should not be limited to 
healthy individuals and use longitudinal designs. 
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ZUSAMMENFASSUNG 
  
Strategien zur kognitiven Leistungssteigerung erscheinen notwendig, um den ständig 
wachsenden Anforderungen in der Ausbildung, am Arbeitsplatz sowie auch in sozialen 
Bereichen des Lebens gerecht zu werden und dem Erfolgsdruck standzuhalten. Der nicht 
medizinisch indizierte Gebrauch von verschreibungspflichtigen Medikamenten und der 
Gebrauch von illegalen Drogen und Alkohol zur Leistungssteigerung am Arbeitsplatz oder in 
der Ausbildung werden als pharmakologisches Neuroenhancement bezeichnet. Im 
vergangenen Jahrzehnt wurde sowohl in der wissenschaftlichen und bioethischen Literatur als 
auch in Medien und Politik vermehrt über pharmakologisches Neuroenhancement als 
Instrument zur Verbesserung der Konzentration und Aufmerksamkeit und Reduktion von 
Müdigkeit debattiert. Das Produktionswachstum von verschreibungspflichtigen Stimulanzien 
ging einher mit einem Anstieg an Publikationen zum Thema “Cognitive Enhancement“ und 
“Neuroenhancement“. Die beiden Anstiege müssen jedoch prinzipiell unabhängig 
voneinander erklärt werden. Die Zunahme der Produktion von verschreibungspflichtigen 
Medikamenten weist darauf hin, dass immer mehr Personen mit einer psychischen Störung 
medizinisch behandelt werden, was grundsätzlich eine positive Entwicklung widerspiegeln 
kann. Beim Zuwachs an Publikationen zum nicht medizinischen Gebrauch von 
Medikamenten oder pharmakologischem Neuroenhancement stellt sich hingegen die Frage, 
ob auch der Substanzgebrauch zur kognitiven Leistungssteigerung stetig zunimmt. Dass 
gesunde Personen ohne medizinische Notwendigkeit verschreibungspflichtige Stimulanzien 
und illegale Drogen konsumieren, um damit ihre kognitive Leistungsfähigkeit zu verbessern, 
ist dabei nichts Neues. Neu ist lediglich, dass dafür die Begriffe “Cognitive Enhancement“ 
und “Neuroenhancement“ verwendet werden. Studien, die eine hohe Prävalenz von 
pharmakologischem Neuroenhancement berichteten, wiesen partiell Mängel im Studiendesign 
oder Repräsentativität der Stichprobe auf und wurden von den Medien teilweise falsch 
interpretiert.  
Zu Beginn dieser Dissertation lagen noch keine Daten zum pharmakologischen 
Neuroenhancement in der Schweiz vor. Ergebnisse einer Stressstudie bei Schweizer 
Angestellten und Expertenmeinungen wiesen jedoch darauf hin, dass der Gebrauch von 
psychoaktiven Substanzen zur Leistungsverbesserung auch in der Schweiz stattfindet. Die 
erste Studie bei Schweizer Studierenden kam zum Schluss, dass bereits jede/r siebte 
Studierende verschreibungspflichtige Medikamente oder andere psychoaktive Substanzen 
eingesetzt hatte, um damit die Gehirnleistung im Studium zu verbessern. Konsistent mit 
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Studien aus Europa und den USA, wurde auch in der Schweiz Ritalin®, ein Medikament mit 
dem Wirkstoff Methylphenidat, am häufigsten zur Verbesserung der Studienleistung 
eingesetzt. Der nicht medizinisch indizierte Gebrauch von Methylphenidat und anderen 
psychoaktiven Substanzen zur kognitiven Leistungssteigerung oder Stimmungsaufhellung 
kann negative Konsequenzen für die Gesundheit von gesunden Personen haben. Daher war 
eines der Ziele der vorliegenden Dissertation, die Lebenszeit- und 12-Monats-Prävalenz von 
pharmakologischem Neuroenhancement in der Schweiz zu bestimmen, um evidenzbasiertes 
Wissen für Politik und Prävention zu generieren. 
Die ersten beiden Studien dieser Dissertation beziehen sich auf die erste umfassende, 
repräsentative Online-Umfrage zum Thema pharmakologisches Neuroenhancement in 
Europa. Die Daten wurden mithilfe eines nationalen Internet-Panels erhoben. Die Umfrage 
wurde in Anlehnung an eine zuvor durchgeführte Machbarkeitsstudie zu Neuroenhancement 
in der Schweiz konzipiert. Insgesamt haben mehr als 10,000 Personen an der Online-Umfrage 
teilgenommen und die Daten wurden nach den Bevölkerungsmerkmalen Alter, Geschlecht 
und Sprachregion gewichtet. Die erste Studie bezieht sich auf die Prävalenz und zeigt auf, 
dass 4.0% der Umfrageteilnehmenden bereits einmal verschreibungspflichtige Medikamente 
oder Drogen zur kognitiven Leistungssteigerung oder Stimmungsaufhellung am Arbeitsplatz 
oder in der Ausbildung eingesetzt haben. Nur die Hälfte davon (2.1%) berichtete auch von 
pharmakologischem Neuroenhancement im vergangenen Jahr und der regelmässige Gebrauch 
war selten. Der Gebrauch von psychoaktiven Substanzen zur Stimmungsaufhellung wurde 
häufiger berichtet als der Gebrauch zur direkten kognitiven Leistungssteigerung, und beide 
Formen wurden mit Ausbildungsstatus, illegalem Drogenkonsum, häufigem Stress, subjektiv 
schlecht eingeschätzter Gesundheit und der Diagnose einer psychischen Störung in 
Verbindung gebracht.  
In der zweiten Teilstudie dieser Arbeit wurde anhand der Daten zu Stress, 
Selbstwirksamkeitserwartung, psychischer Gesundheit und illegalem Drogenkonsum in den 
letzten 12 Monaten die Relevanz von Stress, Selbstwirksamkeit und Selbstmedikation für 
pharmakologisches Neuroenhancement untersucht. Die aktuelle medizinische Behandlung 
einer psychischen Störung war der beste Prädiktor für den Gebrauch von psychoaktiven 
Substanzen sowohl zur kognitiven Leistungssteigerung als auch zur Stimmungsaufhellung. 
Cannabiskonsum und häufiger Stress sowie Langzeitstress am Arbeitsplatz oder in der 
Ausbildung waren weitere Prädiktoren für beide Formen von pharmakologischem 
Neuroenhancement. Zeitdruck und negative Stressoren am Arbeitsplatz oder in der 
Ausbildung trugen nicht zur Vorhersage im Gesamtmodell bei. Der Gebrauch von 
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psychoaktiven Substanzen zur Stimmungsaufhellung stand in positivem Zusammenhang mit 
weiblichem Geschlecht und in negativem mit der Selbstwirksamkeitserwartung. Der 
Gebrauch von psychoaktiven Substanzen zur kognitiven Leistungssteigerung wurde positiv 
assoziiert mit männlichem Geschlecht, Ausbildungsstatus und dem Gebrauch von weiteren 
illegalen Drogen nebst Cannabis. Die Ergebnisse dieser Studie deuten darauf hin, dass grosse 
Unterschiede existieren zwischen gesunden Personen, die pharmakologisches 
Neuroenhancement als moderate Selbstmedikation zur temporären Stressbewältigung 
einsetzen und Personen mit psychischen Störungen, die pharmakologisches 
Neuroenhancement als intensive Selbstmedikation zur Bewältigung von Stress, Symptomen 
und Medikamentennebenwirkungen einsetzen. 
Die dritte Studie der vorliegenden Dissertation hatte zum Ziel, Unterschiede in Kognition, 
sozialem Verhalten und Persönlichkeit zu finden zwischen Personen, die regelmässig ohne 
Indikation Methylphenidat zur kognitiven Leistungssteigerung einsetzen und gesunden 
Personen als Kontrollgruppe ohne Stimulanziengebrauch. Während frühere Studien den 
Gebrauch von psychoaktiven Substanzen zur kognitiven Leistungssteigerung als mit 
vorhandenen kognitiven Defiziten assoziiert berichtet haben, zeigten Personen, die 
regelmässig Methylphenidat zur kognitiven Leistungssteigerung einsetzen, während der 
Testung jedoch abstinent waren, keine kognitiven Defizite und waren der Kontrollgruppe im 
strategischen Denken und bei der Entscheidungsfindung sogar überlegen. Die 
neuropsychologische Untersuchung konnte zudem zeigen, dass Personen, die Substanzen zur 
kognitiven Leistungssteigerung einsetzten, ein ähnliches Persönlichkeitsprofil aufwiesen wie 
Personen, die gelegentlich Kokain konsumieren. Sie zeigten höhere Werte für Impulsivität, 
Novelty Seeking, Machiavellismus und tiefere Werte für Social Reward Dependence als die 
Kontrollgruppe. Ausserdem verhielten sie sich häufiger eigennützig, weniger empathisch und 
weniger prosozial in sozialen Interaktionen, verglichen mit der Kontrollgruppe. Die hoch 
spezifische Persönlichkeitsstruktur von gesunden Personen, die Methylphenidat zur 
kognitiven Leistungssteigerung einsetzen, und die Schwierigkeit, gesunde Personen zu finden, 
die regelmässig Methylphenidat zur kognitiven Leistungssteigerung einsetzen, geben wenig 
Anlass zur Sorge, dass sich der Gebrauch von verschreibungspflichtigen Stimulanzien zur 
kognitiven Leistungssteigerung in naher Zukunft stark verbreiten würde. 
In der Synopse aller Befunde kommt pharmakologisches Neuroenhancement in der 
Schweiz zwar vor, liegt aber weit hinter den Konsumgewohnheiten in den USA zurück. In der 
Schweiz ist der Gebrauch von psychoaktiven Substanzen zur Stimmungsaufhellung weiter 
verbreitet als der Gebrauch zur direkten kognitiven Leistungssteigerung. Ausbildungsstatus, 
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häufiger Stress, der Konsum von illegalen Drogen und die medizinische Behandlung einer 
psychischen Störung sind wichtige Prädiktoren für beide Formen von Neuroenhancement. 
Pharmakologisches Neuroenhancement als Selbstmedikation zur Reduktion von Symptomen 
einer psychischen Störung und damit verbundenem Stress wurde als wichtige Angelegenheit 
des öffentlichen Gesundheitswesens identifiziert, die bis heute nur wenig Aufmerksamkeit 
erhalten hat. Die Vermutung, dass gesunde Personen immer häufiger psychoaktive 
Substanzen zur kognitiven Leistungssteigerung einsetzen werden und dies somit eine gefragte 
Strategie zur Verbesserung der Arbeits- oder Studienleistung wird, konnte anhand der 
vorliegenden Ergebnisse bislang nicht bestätigt werden. Die Beobachtung der Entwicklung 
von pharmakologischem Neuroenhancement in der Schweiz ist jedoch unerlässlich, um auch 
auf politischer Ebene effektive Strategien im Anlassfall bereitstellen zu können. Allerdings 
sollte sich zukünftige Forschung wieder weg von der Selbstoptimierung von ohnehin gut 
funktionierenden Personen und hin zur Erhaltung und Wiederherstellung der Gesundheit in 
vulnerablen Gruppen der Bevölkerung bewegen. Während der regelmässige Gebrauch von 
psychoaktiven Substanzen zur kognitiven Leistungssteigerung in der Schweiz eher eine 
Seltenheit darstellt, ist der Gebrauch von Alkohol und Cannabis zur Stressbewältigung 
verbreitet und wirkt sich negativ auf die Gesundheit der Bevölkerung aus. Zukünftige 
Forschung zu pharmakologischem Neuroenhancement sollte die Komplexität des Gebrauchs 
von psychoaktiven Substanzen zur Verbesserung der Arbeits- oder Studienleistung adäquat 
berücksichtigen. Basierend auf den vorliegenden Ergebnissen wird empfohlen, 
Längsschnittstudien zu pharmakologischem Neuroenhancement zu planen, die sich nicht nur 
auf den Substanzgebrauch von gesunden Personen beschränken. 
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1.1 Thesis outline 
The present thesis addresses the issue of pharmacological neuroenhancement in 
Switzerland, and is structured in five main chapters. The first chapter provides a theoretical 
background of pharmacological neuroenhancement and reviews recent epidemiological 
findings on pharmacological neuroenhancement in the United States, Europe, and 
Switzerland. A clear definition of pharmacological neuroenhancement is presented, and 
several theoretical models about motives for pharmacological neuroenhancement are outlined 
and discussed. Relevant literature concerning the efficacy and consequences of 
pharmacological neuroenhancement is summarized, and important ethical and legal 
considerations are investigated. Finally, the first chapter presents an overview of the original 
research conducted in the present thesis and an outline of aims and hypotheses of all three 
studies. Chapter 2 contains the first study which addressed the prevalence of and motives for 
pharmacological neuroenhancement among Swiss employees and students. In the second 
study, delineated in Chapter 3, associations of stress and self-efficacy with pharmacological 
neuroenhancement, and the application of two self-medication models for pharmacological 
neuroenhancement are investigated. The third study, presented in Chapter 4, examines 
cognitive, social, and personality characteristics of healthy individuals with regular 
methylphenidate use for cognitive enhancement compared to stimulant-naïve controls. In the 
final chapter, the findings of the three studies are summarized, strengths and limitations are 
discussed, and implications for policy, prevention, and future research are suggested.  
1.2 The neuroenhancement debate 
There seems to be gradual awareness that many people are interested in enhancing 
themselves. They would like to be smarter, more self-confident, better looking, and 
thoroughly happy (Miller & Wilsdon, 2006). The growth in the market for so called human 
enhancement agents, such as drugs with beneficial effects on cognition, has been driven by a 
perfect bond of manufacturers (pharmaceutical companies), distributors (doctors and 
pharmacists), and a new generation obsessed with vanity and the defiance of age (Abraham, 
2010; Miller & Wilsdon, 2006). Therefore, it is assumed that college students, office 
executives, and scientists use pharmaceuticals as little helpers to achieve the best grade, bonus 
or more publications and that this use will increase in the near future (Greely et al., 2008; 
Sahakian & Morein-Zamir, 2007). The nonmedical use of prescription drugs, alcohol or 
illegal drugs of abuse for the purpose of cognitive or mood enhancement at work or while 
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studying is referred to as pharmacological neuroenhancement (Maier & Schaub, 2015). The 
terms cognitive enhancement and brain doping are used when the use aims to improve 
cognitive function immediately for learning or other tasks with high cognitive demands. 
Nonmedical prescription drug misuse for academic performance enhancement was more 
prevalent among U.S. college students (McCabe, West, Teter, & Boyd, 2014; Weyandt et al., 
2009) than in Europe (Franke et al., 2011; Maier & Schaub, 2015). However, regular use of 
pharmacological neuroenhancement is neither common in the United States nor in Europe, 
and the use of such drugs as study aid is usually limited to specific time periods, such as exam 
preparation (Hildt, Lieb, & Franke, 2014; Maier, Liechti, Herzig, & Schaub, 2013). 
Nevertheless, irregular and low-dose usage of drugs for neuroenhancement is associated with 
adverse reactions and the risks of long-term use are unknown (Racine & Forlini, 2008). The 
potential negative consequences are often trivialized by users, especially with medications 
approved and accepted to treat mental disorders in children (Forlini & Racine, 2009). This 
may falsely imply that the use is safe in healthy adult individuals as well. So far, no drug has 
been proven to be safe and effective when regularly used for cognitive enhancement in 
healthy individuals (Schleim & Quednow, 2015). 
A recent increase in media coverage of innovations in neuroscience has contributed to the 
awareness of beneficial drug effects in patients (Farah et al., 2004; Partridge, Bell, Lucke, 
Yeates, & Hall, 2011). Moreover, the twenty-first century was titled “the century of 
neuroscience”, predicting that humans will improve their ability to modify their own brain 
(Farah et al., 2004). Prescription drugs developed to treat symptoms of mental disorders, such 
as deficits in memory, learning, attention, and motivation, became the main focus of 
enhancement in healthy individuals. 
However, the nonmedical use of prescription drugs to improve cognitive function in 
healthy individuals beyond what is necessary to sustain or restore health (Juengst, 1998) is 
nothing new and was already prevalent among college students more than ten years ago 
(Farah et al., 2004; Schleim & Quednow, 2015; Wood, Sage, Shuman, & Anagnostaras, 
2014). Methylphenidate (e.g., Ritalin®, Concerta®, Medikinet®) and amphetamines (e.g., 
Adderall®), used for the treatment of attention-deficit hyperactivity disorder (ADHD), and 
modafinil (e.g., Modasomil®, Provigil®), used for the treatment of narcolepsy, are the 
prescription drugs most frequently discussed as potential cognitive enhancers in healthy 
individuals (Farah, Smith, Ilieva, & Hamilton, 2014; Repantis, Schlattmann, Laisney, & 
Heuser, 2010). Further medications either developed to treat cognitive impairment associated 
with dementia or developed based on theoretical understanding of complex cognitive 
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processes underlying learning and memory were characterized as potential cognitive 
enhancers among healthy individuals as well (Repantis, Laisney, & Heuser, 2010; Wade, 
Forlini, & Racine, 2014). Although additional medication altering the central nervous system 
in a desirable way were promised, high development costs of new drugs and difficulties with 
their clinical approval processes have caused the abandonment of research and production in 
some companies (Schleim & Quednow, 2015). 
The public debate on neuroenhancement begun when Sahakian and Morein-Zamir (2007) 
claimed that nonmedical prescription drug use was increasingly reported by shift-work 
employees, such as surgeons and nurses, military personal and academic professionals. The 
authors’ understanding of function of cognitive enhancement drug use was to study longer, 
work more efficiently, or to simply cope with stress. At the same time, they wondered how 
many of their scientific colleagues use cognitive enhancement drugs. In a non-representative 
online poll among readers of the scientific journal Nature, every fifth among 1400 
respondents indicated to have already used prescription drugs, such as methylphenidate, 
modafinil, or beta-blockers to improve cognitive function or to reduce anxiety (Maher, 2008).  
While early scientific investigations preferred terms with negative notations, such as 
prescription drug abuse and misuse, bioethical literature rather described the desired effect as 
cognitive or performance enhancement (Racine & Forlini, 2008). The trend to use the term 
“enhancement” when referring to psychoactive substance use aiming to improve working or 
studying performance has even strengthened recently. Although enhanced neurotransmission 
is not necessarily related to actual performance enhancement (Nyberg, 2014; Repantis, 2013). 
The efficacy of the so called pharmacological “enhancers” can vary as a function of 
mechanism, dose, baseline performance, baseline dopamine levels, task, and further inter- and 
intra-individual differences in responding to the substance (Clatworthy et al., 2009; Husain & 
Mehta, 2011; van der Schaaf, Fallon, Ter Huurne, Buitelaar, & Cools, 2013). Consequently, 
cognitive or at least motivational enhancement by using psychoactive substances in healthy 
individuals is possible under certain conditions, but side effects, missing effects, and even 
contrary effects are also likely to occur (Repantis, 2013; Wood et al., 2014). Therefore, 
Repantis et al. (2010) claimed that the high expectations regarding the effectiveness of these 
drugs exceed their actual effects. This was confirmed in a study on pharmacological 
neuroenhancement among Swiss students in which only a small majority reported that their 
expectations were fulfilled while approximately half of them considered the repeated use to 
improve academic performance (Maier et al., 2013). 
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This is also the reason why the often made comparison between brain doping and doping 
in sports is not appropriate, although it may seem self-evident. While doping in sports is 
effective in improving physical performance, the effect of drugs used for pharmacological 
enhancement is more complex and difficult to predict. Nevertheless, it is claimed that both 
forms of doping share a competitive intention and both users assume that their competitors 
dope as well (Cakic, 2009; Lucke, Bell, Partridge, & Hall, 2011a). However, pharmacological 
neuroenhancement is not solely based on competitive motives and curiosity is an important 
motive for experimental use (Singh, Bard, & Jackson, 2014). 
1.3 Epidemiology of pharmacological neuroenhancement 
1.3.1 Difficulties in interpreting study findings 
Despite a large number of recent studies on pharmacological neuroenhancement, the 
majority of the conducted studies show a lack of representativeness of samples and specify 
mainly students’ use (Maier & Schaub, 2015). Furthermore, the comparison of studies is 
difficult due to significant differences in the definition of the construct, the inclusion criteria 
chosen, and the substances included in the studies (Barrett, Meisner, & Stewart, 2008; Maier 
& Schaub, 2015). Moreover, recent research has mainly focused on the prevalence of 
pharmacological cognitive enhancement (PCE), however rarely addressed pharmacological 
mood enhancement (PME). These issues will be addressed in the following chapter, after an 
overview of existent studies on the prevalence of neuroenhancement. 
1.3.2 Prevalence in the United States 
The nonmedical use of prescription drugs at U.S. colleges has been the origin of the recent 
neuroenhancement debate and has influenced subsequent studies in Europe remarkably 
(McCabe, Knight, Teter, & Wechsler, 2005; McCabe, 2008; Novak, Kroutil, Williams, & Van 
Brunt, 2007). The nonmedical use of prescription stimulants, primarily ADHD medications, 
has been reported to be highly prevalent among U.S. college students (Arria et al., 2008; Chen 
et al., 2014; Hartung et al., 2013; Rabiner, Anastopoulos, Costello, Hoyle, & Swartzwelder, 
2010). In 2001, 6.9% of a representative student sample across 199 U.S. universities 
(N·=·10,904) reported the nonmedical use of prescription stimulants. A survey at a public 
university (N·=·1,811) revealed that even 34% of the respondents reported the nonmedical 
use of ADHD stimulants in periods of high academic stress (DeSantis, Webb, & Noar, 2008). 
The National Survey on Drug Use and Health (NSDUH), the Monitoring the Future (MTF), 
and the National Epidemiological Survey on Alcohol and Related Conditions (NESARC) are 
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the three largest national surveys on nonmedical prescription drug use. They indicated that 
especially young adults from 18 to 25 years of age showed high prevalence rates of 
prescription drug misuse (Kroutil et al., 2006; McCabe, Boyd, & Teter, 2009). In a review of 
21 studies (N·=·113,145), Wilens et al. (2008) found a past-year prevalence of nonmedical 
prescription stimulant use among college students of 5% to 35%, however without specifying 
the purpose of the nonmedical use. Nonetheless, even these large U.S. national studies had 
failed to identify the motives for nonmedical prescription stimulant use (Boyd & McCabe, 
2008). In the same year, Racine and Forlini (2008) specified that nonmedical stimulant use for 
academic performance enhancement among college students ranged from 3% to 11%. This 
was in line with a previous review on the misuse of study drugs which suggested a lifetime 
prevalence of 7% and a past-year prevalence of 4% (Sussman, Pentz, Spruijt-Metz, & Miller, 
2006). However, a recent study confirmed the increasing trend of nonmedical prescription 
stimulant use among U.S. college students which parallels an increase in medical use 
(McCabe et al., 2014). Again, the purpose of use was not specified. 
1.3.3 Prevalence in Europe 
The prevalence of pharmacological neuroenhancement in Europe is reported to be lower 
than in the United States (Maier & Schaub, 2015). Nevertheless, pharmacological 
neuroenhancement is prevalent among European students and lifetime and 12-month 
prevalence range from 1% to 20% (Dietz et al., 2013; Franke et al., 2013; Mache, 
Eickenhorst, Vitzthum, Klapp, & Groneberg, 2012; Middendorff, Poskowsky, & Isserstedt, 
2012). One of the first studies on pharmacological neuroenhancement use among German 
students (N·=·512) revealed that 0.8% used prescription stimulants, such as methylphenidate 
and amphetamines, and that 2.9% used illegal stimulants such as amphetamine, cocaine, and 
ecstasy to achieve better academic performance (Franke et al., 2011). In fact, this was one of 
the few studies which found that the use of illegal stimulant drugs for cognitive enhancement 
was more prevalent than the use of prescription drugs for cognitive enhancement.  
Further studies among German students revealed a prevalence of pharmacological 
neuroenhancement of 2% (Mache et al., 2012) and 7% (Eickenhorst, Vitzthum, Klapp, 
Groneberg, & Mache, 2012). The German study with the largest student sample (N·=·8,000) 
revealed that 84% of the students were informed about students’ substance use for academic 
performance enhancement, but only 5% reported having used prescription drugs or illegal 
drugs of abuse for pharmacological neuroenhancement (Middendorff et al., 2012). This study 
indicated that various prescription drugs (1.3%), cannabis (1.2%), and methylphenidate 
(1.0%) were the substances most commonly used to improve study performance. A recent 
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study using the randomized response technique found a past-year prevalence of 
neuroenhancement of 20% among German students (Dietz et al., 2013). However, this rate 
appears to be overestimated considering that caffeinated tablets were included in the 
definition of neuroenhancement.  
Studies in other European countries found similar rates for neuroenhancement among 
college students. In a recent study among UK students (N·=·877), less than 10% reported the 
lifetime use of methylphenidate, modafinil, or amphetamines for cognitive enhancement and 
less than 4% reported current pharmacological neuroenhancement (Singh et al., 2014). A 
study among Flemish students (N·=·18,000) reported a lifetime prevalence of stimulant use of 
6.9% and a past-year prevalence of 4.3% (Van Hal, Rosiers, Ponnet, & Wouters, 2013). 
Nonmedical use was higher during exam periods (Van Hal et al., 2013). A study among 
Italian undergraduate students (N·=·77) revealed a lifetime prevalence of substance use for 
cognitive enhancement of 16.0%, but the medication was primarily bought at pharmacies and 
it remained unclear whether the students misused prescription drugs or bought over-the-
counter drugs for enhancement purposes (Castaldi et al., 2012). 
 Only one German study (N·=·3,000) addressed pharmacological neuroenhancement 
among employees, at the age of 20 to 50 years old. The study revealed that 17% reported 
using prescription drugs for cognitive or mood enhancement at work, but only 5% reported 
nonmedical use of prescription drugs for neuroenhancement (DAK, 2009). These findings 
illustrate another aspect of the difficulty to classify and define neuroenhancement. However, 
the regular nonmedical use of prescription drugs for enhancement purpose was only reported 
by 1-2% of respondents (DAK, 2009). 
1.3.4 Prevalence in Switzerland 
At the beginning of this thesis, the prevalence of pharmacological neuroenhancement in 
Switzerland was largely unknown (Bruggisser, Bodmer, & Liechti, 2012). Only one non-
representative survey among Swiss employees (N·=·1,006) indicated that stress has been 
increasing and that 4% of the respondents reported past-year use of substances to improve 
their cognitive performance or their mood at work (Grebner, Berlowitz, Alvarado, & Cassina, 
2010). This single study and few unpublished student theses, however, were the only evidence 
for pharmacological neuroenhancement in Switzerland. Nonetheless, methylphenidate 
prescriptions increased between 2006 and 2009 (Kühne & Rapold, 2011). 
We conducted the first Swiss study on pharmacological neuroenhancement among 
students of three Swiss universities (N·=·6,275) which revealed that 13.8% had already used 
prescription drugs, alcohol or illegal drugs to improve cognitive function while studying 
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(Maier et al., 2013). Methylphenidate (4.1%), sedatives (2.7%), and beta-blockers (1.2%) 
were the prescription drugs most likely used for enhancement reasons. Surprisingly, 5.6% of 
the students reported having used alcohol to help study and 2.5% reported having used 
cannabis for neuroenhancement, whereas the use of illegal stimulants such as amphetamine 
and cocaine was mainly reported for recreational reasons and not to help studying. 
Pharmacological neuroenhancement was mainly reported during exam preparation but not 
during exams, and daily use of neuroenhancement was uncommon. Products containing 
caffeine, on the other hand, were used for enhancement purposes on a daily basis. However, 
the main motives for neuroenhancement were increased cognitive performance to support 
learning and increased relaxation to improve sleep to study better the following day. In line 
with previous research, friends were the main source of supply for prescription and illegal 
drugs used for neuroenhancement purposes (Bavarian, Flay, Ketcham, & Smit, 2013; Maier et 
al., 2013). Students justified pharmacological neuroenhancement when indicated and 
medically advised for the treatment of mental health or sleeping disorders and only 15.5% 
reported seeing no justifiable reason for neuroenhancement at all. 
A second study that focused on Swiss university students (N·=·1,765) found that 6.2% had 
used methylphenidate, modafinil, or amphetamines for cognitive enhancement at least once 
(Ott & Biller-Andorno, 2014). The cognitive enhancement users were mostly male, showed 
little or no interest in religion, and reported illegal drug use more frequently (Ott & Biller-
Andorno, 2014). In addition, a recent study on young Swiss men (N·=·5,967) found that 3% 
reported using neuroenhancement drugs without specifying the reason for use (Deline et al., 
2014). Nevertheless, the authors assumed that more frequent use among non-college males 
aimed to get high while sporadic use among students might indicate cognitive enhancement to 
improve academic success (Deline et al., 2014). 
Swiss psychiatrists and general practitioners reported only few requests for non-indicated 
drugs for neuroenhancement purposes (Ott, Lenk, Miller, Neuhaus Bühler, & Biller-Andorno, 
2012). These low request rates are likely to be explained by the fact that students receive 
prescription drugs for neuroenhancement most commonly from friends (Maier et al., 2013; 
Ott & Biller-Andorno, 2014). In their study, Ott et al. (2012) included four clinical case 
scenarios of requests for pharmacological neuroenhancement and investigated how Swiss 
practitioners would decide on neuroenhancement requests. Most respondents would not 
prescribe medication without having diagnosed a clear indication but two thirds approved 
exceptions depending on individual’s suffering. More than half of them were willing to 
prescribe drugs to a student who is in urgent need for passing his final exams if no therapeutic 
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alternative was available. Beta-blockers were the drugs most indicated. Practitioners’ 
willingness to prescribe drugs for a scientist’s jetlag was considerably low and modafinil 
would have been the drug most likely prescribed. However, if the case scenario referred to a 
young woman reporting low self-esteem or a single mother with two kids, who is 
overwhelmed by caring for her terminally ill mother, the practitioners were noticeably more 
likely to prescribe a drug, most commonly antidepressants. In summary, Swiss practitioners 
showed considerable openness concerning neuroenhancement without even being familiar 
with the term neuroenhancement (Ott et al., 2012). Given that physician’s subjective norms 
and attitudes have a strong influence on their prescribing behavior (Ponnet, Wouters, Van 
Hal, Heirman, & Walrave, 2014), the dialogue about evidence-based findings of health risks 
and side effects of neuroenhancement drugs is strongly recommended. 
1.4 Definition of pharmacological neuroenhancement 
Pharmacological neuroenhancement refers to the misuse of prescription drugs, alcohol, 
and illegal drugs for the purpose of enhancing cognition, mood, or pro-social behavior to 
ultimately perform better at work or to improve study performance (de Jongh, Bolt, Schermer, 
& Olivier, 2008; Franke & Lieb, 2010; Maier & Schaub, 2015). In our overview article on 
pharmacological neuroenhancement in Europe, we provided a non-exhaustive list of 
psychoactive substances used as potential neuroenhancers (see Figure 1). The prescription 
drug most frequently misused for neuroenhancement purposes is methylphenidate (Maier & 
Schaub, 2015; McCabe et al., 2014; Outram, 2010). Modafinil and amphetamine salts are also 
frequently discussed in the context of neuroenhancement. The use of antidepressants for 
pharmacological mood enhancement was found to be prevalent among German surgeons 
(Franke et al., 2013) although studies revealed no effects among healthy individuals 
(Repantis, Schlattmann, Laisney, & Heuser, 2008). However, the efficacy of a drug is of 
secondary importance for the definition of neuroenhancement while its expected efficacy and 
the intention of improving cognition or mood is  
Most studies have solely addressed the misuse of prescription and other illicit stimulants 
for cognitive enhancement (Arria et al., 2008; Franke et al., 2011; Ott & Biller-Andorno, 
2014; Wilens et al., 2008) and did not examine the use of other psychoactive substances with 
rather sedative but potentially cognitive or mood enhancing effects. Notwithstanding, the 
misuse of prescription drugs happens for many of the same reasons as alcohol and illegal 
drugs and both are problematic if they become a normalized feature of everyday life (Silva, 
Kecojevic, & Lankenau, 2013). Few European studies considered alcohol, cannabis, and 
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tranquilizers as means of cognitive enhancement (e.g., increased concentration at low doses) 
and enhanced psychological well-being (e.g., relaxation, stress relieve; Mache et al., 2012; 
Maier et al., 2013; Middendorff et al., 2012). The motives for the use of psychoactive 
substances indicate whether the use is referred to as neuroenhancement or not. Maier and 
Schaub (2015) argued that even a post-work beer to cope with stress experienced at work or 
in education might be considered as neuroenhancement if not used recreationally. Including 
such examples would lead to a substantial increase of prevalence of pharmacological 
neuroenhancement.  
Furthermore, over-the-counter drugs and freely available products with enhancing effects, 
such as caffeinated products, vitamins, and food supplements are called smart drugs as well 
(Singh et al., 2014). Thus, they are sometimes included under a broad definition of the term 
pharmacological neuroenhancement (Franke & Lieb, 2010). However, they are excluded by 
the narrow definition and instead referred to as soft enhancement (Maier et al., 2013; Maier & 
Schaub, 2015; Middendorff et al., 2012). The use of those substances as functional means to 
improve performance at work or while studying is a key aspect of both enhancement types 
(Wolff & Brand, 2013). Yet, serious adverse reactions result rather of the misuse of 
prescription drugs, illegal drugs, or high quantities of alcohol than soft enhancement. The 
inclusion of soft-enhancers would again cause an augmentation of the prevalence of 
pharmacological neuroenhancement. Therefore, a well-reasoned and clear definition of 
neuroenhancement is strongly recommended for studies on pharmacological 
neuroenhancement. 
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Figure 1. The definition of pharmacological neuroenhancement based on users’ intention and behavior, and the 
substances used for cognitive performance enhancement or increased psychological well-being in Europe. The 
list of substances is not exhaustive (Maier & Schaub, 2015). 
 
Several non-pharmacological alternatives such as cognitive training, mindfulness 
meditation, transcranial magnetic stimulation (TMS), and transcranial direct current 
stimulation (tDCS) are excluded here despite the fact that they show promising results for 
cognitive and mood enhancement in healthy individuals (Bostrom & Sandberg, 2009; 
Coffman, Clark, & Parasuraman, 2014; Dresler et al., 2013; Garland, Hanley, Farb, & 
Froeliger, 2013). In particular, the approach and the motives for using non-pharmacological 
enhancement technologies are comparable with pharmacological neuroenhancement. 
PRESCRIPTION DRUGS 
 
Methylphenidate  
Modafinil  
Amphetamines 
Ephedrine  
Antidepressants 
Anti-dementia drugs  
Tranquilizers 
Beta-blockers 
DRUGS OF ABUSE 
 
Alcohol 
Cannabis 
Cocaine 
Amphetamines (e.g., Speed) 
MDMA (Ecstasy) 
Methamphetamine (e.g., Crystal Meth, Thai-pills) 
Heroin  
 
“SOFT ENHANCERS” 
 
Caffeine-containing products (e.g., coffee, 
caffeine tablets, energy drink, tea) 
Over-the-counter drugs  
Food supplements (e.g., vitamins and tonics) 
Nicotine  
 
PHARMACOLOGICAL 
NEUROENHANCEMENT  
 
IN THE WORKPLACE AND EDUCATION 
 
If used explicitly to enhance cognition, mood, or pro-
social behavior 
If used without a 
prescription or for 
another purpose than 
prescribed
“SOFT ENHANCEMENT“ 
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1.5 Motives for pharmacological neuroenhancement 
1.5.1 Cognitive enhancement vs. mood enhancement 
Explicit motives for pharmacological neuroenhancement are essential in terms of defining 
psychoactive substance use as neuroenhancement (see previous section). Depending on the 
given task and one’s current physical and psychological condition, pharmacological 
neuroenhancement users aim to improve their cognitive function, mood, and/or prosocial 
behavior (de Jongh et al., 2008). Scientific literature and media focus on pharmacological 
cognitive enhancement aiming to enhance memory, learning, attention, and vigilance (Farah 
et al., 2014; Partridge et al., 2011). Enhanced cognitive function is desirable to increase study 
performance immediately or to augment student’s grade point average in the long-term 
(Greely et al., 2008; Rabiner et al., 2009a). Mui et al. (2013) claim that while well-being and 
successful social interactions also improve performance at work and in education, they are 
rarely studied. Presumably because the objective assessment of mood enhancement is difficult 
and because the absence of a mental disorder is falsely interpreted as happiness and feeling 
good (Cloninger & Zohar, 2011; Earp, Sandberg, Kahane, & Savulescu, 2014). Why would 
one who feels good take medication to feel better? The same question asked both for optimal 
cognition and recreational drug use is likely to reveal more intuitive answers. 
1.5.2 Stress and self-efficacy 
Due to ever-increasing demands in education, the workplace, and social life, many 
individuals feel overwhelmed by the amount of work and have to develop new strategies to 
cope with stress (Lazarus, 1989; Park & Iacocca, 2014). As a consequence of enthusiastic 
media reports, the use of psychoactive substances or so-called “smart” or “study drugs” 
(Partridge et al., 2011; Schleim, 2014b) might be perceived as successful stress coping 
strategy to maintain or improve performance in the short-term (Park & Iacocca, 2014). 
However, self-efficacy expectations determine the initiation of coping behavior and the 
efforts invested to manage stress (Bandura, 1977). 
Good performance leads to higher self-esteem which is ultimately related to greater 
happiness (Baumeister, Campbell, Krueger, & Vohs, 2003). People with low self-esteem and 
low self-efficacy might be more likely to use drugs for pharmacological neuroenhancement to 
overcome test anxiety or to mitigate perceived weaknesses. Low self-efficacy among 
individuals who use psychoactive substances as study aids might also explain why 
neuroenhancement users are less optimistic about their academic success and personal 
development than non-users (Middendorff et al., 2012). However, people with high self-
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esteem are known to be keen to experiment (Baumeister et al., 2003) and might, therefore, 
also be interested in pharmacological cognitive enhancement.  
Moreover, stimulants were found to have beneficial effects on self-regulation and studies 
suggest that users increase their study efforts after stimulant use independently of a 
substance’s effect (Advokat & Scheithauer, 2013). Thus, even if self-efficacy is low, self-
regulation could be improved by stimulants under certain conditions which would justify the 
prescription misuse. An increase in self-confidence after methylphenidate use was also 
suggested by an earlier study (Bray et al., 2004). This is likely to occur because recreational 
stimulants such as cocaine share the same mechanisms of action which results in increased 
arousal and self-confidence of the users (Müller & Schumann, 2011; Wood et al., 2014). 
However, overestimation of one’s own capabilities can be a further consequence of stimulant 
use, and healthy individuals show more risky choices after methylphenidate administration, 
while ADHD patients show no change (Maul & Advokat, 2013). 
Bandura's (1986) social cognitive theory states that attainable goals, self-motivation, and 
controllable outcomes are crucial for self-efficacy and personal development. If individuals 
perceive pharmacological neuroenhancement as being necessary to achieve their goals, low 
self-efficacy and repeated neuroenhancement might result (Bavarian et al., 2013). However, 
the mechanisms of action of certain substances used for cognitive enhancement might have 
beneficial effects on self-motivation. When effect expectations are fulfilled, the outcome (e.g., 
good grade) might be perceived as more controllable and repeated pharmacological 
enhancement is more likely to occur.  
1.5.3 Self-medication 
Broadly defined, every substance use that follows a certain intention to improve a certain 
mental or physical state, without being advised by a doctor, would be considered self-
medication. Responsible self-medication with indicated over-the-counter drugs for self-
recognized conditions is an important element of self-care that can reduce the burden on 
health care systems (WHO, 1998). However, Khantzians' (1997) self-medication hypothesis 
of addictive disorders claims that the use of legal and illegal drugs as initially successful self-
medication might result in addiction. The addictive potential of drugs used for 
neuroenhancement, especially psychostimulants, is questionable and depends strongly on dose 
and frequency of use (Compton & Volkow, 2006). Nevertheless, not the physical but the 
psychological addiction might be a concern of neuroenhancement drugs because activities can 
be experienced as more rewarding (Volkow & Swanson, 2008) and one might feel unable to 
succeed without the drugs (Wulf, Joksimovic, & Tress, 2011). However, pharmacological 
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neuroenhancement is a form of self-medication somewhere between healthy self-care and 
addiction. Moreover, it is unclear whether pharmacological neuroenhancement is misuse or 
self-treatment, especially when used to treat the symptoms of an undiagnosed mental disorder 
unconsciously (Peterkin, Crone, Sheridan, & Wise, 2011). Self-medication as an explanation 
model for pharmacological neuroenhancement seems appropriate and necessary to further 
discuss (Ragan, Bard, & Singh, 2013). The risks of self-medication, such as incorrect drug 
choice, polydrug use, and associated drug interactions (Ruiz, 2010) have to be discussed in 
terms of harm reduction. Consideration of these risks is of utmost importance in individuals 
with mental disorders and co-occurring substance abuse to self-medicate themselves beyond 
their prescription or to cope with adverse medication effects (Kasten, 1999).  
Generally, the pharmacological neuroenhancement is associated with improving some 
capacity or function beyond the normal ability which was called a functional-augmentative 
approach to enhancement (Earp et al., 2014). Instead of focusing only on increasing specific 
functions, Earp et al. (2014) suggested in their welfarist approach to enhancement to focus on 
biological and psychological changes which increase the quality of life. Therefore, they 
proposed that diminishment of a higher-order capacity can be a form of enhancement. When 
reduced neural activity results in reduced emotional intensity of unpleasant or traumatic 
memories this  
1.5.4 Lifestyle choice 
In some cases, pharmacological neuroenhancement might be perceived as a lifestyle choice 
based on own decisions and without having a serious underlying problem that needs to be 
compensated (Racine & Forlini, 2008). Although pharmacological neuroenhancement often 
aims to cope with stress, test anxiety, and problems with time management, it is also used by 
individuals with high baseline performance who want to perform even better (Sahakian & 
Morein-Zamir, 2011; Sattler & Wiegel, 2013). To maintain a suitable work-life balance is an 
important topic and improving one’s own grades might be of secondary importance (Hildt et 
al., 2014; Maier et al., 2013). Being more efficient at work or while studying results in having 
more time to spend with friends and family. Therefore, pharmacological neuroenhancement 
might also aim to pass an exam or to finish a work task briefly to invest more time in social 
relationships. However, because of unknown side effects and long-term effects of 
psychoactive substances used for pharmacological neuroenhancement and frequent concurrent 
recreational drug use (McCabe et al., 2014), this lifestyle might not be the healthiest one. 
Stress might even increase over time instead of being reduced (Wolff, Brand, Baumgarten, 
Lösel, & Ziegler, 2014).  
  31 General Introduction 
1.6 Pharmacological neuroenhancement in healthy individuals 
1.6.1 Efficacy of pharmacological neuroenhancement in healthy individuals  
The efficacy and safety of pharmacological neuroenhancement in healthy individuals is a 
controversially discussed topic in the current neuroenhancement debate (Bagot & Kaminer, 
2014; Farah et al., 2014; Repantis, 2013). While prescription drugs are safe and effective for 
the indicated treatment of disorders under the supervision of an experienced physician (Rubia 
et al., 2013), medical safety is not provided for nonmedical use (Wood et al., 2014). 
Nonmedical use refers to the use of prescription drugs by healthy individuals as well as to the 
inappropriate use of prescribed medication in patients (Maier & Schaub, 2015; McCabe et al., 
2009). In particular, the use of prescription drugs, such as psychostimulants, might affect 
neuroplasticity and may, therefore, alter cognitive function, behavior, and even the personality 
of users (Nyberg, 2014). 
Positively altered exam outcomes after pharmacological neuroenhancement depend on the 
neural activity of specific cognitive functions, dose, and task demands (de Jongh et al., 2008; 
Repantis, Schlattmann, et al., 2010; Wood et al., 2014). Prescription stimulants may lead to an 
increased function in one cognitive domain, while a second associated cognitive function 
might be decreased at the same time (de Jongh et al., 2008; Husain & Mehta, 2011). For 
example, cognitive control increases task performance in simple working memory tasks, but 
is related to mental inflexibility or compulsivity which could decrease performance in more 
complex tasks (van der Schaaf et al., 2013). Moreover, the dose-effect-relationship is an 
important aspect to discuss with regard to several adverse side effects of inappropriate use 
such as overdose (Wood et al., 2014). Apart from the challenging control of this relationship, 
resulting health risks such as addiction justify the legal control of such drugs (Dubljević, 
2013). 
Given that each drug effect is influenced by the drug, set, and setting (Zinberg, 1986), the 
discussion about effects of pharmacological neuroenhancement has to be extended above the 
single mechanisms of a potential substance’s action. The importance of individual differences 
in terms of the present physical and mental condition and an individual’s environment on the 
drug’s effect cannot be neglected (Zinberg, 1986). When an individual’s resources are rather 
low because of being sleep-deprived, stressed, or suffering from test anxiety, benefits from 
neuroenhancement use are more likely to occur (de Jongh et al., 2008). Moreover, low 
baseline performance and genetic predisposition, such as low dopamine levels, are also 
associated with greater benefits from neuroenhancement (de Jongh et al., 2008; Farah et al., 
2014). These differences in an individual’s response to pharmacological neuroenhancement 
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have been described as an inverted U-shape curve (de Jongh et al., 2008). The top of the 
inverted U symbolizes the optimal intermediate catecholamine level while excessively low or 
high levels at both ends were associated with impaired cognitive function (de Jongh et al., 
2008). Enhancement might, therefore, only be possible if this optimal level has not been 
achieved yet. Hence, the well-rested, optimally trained brain is difficult to enhance and 
pharmacological neuroenhancement may then even impair cognition (de Jongh et al., 2008; 
Quednow, 2010). Due to an individual’s responses to prescription drugs and associated 
undesirable side effects, the use of prescription drugs is only recommended under medical 
supervision (Dubljević, 2013). 
1.6.2 Efficacy of prescription stimulant use in healthy individuals 
There is only weak evidence for beneficial effects of pharmacological neuroenhancement 
with prescription stimulants on cognition (Farah et al., 2014; Repantis, 2013). 
Methylphenidate, the drug most commonly used for neuroenhancement, elevates the 
neurotransmission of dopamine and noradrenalin by reuptake inhibition at the respective 
monoamine transporters (Mehta, Sahakian, & Robbins, 2001; Wood et al., 2014). Thus, it is 
assumed to influence the cognitive domains of executive functions and working memory in 
healthy individuals (Repantis, 2013; Smith & Farah, 2011; Wood et al., 2014). 
A placebo-controlled study among young healthy men found improved working memory 
and planning skills after methylphenidate administration (Elliott et al., 1997). However, this 
effect was, limited to novel tasks and even impaired cognitive function was found in 
previously established performance. A study with healthy, sleep-deprived adolescents 
revealed no cognitive test performance effects after the administration of methylphenidate 
(Bray et al., 2004). A further study with methylphenidate administration in healthy individuals 
showed a selective enhancement of declarative memory consolidation after the administration 
of 20 and 40 mg (Linssen, Vuurman, Sambeth, & Riedel, 2012). An increased concentration, 
alertness, and emotional tension as well as a slightly euphoric effect was found after 
administration of 60 mg methylphenidate (Hysek et al., 2014). A recent study on the effects of 
a standard dose of mixed amphetamine salts found no cognition-enhancing effects when a 
standard clinical dose was used (Ilieva & Farah, 2013). However, students who used 
Adderall® as study aid reported a positive influence on mood, energy, and motivation 
(Vrecko, 2013). They reported that though the drug did not make them smarter, work was 
made more pleasant. 
Nevertheless, recent research suggests that changes in emotion and motivation levels 
caused by drug administration, regardless of the drug’s effect, affect mental performance 
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(Mommaerts et al., 2013; Vrecko, 2013). In a double-blind placebo-controlled study, sleep 
deprived participants who assumed themselves to have used methylphenidate performed 
better in a word recall task independent of having received the prescription drug or the 
placebo (Mommaerts et al., 2013). Moreover, methylphenidate improved reward versus 
punishment learning in individuals with high baseline performance of working memory, while 
low-working memory at baseline was associated with impaired learning after methylphenidate 
administration (van der Schaaf et al., 2013). The occasional nonmedical oral use of 
methylphenidate in low doses seems not to be harmful despite side effects, such as sleep 
disorders, tachycardia, headache, sweating, or loss of appetite can occur (Bruggisser et al., 
2012). However, frequent nonmedical stimulant use and non-oral use was associated with 
depressive symptoms (Teter, Falone, Cranford, Boyd, & McCabe, 2010). Moreover, since 
recreational stimulant use has been associated with deficits in the cognitive domains of 
attention, executive functions as well as working and long-term memory (Vonmoos, Hulka, 
Preller, Jenni, Baumgartner, et al., 2013), prescription stimulant use might also be associated 
with cognitive deficits.  
1.6.3 Efficacy of other drug use in healthy individuals 
Furthermore, modafinil showed inconsistent effects on cognitive functions. A single dose 
of 200 mg of modafinil had strong effects on executive function and memory among sleep-
deprived individuals but, contrarily, induced drowsiness among well-rested participants 
(Repantis, Schlattmann, et al., 2010). Modafinil can increase attention and vigilance but has 
no effect on the general cognitive abilities (Gilleen et al., 2014). Moreover, the effect of 
modafinil is believed to be baseline dependent, which means that only students with low 
intelligence quotients benefit from using (Randall, Shneerson, & File, 2005). Furthermore, 
studies found no effect of antidepressants use in healthy individuals (Repantis et al., 2008) 
and the cognition-enhancing effects of anti-dementia drugs are questionable due to specific 
testing situations (e.g., flight simulators; Wade et al., 2014; Yesavage et al., 2002).  
Thus, the translation of study findings from single dose applications within laboratory 
studies to real life consumption is difficult (Schleim, 2014a). However, these findings help 
identify potential effects and side effects of nonmedical use of controlled prescription drugs. 
The prediction of cognitive or mood enhancing effects as well as adverse affects is more 
difficult when using alcohol or illegal drugs or both simultaneously. The initial state of 
euphoria might suddenly change and initial beneficial effects can transform into undesired 
intoxication (Maier & Schaub, 2015). Moreover, the unknown ingredients of illegally 
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purchased drugs allow no prediction of the drug’s effect, which in turn, depends even more on 
set and setting (Zinberg, 1986) than prescription drug use. 
1.6.4 Personality 
Pharmacological neuroenhancement might alter personality while, on the other hand, 
personality is assumed to influence the willingness to use pharmacological 
neuroenhancement. Critics of pharmacological neuroenhancement raise concerns about the 
users authenticity and claim that one’s personality might change in an undesirable way as a 
consequence of chronic illicit use (de Jongh et al., 2008). However, studies found that 
pharmacological neuroenhancement was associated positively with sensation seeking, 
impulsivity, neuroticism, aggression, and negatively with consciousness (Middendorff et al., 
2012; Rabiner et al., 2009a; Weyandt et al., 2013). Moreover, the individual variability in 
baseline levels of dopamine is closely related to personality traits such as impulsiveness (van 
der Schaaf et al., 2013). Impulsive individuals benefit the strongest from stimulant use as 
similar to ADHD patients that reduce impulsivity symptoms medically (Smith & Farah, 
2011). Recreational stimulant users revealed higher levels of self-reported impulsivity and 
showed novelty seeking and more ADHD symptoms compared to stimulant-naïve controls 
(Vonmoos, Hulka, Preller, Jenni, Baumgartner, et al., 2013; Vonmoos, Hulka, Preller, Jenni, 
Schulz, et al., 2013). Additionally, recreational stimulant users behaved less prosocial and less 
empathic, showed deficits in theory of mind, and reported having a smaller social network 
(Hulka et al., 2014; Preller, Hulka, et al., 2014). Studies considering the nonmedical use of 
methylphenidate in healthy individuals have only addressed acute methylphenidate effects on 
social cognition and behavior (Hysek et al., 2014; Schmid et al., 2014) while the effects of 
chronic use on social behavior are largely unknown.  
Nevertheless, Quednow (2010) proposed that particularly narcissistic and ambitious 
people might be more interested in pharmacological cognitive enhancement. Narcissists have 
a grandiose view of their self and high self-esteem (Baumeister et al., 2003). Both high and 
low self-esteem can lead to alienating others because of difficulties with interpersonal 
interactions (Baumeister et al., 2003). Research on the so-called “dark triad” of personality 
traits has revealed that subclinical narcissism is closely related to Machiavellianism and 
subclinical psychopathy (Rauthmann & Kolar, 2012) Manipulative, opportunistic, and 
antisocial behavior might, therefore, be potential personality features of pharmacological 
cognitive enhancement users as well. 
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1.7 Ethical and legal considerations 
The bioethical debate on neuroenhancement focused mainly on the use of psychoactive 
substances for cognitive enhancement in healthy individuals and has discussed the ethics of 
cognitive enhancement in-depth (Bostrom & Sandberg, 2009; Farah et al., 2004; Maslen, 
Faulmüller, & Savulescu, 2014; Sahakian & Morein-Zamir, 2007). In particular, the most 
discussed topics were the safety of drugs used for cognitive enhancement and potential 
inequalities which might develop or exaggerate, given that an effective and safe drug would 
be brought to market. Nevertheless, Advokat and Scheithauer (2013) claimed that medical 
and legal consequences of cognitive enhancement use are often underappreciated in the 
ethical debate. 
Sahakian and Morein-Zamir (2007) raised four concerns regarding the use of potentially 
cognition-enhancing drugs which were confirmed by the Nature readership who participated 
in the journal’s poll about cognitive enhancement (Maher, 2008). Respondents were afraid of 
potential side effects of nonmedical prescription drug use and unknown risk of addiction, of 
drug-induced changes in personality, of peer pressure to use such drugs, and of inequality 
regarding the accessibility of drugs for cognitive enhancement (Maher, 2008).  
However, Greely et al. (2008) called for an evidence-based approach considering the risks 
and benefits of potentially cognition-enhancing drugs and argued that healthy adults should 
decide for themselves whether or not to engage in pharmacological cognitive enhancement. 
Adults are, in fact, assumed to be responsible for their health state but drug abuse and 
addiction as a resulting worst case scenario of neuroenhancement might diminish their ability 
to decide rationally (Dubljević, 2013). Nevertheless, Greely et al. (2008) suggested that 
cognitive enhancement with methylphenidate, modafinil, and amphetamines is already 
common and would even increase in the near future (Greely et al., 2008). This publication has 
been followed by lots of criticism because of the poor quality of evidence of their statements 
(Lucke, Bell, Partridge, & Hall, 2011b; Outram, 2010). 
Nevertheless, there were also positive reactions and two directions of bioethical thinking 
about neuroenhancement were established. While some researchers investigated the dangers 
of cognitive enhancement on the individual level and resulting potential negative 
consequences for the society (Outram, 2010), others focused on potential benefits for personal 
development and economic gain for society (Greely, 2013; Greely et al., 2008). Both sides 
addressed normative questions about the regulation and accessibility of cognition-enhancing 
drugs for healthy individuals. However, the whole bioethical debate has been based on the 
assumptions that the use of prescription stimulants for cognitive enhancement is prevalent and 
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will spread in the near future and that a more or less safe and effective cognition-enhancing 
drug will be developed (Greely et al., 2008; Sahakian & Morein-Zamir, 2007). Schleim and 
Quednow (2015) subsequently termed these assumptions as neuroenhancement prevalence 
hypothesis and neuroenhancement optimism hypothesis. Moreover, Quednow (2010) 
questioned the need of a debate on a technology that will probably never be realized and 
supposed further that only a specific personality type would show interest in pharmacological 
cognitive enhancement. This would not support the prediction of an increase of cognitive 
enhancement among healthy individuals.  
Despite the lack of evidence for effective and safe cognition-enhancing drugs, 
pharmacological cognitive enhancement is seen as cheating, and it is assumed that individuals 
might be coerced to use them if other’s would do so as well (Maslen et al., 2014). Hence, the 
bioethical debate strengthens the importance of scientific research on neuroenhancement 
(Maslen et al., 2014) but no clear recommendations for regulations are phrased. However, 
Dubljević (2013) argued that a moderate permissible regulation of enhancement stimulants 
might be most appropriate. He compared the use of methylphenidate and other drugs and 
rejected the idea that methylphenidate might act as gateway to illegal drug use, which had 
been an argument for prohibition. Nevertheless, he emphasized the danger profile of 
prescription stimulants which legitimates that these drugs are controlled by the narcotics law 
and require a physician’s prescription. 
The nonmedical use of prescription drugs for cognitive enhancement has received 
attention in policies across the world. It was first discussed in the U.S. Presidents Council on 
Bioethics in 2003 with regard to the distinction between therapy and enhancement, which still 
remains an ethically unsolved issue (Maslen et al., 2014). Moreover, the UK Parliament 
released a brief report addressing the use of prescription drugs for cognitive enhancement in 
which concerns about possible regulations were raised (POST, 2007). Furthermore, the Italian 
National Bioethics Commission has discussed the development of cognitive enhancement use 
without having a solution, however, addressing the often mentioned concerns of fairness, 
merit, safety and coercion (CNB, 2013). A similar Swiss report has labeled trade-offs between 
justifiable and illegal human enhancement and predicted future development of enhancing 
technologies for the first time (Eckhardt, Bachmann, Marti, Rütsche, & Telser, 2011). 
The awareness of pharmacological neuroenhancement in Switzerland and its impact on 
public health was raised and debated in policy even before evidence-based data on 
neuroenhancement in Switzerland were available. In 2009, a female Swiss politician 
submitted a postulate to the Swiss National Council proposing that the Swiss Federal Council 
  37 General Introduction 
should conduct a study on the nonmedical prescription drug use for cognitive enhancement. In 
her letter, she pointed out that stimulant prescriptions were increasing, that Novartis planned 
to introduce 600 new medications for cognitive enhancement, and that drug dependency is 
rarely investigated in Switzerland despite being a big public health issue (Fehr, 2009). The 
Swiss Federal Council accepted the postulate and announced a report for 2011 which was 
finally published in May 2014 (Eckhardt, 2014). The report identified potential misuse of 
ADHD medications for neuroenhancement and suggested the implementation of guidelines 
for Swiss practitioners. Furthermore, a public information campaign on ADHD and 
methylphenidate use was recommended (Eckhardt, 2014). However, based on this report the 
Swiss Federal Council announced in a media release at the end of 2014 that there is currently 
no need for additional regulations of the prescription of ADHD medications in Switzerland. 
The well reasoned conclusion was drawn, inter alia, taking into consideration our study 
findings on neuroenhancement among Swiss students (Maier et al., 2013) and on 
neuroenhancement in the Swiss general population (Maier & Schaub, 2014). The findings of 
the latter study will be presented and interpreted in-depth in the first two original research 
articles of the present thesis. 
1.8 Overview of the original research 
Having reached the conclusion that pharmacological neuroenhancement is prevalent 
among Swiss university students (Maier et al., 2013), we were interested in the current 
situation concerning neuroenhancement in the general population. As mentioned above, only 
one non-representative study investigated substance use to improve cognitive performance or 
mood at work among Swiss employees, and revealed a past-year prevalence of 4% (Grebner 
et al., 2010). Unfortunately, the authors missed to specify the substances used and it was, 
hence, unclear whether this number only reflected the use of freely available or also medically 
indicated substances which would not be considered for neuroenhancement. The previously 
mentioned study among German employees found a past-year prevalence of 5% but regular 
use was rare (DAK, 2009). Nevertheless, psychoactive substance use at work is associated 
with risks of impaired instead of enhanced cognition and might cause accidents or negative 
health consequences. The Swiss Accident Insurance Fund (SUVA) has launched a project 
called Progrès, aiming to address the increase in occupational illness as a consequence of 
exposure to risk factors at work. Impaired mental health as a consequence of chronic stress or 
substance use to cope with stress is associated with high costs for the healthcare system. This 
constitutes the need for early detection and early prevention of impaired mental health and 
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trends in unhealthy behavior. Within this project, SUVA funded the first representative study 
on pharmacological enhancement at work and in education, which we conducted in 2013. 
Following our feasibility study conducted to implement the most appropriate survey on 
pharmacological neuroenhancement in Switzerland (Schaub & Maier, 2012), we administered 
a questionnaire which contained items regarding socio-demographic data, stress at work and 
in education, physical and mental health, and psychoactive substance use. We used pictures to 
present packages, blister packs, and pills of the prescription and over-the-counter drugs 
mentioned in the survey to facilitate user’s recognition and hypothesized 
 
1 a) that the lifetime prevalence of pharmacological neuroenhancement in the  
  Swiss general population was lower than 5%,  
1 b) that pharmacological neuroenhancement was associated with higher  
  levels of stress and more illegal drug use, 
1 c) that ADHD medications are the most commonly used neuroenhancers, 
1 d) and that alcohol and cannabis users would not respond positive to the  
  neuroenhancement items even if they were using these psychoactive  
  drugs optional for direct or indirect enhancement purposes. 
 
German experts rated stress at work and the new normal of the 24 hours society as the 
most causal factors for neuroenhancement (DAK, 2009). In addition, stress at work or in 
education has been the most prominently discussed reason for pharmacological 
neuroenhancement (Siegrist & Rödel, 2006; Wolff & Brand, 2013). Moreover, the first Swiss 
studies on pharmacological neuroenhancement confirmed the positive relationship between 
stress and substance use for cognitive enhancement (Deline et al., 2014; Grebner et al., 2010; 
Maier et al., 2013; Ott & Biller-Andorno, 2014). Thus, we were interested in how much 
variance of psychoactive substance use for cognitive and mood enhancement in the past 12 
months would be explained by stress at work and in education in a prediction model. The 
interpretation of stress at work is closely related to available coping strategies (Lazarus, 1989) 
and self-efficacy expectations (Bandura, 1982) as discussed in the section on motives for 
pharmacological neuroenhancement. Pharmacological neuroenhancement in healthy 
individuals as a strategy to cope with stress, however, is a form of moderate self-medication 
and the substances used are functional means to reduce stress and to improve performance 
under stress (Wolff et al., 2014). This was the first study to introduce the concept of self-
medication in order to investigate pharmacological neuroenhancement. It seemed reasonable 
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to include such a strong construct in the thesis, because it is suitable to explain the behavior of 
pharmacological neuroenhancement users concisely. Furthermore, the construct of self-
medication enables an open dialogue about risks of pharmacological neuroenhancement 
beyond the mechanisms of action of single substances used (Kasten, 1999). 
We included individuals with a current or past mental health disorder such as ADHD, 
narcolepsy, or depression in the study. We assumed that some might misuse their prescription 
drugs indicated for the treatment of their mental disorder for neuroenhancement purposes. In 
addition, we suggested that they might report the nonmedical use of further prescription drugs 
or other illegal psychoactive substances to improve performance at work or while studying. 
This additional substance use was proposed to reduce symptoms and side effects of their 
mental disorder or their prescribed medication (Kasten, 1999) as serious self-medication. 
Although cognition-enhancing drugs were developed to treat cognitive deficits and improve 
quality of life for individuals with a mental disorder (Sahakian & Morein-Zamir, 2007), the 
nonmedical use of those drugs among healthy individuals became the main focus of the 
neuroenhancement debate. Individuals with a mental disorder were often excluded from 
studies without considering that they might enhance themselves beyond their prescribed 
medication (Frauger et al., 2011; Jardin, Looby, & Earleywine, 2011; Maier & Schaub, 2015). 
In the second study of the thesis, we investigated the importance of stress, self-efficacy, and 
mental health as prediction models for pharmacological cognitive enhancement and mood 
enhancement independently. We hypothesized that both forms were associated with  
 
2 a)  stress and long-term stress (moderate self-medication), 
2 b)  illegal drug use (moderate self-medication), 
2 c)  and mental disorders (serious self-medication). 
 
2 d)  Further hypotheses were, that cognitive enhancement is associated with  
  time pressure and other negative professional or academic stressors  
  (moderate self-medication) 
2e) and that mood enhancement is associated with low self-efficacy   
  (moderate self-medication). 
 
The first two studies aimed to provide the most representative monitoring of nonmedical 
prescription and other illegal drug use for pharmacological neuroenhancement in Switzerland, 
to identify motives for and predictors of pharmacological neuroenhancement, and to make 
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implications for policy, prevention or intervention if required. While these two studies had 
focused on a broad range of potential enhancement situations, we had a special interest in the 
consequences of cognitive enhancement in healthy individuals. Therefore, we examined 
cognitive and social cognitive differences between healthy individuals who used 
methylphenidate (Ritalin®) for cognitive enhancement on a regular basis and stimulant-naïve 
controls. Prescription stimulants such as methylphenidate share similar mechanisms of action 
with illegal drugs such as cocaine (Wood et al., 2014). As studies revealed impaired cognitive 
functions and altered social cognition in recreational stimulant users (Preller, Hulka, et al., 
2014; Vonmoos, Hulka, Preller, Jenni, Baumgartner, et al., 2013), we hypothesized  
 
3 a)  that healthy recently abstinent cognitive enhancement users perform  
  worse in cognitive tasks than stimulant-naïve controls,  
3 b)  that healthy recently abstinent cognitive enhancement users behave more  
  self-serving, less prosocial and less empathic in social interactions  
  compared to controls,  
3 c)  that the personality profile of regular cognitive enhancement users was  
  similar to recreational stimulant users and, therefore, highly impulsive, 
3 d)  and that healthy cognitive enhancement users show the dark triad   
  personality traits: narcissism, Machiavellianism, and psychopathy. 
 
Along with the careful consideration of the scientific literature on pharmacological 
neuroenhancement, the general introduction faced several relevant topics and investigated not 
only the prevalence in Switzerland, but also the motives for use (Wolff et al., 2014). The 
following original research articles address every mentioned issue and provide a substantial 
contribution to the current neuroenhancement debate on various levels. 
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2.1 Abstract  
Aims To investigate the prevalence of and motives for pharmacological neuroenhancement 
(PNE) among the general population, defined as the nonmedical use of prescription drugs or 
the use of drugs of abuse for the purpose of cognitive enhancement or for mood enhancement 
at work or for studying.  
 
Design A population-based cross-sectional study using a self-administered online survey.  
Setting A telephone-recruited highly representative Internet panel in Switzerland.  
Participants A total of 10,171 Swiss employees and students (unweighted N = 10,084) aged 
15 to 74 years old (female/male: 4,738/5,433; mean age: 39.1 ± 13.3).  
Measurements Self-report data on PNE and correlates were weighted for age, sex, and 
language region to create national-level estimates of the prevalence of PNE. A hierarchical 
logistic stepwise regression procedure was used to identify predictors of PNE.  
 
Findings The lifetime prevalence of PNE was 4.0%, the past-year prevalence was 2.1%. 
Lifetime pharmacological mood enhancement (2.6%) was more prevalent than 
pharmacological cognitive enhancement (0.9%) or both (0.5%). PNE was associated with 
studying rather than work, stress (OR = 1.39; 95% CI = 1.22–1.57), illegal drug use, lifetime 
diagnosis of a mental disorder (OR = 4.58; 95% CI = 3.51–5.97), and perceived poor health 
(OR = 0.78; 95% CI = 0.68–0.90).  
 
Conclusions The first comprehensive and representative large-scale study of PNE in Europe 
revealed that PNE was rare among Swiss employees and students. Pharmacological mood 
enhancement was more prevalent than direct cognitive enhancement and both forms were 
associated with having a mental disorder and illegal drug use. 
 
Key reference terms: Pharmacological neuroenhancement; cognitive enhancement; mood 
enhancement; nonmedical prescription drug use; illegal drug use 
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2.2 Introduction 
The use of prescription drugs or drugs of abuse by healthy individuals to enhance 
cognitive or affective function (de Jongh et al., 2008; Repantis, 2013) is termed 
pharmacological neuroenhancement (PNE) when explicitly used for the purpose of improved 
performance at work or in education (Maier & Schaub, 2015). Healthy users assume that 
prescription drugs that improve mood or cognitive performance in patients with poor mental 
health might have similar enhancing effects in healthy individuals (Husain & Mehta, 2011).  
The prevalence of PNE, especially with illicit stimulants, is well researched among U.S. 
college students (Arria & DuPont, 2010; DeSantis et al., 2008; McCabe et al., 2005, 2014; 
Weyandt et al., 2013). Recently, several European studies have concluded that the use of 
psychoactive substances for cognitive enhancement among students is less prevalent than in 
the United States (Castaldi et al., 2012; Eickenhorst et al., 2012; Franke et al., 2011). In 
Switzerland, three studies have addressed the prevalence of PNE among students and young 
Swiss men and found a lifetime prevalence of PNE of 3% to 14% but only rare current regular 
use (Deline et al., 2014; Maier et al., 2013; Ott & Biller-Andorno, 2014). Consistent with 
previous research, all Swiss studies found a positive association between recreational drug use 
and PNE (Deline et al., 2014; Maier et al., 2013; McCabe et al., 2005; Ott & Biller-Andorno, 
2014).  
Despite a growing number of research publications on the topic of PNE, the 
generalizability of the research results is problematic because the inclusion of substances used 
for PNE differs greatly between different studies (Maier & Schaub, 2015; Schleim, 2014b). 
More difficulties in interpreting results on the prevalence of PNE arise, however, because of 
country differences in approval of medication for the treatment of mental health disorders. 
Moreover, users are often not aware of the trade names of the prescription drugs, and this lack 
of awareness may bias the outcome of the prevalence of drug use in surveys. A substantial 
advantage of using Internet-based online surveys is the presentation of pictures of putatively 
enhancing drugs to facilitate the recognition of the drugs that have been used (Novak et al., 
2007). The present study is the first study in Europe on the topic of PNE that combined 
questions about the prevalence of the use of prescription and over-the-counter drugs with 
pictures of the pills, blister, and packaging. Additionally, previous studies on the prevalence 
of and attitudes toward PNE focused primarily on vulnerable groups, such as students (Arria 
& DuPont, 2010; Franke et al., 2011; Rabiner et al., 2009a; Weyandt et al., 2013), scientists 
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(Maher, 2008), physicians (Merlo, Singhakant, Cummings, & Cottler, 2013), and pilots 
(Mumenthaler et al., 2003; Yesavage et al., 2002), but never on the general population.  
This study was designed to investigate the epidemiology of PNE among employees and 
students in Switzerland, to identify relevant substances used for direct cognitive enhancement 
(PCE), or increased psychological well-being and mood enhancement (PME). Moreover, we 
investigated the motives for use and the differences between people experienced with PNE 
and non-users to reveal potential predictors for PNE. 
2.3 Materials and methods 
2.3.1 Participants and enrollment procedure  
Participants were drawn from the representative Internet panel of the LINK institute for 
market and social research in Switzerland, which consists of more than 130,000 people living 
in Switzerland who consented to be contacted for public opinion surveys administered 
through the Internet. The LINK institute uses a computer-assisted telephone interviewing 
system to recruit panelists representing the Swiss general public. These panelists are 
representative of the 15- to 74-year-old population of Switzerland that uses the Internet at 
least once per week for private purposes and is able to answer a questionnaire in German, 
French, or Italian. The study was conducted during March 2013, and participants were 
rewarded with one of the following incentives, equal to a value of approximately 2 Euros: 
points for supermarkets, bookshops, or donation campaigns.  
A total of 39,996 e-mail invitations were sent out, and 18,094 began the survey, or about 
45.2% of the invitations. Of the 18,094 panelists who responded, 12,404 met the eligibility 
criteria (currently employed or in education, and quota not yet fulfilled) and were needed for 
the study. A total of 10,084 (82.3%) completed the survey, and 2,320 (18.7%) did not 
complete the survey (see participant flow diagram; Fig. 1). 
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Figure 2. Flowchart of the sample composition using the Swiss Internet panel of the LINK institute. 
 
Self-report data on pharmacological neuroenhancement and correlates were weighted for 
age, sex, and language region to create national-level estimates of the prevalence of 
neuroenhancement. The definition of quota cells for the sample was based on the data of the 
constant resident population of Switzerland (STATPOP) published by the Federal Statistical 
Office. Informed consent was obtained from all individual participants included in the study. 
The final weighted sample consisted of 10,171 participants and will be the sample referred to 
in the present paper; the number of interviews realized per quota cell, and the resulting 
weighting factor for the data for each language region in Switzerland are provided in 
supplementary materials (Table S1).  
2.3.2 Outcome measures 
A self-administered online questionnaire, based on previous surveys on substance use at 
work or for studying, was used to investigate the prevalence of and motives for PNE as well 
as important correlates such as socio-demographic data, stress, and physical and mental 
health; a specification of the questionnaire design is provided in the supplementary materials 
(Methods S1). The questionnaire was pretested with 103 participants of the LINK Internet 
panel and improved accordingly.  
Participants were ask whether they have heard of PNE before, and whether they knew 
other people using prescription drugs or drugs of abuse intentionally to enhance cognition or 
mood at work or for studying. The prevalence of and the two main motives for PNE at work 
• 39,996 invitations
• 4,590 direct participation (11.4%) 
• 12,224 after the 1st reminder (30.6%)
• 1,280 after the 2nd reminder (3.2%) 
18,094
• 2,155 Quota-Overflow (11.9%)
• 3,535 Screen-Out (19.5%)
12,404
• 2,320 Dropout 
(18.7%)
10,084
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or for studying were examined through two principal questions. First, participants were asked 
whether they had ever used prescription drugs or other psychoactive drugs of abuse to 
enhance their cognitive performance at work or for studying. Second, they were asked 
whether they had ever used prescription drugs or other psychoactive drugs of abuse to 
enhance their mood at work or for studying. The group of people who answered at least one 
of these two questions positively will be referred to as PNE users hereafter. Cognitive and 
mood enhancement were the two main motives of interest, but all participants had to indicate 
for every substance used whether the use aimed also for neuroenhancement purposes (to 
enhance concentration, alertness, and vigilance; to reduce nervousness, to enhance mood at 
work or for studying; and to relax after stress at work or in education). 
2.3.3 Statistical analysis 
Descriptive statistics provided information about the prevalence and the substances used 
for PNE; the prevalence of the use of alcohol, illegal drugs, and legally available soft 
enhancers; the frequency of stress; and the state of physical and mental health of the 
participants. Initially, we performed separate logistic regression analyses (subsequently 
termed ‘univariate analyses’) to evaluate the ability of each independent variable to predict 
the lifetime use of PNE. Variable selection comprised the following steps: (1) Significant 
predictors from the univariate analyses were entered into the preliminary multivariate model; 
(2) Variables that were not significant were removed one by one; variables with the highest p-
values were removed first (backward selection); and (3) To address suppressor effects, the 
resulting model was verified by tentatively adding the aforementioned excluded variables 
separately to the regression model. Only significant variables were retained in the overall 
multivariate model for each outcome variable (forward selection; Streiner, 2013). 
Nagelkerke’s R-square was calculated as a goodness-of-fit measure for all multivariate 
models. All quantitative analyses were conducted using IBM SPSS Statistics Version 22 
(SPSS Inc., Chicago, IL, USA), and P < .05 was set as the significance level.  
2.4 Results 
2.4.1 Participant characteristics 
The stratified sample showed an equal distribution of sex and a mean age of 39.1 years 
(SD = 13.3). The majority of participants were German-speaking and worked full- or part-
time. Three of four participants (71.6%) had already heard of PNE. One-quarter of the sample 
was aware of one (14.3%) or even more (11.5%) people in their circle of acquaintances who 
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had used prescription drugs or drugs of abuse at least once to enhance their cognitive 
performance (PCE) at work or education. One-fifth of the participants, however, knew one 
(11.6%) or more (8.2%) people who had used psychoactive substances for increased 
psychological well-being (PME) at work or education. Participants who knew at least one 
PNE user (35.0%) were seven times more likely to report their own experiences of PNE (OR 
= 7.03; 95% CI 5.55–8.90). Moreover, a small number of participants reported that their 
friends had already recommended to them the use of PCE (4.3%) or PME (2.3%). A narrow 
majority of the sample did not see any justification for PNE (57.7%), and only a few people 
were willing to use prescription drugs (8.7%) or drugs of abuse (4.0%) to improve their 
performance at work or for studying, even if the hypothetical case that the drugs were 
effective was true. Furthermore, the majority of the participants believed that the use of 
prescription drugs and drugs of abuse for PNE might be harmful (74.3% and 85.3%, 
respectively). 
2.4.2 Prevalence of PNE 
The participant characteristics for the analysis of lifetime PNE are presented in Table 1. 
Of the study participants, 4.0% (n = 411) reported the use of prescription drugs or drugs of 
abuse to perform better at work or for studying (PNE). Lifetime pharmacological mood 
enhancement to perform better at work or in education (2.6%) was more prevalent than 
pharmacological cognitive enhancement (0.9%) or both (0.5%). The past-year prevalence of 
PNE was 2.1% (n = 215).  
2.4.3 Univariate predictors of lifetime PNE 
As shown in Table 1, all variables, except sex, were univariate predictors of lifetime PNE. 
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Table 1. Participant characteristics of the study population with and without experience with PNE and the odds 
ratios (OR) for the univariate associations of each variable with lifetime PNE 
Total  
N = 10,171 
PNE  
n = 411 
No PNE  
n = 9,760 OR (95% CI) p 
Sex  
Male 53.4% (5,433) 3.7% (202) 96.3% (5,231) 
Female 46.6% (4,738) 4.4% (208) 95.6% (4,529) 1.19 (0.98–1.45) .08 
Age group 
15-24 years 18.4% (1,876) 5.5% (104) 94.5% (1,772) 
25-34 years 21.1% (2,144) 4.1% (88) 95.9% (2,056) 0.73 (0.55–0.98) .04 
35-44 years 22.1% (2,251) 3.9% (87) 96.1% (2,164) 0.68 (0.51–0.91) .01 
45-74 years 38.3% (3,899) 3.4% (132) 96.6% (3,767) 0.60 (0.46–0.77) < .01 
Linguistic region 
German 73.3% (7,456) 3.8% (285) 96.2% (7,171) 
French 22.6% (2,302) 5.0% (115) 95.0% (2,187) 1.33 (1.06–1.66) .01 
Italian 4.0% (412) 2.4% (10) 97.6% (402) 0.60 (0.31–1.15) .12 
Professional activity 
In education 13.5% (1,375) 6.8% (93) 93.2% (1,282) 
Full-time work ≥ 90% 54.6% (5,553) 3.3% (182) 96.7% (5,371) 0.47 (0.36–0.61) < .01 
Part-time work < 90% 31.9% (3,243) 4.2% (135) 95.8% (3,107) 0.60 (0.46–0.79) < .01 
Monthly income a       
< 6000 CHF  25.2% (2,025) 6.0% (122) 94.0% (1,903)   
6000-10 000 CHF  44.2% (3,547) 3.3% (117) 96.7% (3,430) 0.53 (0.41–0.69) < .01 
> 10 000 CHF  30.6% (2,454) 3.6% (89) 96.4% (2,366) 0.58 (0.44–0.77) < .01 
Relationship       
None / temporary  27.4% (2,788) 5.5% (152) 94.5% (2,636)   
Stable  72.6% (7,383) 3.5% (259) 96.5% (7,124)  0.63 (0.51–0.77) < .01 
Children at home <18       
None  64.2% (6,534) 4.6% (299) 95.4% (6,235)   
At least one  35.8% (3,636) 3.1% (111) 96.9% (3,525) 0.66 (0.53–0.82) < .01 
Perceived health  
SF-12, scale 1-5   3.49 (0.79)  3.04 (0.87) 3.50 (0.79) 0.47 (0.41–0.53) < .01 
Stress (12 m)  
SECO, scale 1-5   3.22 (0.94) 3.81 (0.95) 3.20 (0.93) 2.04 (1.83–2.28) < .01 
Psychological consulting       
Never  79.6% (8,091) 1.9% (156) 98.1% (7,935)   
At least once  20.4% (2,080) 12.3% (255) 87.7% (1,825) 7.11 (5.79–8.73) < .01 
Mental disorder b       
Never  78.4% (7,970) 1.5% (118) 98.5% (7,852)   
At least one  21.6% (2,201) 13.3% (293) 86.7% (1,908) 10.20 (8.19–12.71) < .01 
Data are % (number) or mean (standard deviation) weighted for age, sex, and language region. a No information 
provided by n = 2,144, all other variables complete. b ADD/ADHD, narcolepsy, depression, anxiety disorder, 
dependency (lifetime diagnosis). PNE: pharmacological neuroenhancement. SECO: State Secretariat for 
Economic Affairs. SF-12: The 12-Item Short Form Health Survey.  
 
 
Lifetime use of drugs of abuse and soft enhancers as univariate predictors for PNE are 
displayed in Table 2. The lifetime use of tobacco, illegal drugs, and over-the-counter (OTC) 
drugs was more prevalent among PNE users. No association was found for lifetime use of 
alcohol and caffeine products. 
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Table 2. Lifetime use of legal and illegal drugs of abuse and potential soft enhancers in the sample and the odds 
ratios (OR) for the univariate associations of substance use with lifetime PNE 
 
Total 
N = 10,171 
PNE 
n = 411 
No PNE 
n = 9,760 OR (95% CI) p 
Lifetime drug use       
Alcohol  93.8% (9,541) 95.0% (390) 93.8% (9,151) 1.26 (0.80–2.0) .32 
Tobacco use 63.2% (6,424) 76.2% (313) 62.6% (6,111) 1.91 (1.52–2.41) < .01 
Cannabis  32.1% (3,261) 51.5% (211) 31.2% (3,050) 2.33 (1.91–2.85) < .01 
Cocaine  3.7% (378) 17.6% (72) 3.1% (306) 6.62 (5.01–8.74) < .01 
MDMA (ecstasy) 2.7% (274) 12.8% (52) 2.3% (221) 6.32 (4.60–8.69) < .01 
Amphetamine  2.0% (207) 12.5% (52) 1.6% (155) 8.89 (6.38–12.39) < .01 
GHB / GBL 0.6% (60) 3.2% (13) 0.5% (46) 7.03 (3.79–13.03) < .01 
Ketamine  0.2% (21) 2.4% (10) 0.1% (11) 22.01 (9.31–52.02) < .01 
Caffeine products a 92.8% (9,439) 93.2% (383) 92.8% (9,057) 1.07 (0.72–1.58) .75 
Vitamins & OTC drugs b 46.0% (4,673) 63.4% (260) 45.2% (4,413) 2.10 (1.71–2.57) < .01 
Data are % (number) weighted for age, sex, and language region. a Coffee, caffeine tablets, and Energy Drinks. b 
Herbal sedatives, vitamins, and tonics. OTC: over-the-counter; PNE: pharmacological neuroenhancement. 
 
 
2.4.4 Multivariate predictors of lifetime PNE 
The overall prediction model resulting from a hierarchical logistic stepwise regression (R2 
= .26) is presented in Table 3 and revealed that the following variables were positively 
associated with lifetime PNE: being in education, frequent stress in the past 12 months, 
psychological consulting, lifetime diagnosis of a mental disorder, and lifetime use of 
cannabis, cocaine, amphetamine, and ketamine. Having minor children at home and perceived 
health were negatively associated with lifetime PNE. 
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Table 3. Odds ratios (OR) for the overall model of the multivariate associations (using stepwise backward and 
forward regression < .05) between participant characteristics and lifetime PNE 
OR (95% CI) p 
Professional activity  
In education  
Full-time work ≥ 90% 0.44 (0.33–0.59) < .01 
Part-time work < 90% 0.46 (0.34–0.63) < .01 
Children at home <18   
None   
At least one 0.76 (0.59–0.98) .03 
Perceived health  
SF-12, scale 1-5 0.78 (0.68–0.90) < .01 
Stress (12 m)  
SECO, scale 1-5 1.39 (1.22–1.57) < .01 
Psychological consulting   
Never   
At least once 2.39 (1.86–3.07) < .01 
Mental disorder a   
Never   
At least one 4.58 (3.51–5.97) < .01 
Lifetime illegal drug use   
Cannabis  1.41 (1.13–1.78) < .01 
Cocaine  2.57 (1.72–3.86) < .01 
Amphetamine  2.96 (1.84–4.77) < .01 
Ketamine  3.18 (1.17–8.67) .02 
Data are weighted for age, sex, and language region. a ADD/ADHD, narcolepsy, depression, anxiety disorder, 
dependency (lifetime diagnosis). SECO: State Secretariat for Economic Affairs. SF-12: The 12-Item Short Form 
Health Survey. N = 10,171. R2 = .07 (Cox & Snell), .26 (Nagelkerke). Model χ2 (11) = 775.549, P <.001. 
 
 
2.4.5 Prescription drugs used for PNE, motives for use, and source of supply 
Tranquilizers and antidepressants were the substances most commonly misused, and 
current prescription drug misuse within the past 30 days was rare for all prescription drug 
categories (Table 4). Of the PNE users, 26.2% reported lifetime nonmedical use of 
tranquillizers, 20.2% of antidepressants, 14.2% of ADD/ADHD medications, 3.5% of beta-
blockers, 1.8% of modafinil, and 0.4% of anti-dementia drugs. The list with the prevalence of 
nonmedical use for each single medication evaluated in the survey is available in the 
supplementary materials (Table S2). The source of supply for the nonmedical use of 
prescription drugs was most commonly the doctor (Table 4). However, the main source of 
supply for ADHD medications was the circle of friends (Table 4). A narrow majority of the 
PNE users reported the desired effects of PNE with prescription drugs (Table 4). 
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Table 4. Prevalence of nonmedical prescription drug use for PNE in the study population (N = 10,171), main 
source of supply, and whether the expectations of use were fulfilled 
LTP 12-MP 30-DP 
Main source of 
supply 
Expectations 
fulfilled 
Nonmedical prescription  
drug use   
Tranquilizers 1.06% (108) 0.59% (60) 0.40% (40) Doctor 53.7% (58) 73.5% (79) 
Antidepressants 0.81% (83) 0.37% (38) 0.18% (18) Doctor 73.8% (61) 70.8% (59) 
ADD/ADHD medication 0.57% (58) 0.29% (29) 0.07% (7) Friend 55.8% (32) 61.0% (35) 
Beta-blockers 0.14% (14) 0.04% (4) 0.04% (4) Doctor 52.8% (8) 72.4% (10) 
Modafinil 0.07% (7) 0.04% (4) 0.02% (2) Friend 31.0% (2)  31.6% (2) 
Anti-dementia drugs 0.02% (2) 0 0 Doctor 100.0% (2) - 
Data are % (number) weighted for age, sex, and language region. LTP: lifetime prevalence; 12-MP: 12-month 
prevalence; 30-DP: 30-days prevalence. 
 
The reported nonmedical use of tranquilizers aimed mainly at improving sleep and 
relaxation after stress at work or in education (33.5%). The main motive for the nonmedical 
use of antidepressants was PME at work or for studying (58.8%) but also PME in leisure 
(38.3%). ADHD medications were most commonly misused for PCE (74.5%). The only two 
people who mentioned the misuse of an anti-dementia drug both used the drug for the purpose 
of PCE. The number of participants who used modafinil and beta-blockers without having a 
prescription was too small to make reliable statements about the motives for use.  
2.4.6 Drugs of abuse used for PNE, motives for use, and source of supply 
Alcohol users mentioned relaxation in leisure time as their most important motive for 
drinking alcohol. Partying and getting high were the main motives for the use of illegal drugs 
of abuse (87.4% for MDMA, 77.7% for cocaine, 73.2% for amphetamine, 59.2% for 
ketamine, and 54.7% for cannabis) except for GHB/GBL in which half of the self-named 
users reported that their use occurred involuntarily. Nevertheless, 15.2% of amphetamine and 
11.6% of cocaine users reported that they had already used their drugs intentionally for PCE 
(Table 5). Moreover, the use of alcohol and cannabis to relax and to calm down after stress at 
work or education, which would be considered as indirect PNE (Maier & Schaub, in press), 
was reported by one-quarter of alcohol users and one-fifth of cannabis users (Table 5). 
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Table 5. Prevalence of PNE motives (M1-M4) among lifetime users of alcohol and illegal drugs of abuse within 
a set of multiple answer options 
 
M1.  
PCE (attention, 
concentration, 
memory) 
M2.  
Reduction of 
nervousness / 
stage fright 
M3.  
PME at work / 
for studying 
M4.  
Relaxation after stress 
at work / education 
Lifetime drug use     
Alcohol, n = 9,541 0.2% (20) 2.4% (233) 0.6% (60) 25.4% (2,428) 
Cannabis, n = 3,261 1.0% (33) 2.4% (78) 1.3% (41) 17.4% (568) 
Cocaine, n = 378 11.6% (44) 2.0% (8) 1.0% (4) 5.7% (22) 
MDMA (ecstasy), n = 274 3.0% (8) 1.1% (3) 0.3% (1) 6.1% (17) 
Amphetamine n = 207 15.2% (31) 2.9% (6) 2.1% (4) 4.5% (9) 
GHB/GBL, n = 60 0 0 0 2.3% (1) 
Ketamine, n = 21  5.1% (1) 4.3% (1) 5.1% (1) 0 
Data are % (number) weighted for age, sex, and language region. PCE: pharmacological cognitive enhancement; 
PME pharmacological mood enhancement. 
 
The main source of supply for illegal drugs was the circle of friends (91.3% for cannabis, 
80.8% for MDMA, 78.7% for amphetamine, 78.0% for cocaine, 69.3% for ketamine, 57.7% 
for GHB/GBL) and less commonly a dealer (41.9% for GHB/GBL, 33.7% for ketamine, 
32.9% for MDMA, 29.1% for cocaine, 27.6% for amphetamine, 14.6% for cannabis). Only a 
minority of users had bought their drugs on the Internet (15.9% for ketamine, 5.9% for 
GHB/GBL, 2.0% for amphetamine, 0.9% for cocaine, 0.7% for MDMA, 0.5% for cannabis) 
or received them from family members (9.4% for ketamine, 5.2% for GHB/GBL, 3.0% for 
cannabis, 2.1% for amphetamine, 2.2% for cocaine, 1.1% for MDMA).  
2.5 Discussion 
This study is the first representative large-scale study of PNE among the Swiss population 
that did not focus solely on students but also on employees and asked about various 
substances used for PNE. The study revealed three main findings: 1) Of the study sample, 
4.0% reported lifetime use of prescription drugs or drugs of abuse for PNE, but only half of 
these respondents (2.1%) reported PNE within the past year; 2) Lifetime diagnosis of a mental 
disorder, experience with professional psychological consulting, stress, being in education, 
minor children at home, perceived poor health, and the lifetime use of cannabis, cocaine, 
amphetamine, and ketamine were the strongest predictors of lifetime PNE; and 3) PME was 
more prevalent than PCE or both PME/PCE.  
According to our study, the lifetime and the 12-month prevalence of PNE were rather low. 
This result is consistent with recent research on substance use for PNE among German and 
Swiss employees (DAK, 2009; Grebner et al., 2010) but shows a lower prevalence compared 
to Swiss student-only surveys (Maier et al., 2013; Ott & Biller-Andorno, 2014). However, 
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PNE has become a major public health issue among U.S. college students (McCabe et al., 
2014) and should be also monitored among youth in Europe. Even if elderly people had more 
years of life in which to try PNE, they were less likely to be experienced with PNE. This 
finding might indicate that a new PNE trend is developing and that the lifetime prevalence for 
the current cohort might increase in the near future. In contrast, the willingness to use 
prescription drugs (8.7%) or psychoactive drugs of abuse (4.0%) for PNE was considerably 
low among the inexperienced study sample. However, the interest in PNE was slightly higher 
in students, and a recent study among UK students revealed that the low prevalence despite 
the high interest might be explained by the lack of availability of prescription drugs (Singh et 
al., 2014). 
Participants who reported a lifetime diagnosis of a mental disorder were more than four 
times more likely to report PNE. Moreover, participants who felt often or very often stressed 
during the past 12 months and participants who rated their health as only poor were also more 
likely to report PNE. Having minor children at home was found to be a protective factor that 
made the occurrence of PNE unlikely. The association between the use of illegal drugs of 
abuse and PNE known from the literature (Maier et al., 2013; McCabe et al., 2005, 2014; 
Weyandt et al., 2009) was shown again in the present study. Participants who reported 
lifetime illegal drug use were two to three times more likely to report PNE. 
Although Switzerland is known as a country with high requirements in regard to 
performance at work or in education, only a few people reported the use of prescription drugs 
or drugs of abuse to improve cognitive performance. The nonmedical use of antidepressants 
and tranquilizers for increased well-being (PME) was more prevalent. The majority of the 
people in this group had previously searched for help because of a mental health problem and 
were assumed to misuse their current or past medication for PNE (DeSantis et al., 2008; 
Gerlach, Dasgupta, Schnoll, & Henningfield, 2014). The finding that the participants reported 
the awareness of other people’s PCE (25.8%) more than other people’s PME (19.8%), even if 
the prevalence of substance use for those purposes was reported vice versa, might indicate an 
underreporting of PCE in the present study. Additionally, the use of sedating substances, such 
as alcohol and cannabis, to relax after stress at work or education was more common than 
illicit stimulant use for PCE and can be seen as a form of indirect PCE if used to increase 
relaxation to perform better the next day (Maier & Schaub, in press). The frequent and high 
use of alcohol (and/or cannabis) as a socially accepted coping strategy might cause even more 
harm than occasional PCE with prescription drugs during short periods in life. 
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2.5.1 Strengths, limitations, and implications 
A major strength of this study is the large sample of employees and students, recruited 
with the Swiss national Internet panel of the LINK institute, which was representative for the 
Swiss population. Furthermore, thorough weighting procedures were used to investigate the 
substance use for the purpose of cognitive and mood enhancement at work or for studying. 
Moreover, this survey included authentic photos of every single medication to facilitate the 
user’s recognition and asked specifically for the nonmedical use and its motives. Additionally, 
two fictitious drugs were included to control for socially desirable responding behavior. 
Nevertheless, the question arises whether the use of such an Internet panel provides 
representative data or not. Do only middle-class Swiss people with good jobs and a good 
social context participate in these surveys, and could it be possible that we underestimate PNE 
in Switzerland because the stressed population who needs to enhance themselves has no time 
to participate in surveys for an Internet panel from time to time? Our data could support this 
assumption because only 13% of the participants were in education and showed a higher 
prevalence of PNE (Weyandt et al., 2013). Moreover, students are presumably less likely to 
engage in an additional Internet panel for surveys if already flooded with invitations to 
participate in research studies at their higher education institution. 
A further limitation is the formulation of the question about PNE. The two main questions 
asked about the use of prescription drugs and drugs of abuse by participants to perform better 
at work or for studying. Most of the participants have most likely not thought about indirect 
enhancement with sedating substances if asked about their substance use aimed at better 
performance, and, therefore, the implementation of a more specific definition would be 
required for a subsequent survey (Maier & Schaub, in press). Additionally, we asked for a 
broad range of potential medications used for PNE (Table S2) but did not address the issue of 
generic medication. 
Because we identified two different types of PNE users with different motives for 
substance use, there are several implications for preventing physical and mental harm. First, 
PNE users without a current or past mental disorder should become aware of possible side 
effects of PNE and potential consequences of their individually chosen (unhealthy) lifestyles. 
Academic institutions and companies could provide students and employees with information 
about strategies other than substance use and develop stress-management training as early 
prevention tools for PNE in healthy individuals. Moreover, awareness of addiction potential 
and risks of nonmedical prescription drug use should be increased, and doctors should be able 
to furnish objective information about the effects and side effects of the prescribed medication 
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and about individual differences in response to the medication. Second, PNE users with an 
underlying mental disorder who receive no or only insufficient treatment should be informed 
about further treatment options. Corporate interventions have to be implemented if the mental 
disorder is associated with the situation at work and job changeover is not desired. Third, 
workplace health promotion should address the issue of stress before PNE occurs. This goal 
could be achieved by strengthening the social and communication skills of the employees and 
the management. Finally, future research should investigate differences between PNE users 
with and without a current or past mental disorder. It is assumed that motives and profiles of 
“healthy” and disadvantaged PNE users differ and that, therefore, different intervention 
measures would be required.  
2.5.2 Conclusions 
Our research constitutes the first comprehensive and representative large-scale study of 
PNE on a national level in Europe. The study revealed that 4.0% of the Swiss population 
reported lifetime PNE but that only 2.1% reported past-year PNE. Lifetime PNE was strongly 
associated with prior diagnosis of at least one mental disorder, with being in education rather 
than employed, and with lifetime use of cannabis and other illegal drugs of abuse. PNE is not 
(yet) common among the Swiss population, but observing further development is 
recommended. 
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2.6 Supplementary Material 
Methods S1 Specification of the questionnaire design. To include all relevant issues, 
question items were taken from existing European questionnaires about (workplace) stress or 
about substance use for cognitive enhancement (BFS, 2013; DAK, 2009; Eurofound, 2010; 
Grebner et al., 2010; Middendorff et al., 2012). Questions about frequency and patterns of 
psychoactive substance use were formulated consistent with the Addiction Monitoring in 
Switzerland criteria (Gmel, Kündig, Notari, Gmel, & Flury, 2013). The questionnaire 
included questions on socio-demographic data, stress at work or in education (Eurofound, 
2010; Grebner et al., 2010; Semmer, Zapf, & Dunckel, 1999), health (BFS, 2013), and 
substance use (Gmel et al., 2013; Middendorff et al., 2012).  
The substance use section considered both the use of alcohol and illegal drugs (cannabis, 
cocaine, MDMA, amphetamines, ketamine, and GHB/GBL) in the study population and the 
nonmedical use of prescription drugs among PNE users. Together with an addiction medicine 
specialist, we examined which medications were potentially used for PNE and evaluated them 
in the survey. For each prescription drug category, respondents had to indicate the frequency 
of use within the past 30 days, motives for use, and whether their expectations regarding the 
medication’s effects were met. These questions were asked for the nonmedical use of the 
following groups of substances: methylphenidate, modafinil, activating antidepressants 
including selective serotonin reuptake inhibitors (SSRI), anti-dementia agents, tranquilizers, 
and beta-blockers. Moreover, all prescription drugs of each category were presented 
graphically with packaging and pills to facilitate recognition by the survey participants 
(Novak et al., 2007). Additionally, all participants had to answer questions about their use of 
freely available “soft” enhancing substances such as tobacco, coffee, caffeine tablets, energy 
drinks, herbal sedatives (e.g., St. John’s Wort, common valerian), and vitamins and tonics 
(e.g., gingko biloba, zinc). For the use of each substance, eight motives were suggested to the 
users randomly: three motives related to direct enhancement at work or in education (to 
enhance cognition, to enhance mood, and to reduce nervousness), one motive related to 
indirect enhancement at work or in education (to relax after stress at work), and four other 
motives for nonmedical use (to get high, enhance mood in leisure time, relax in leisure time, 
work despite pain). Additional general motives for use, such as pleasure or taste (e.g., for 
alcohol), could be mentioned by the participants.  
To control for socially desirable responding, an additional category of “energy boosters” 
with two fake medications (Supraval®, Energyl®) was included (Novak et al., 2007). 
Moreover, the survey contained questions on the past and current diagnosis of mental 
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disorders (ADHD, narcolepsy, depression, anxiety disorder, and substance dependence) that 
are known to be treated with medications often referred to as PNE drugs in scientific literature 
(Farah et al., 2014; Rabiner et al., 2009a).  
 
Table S1. Percentage quota, number of interviews realized (absolute & percentage), and the resulting weighting 
factor for data from the different linguistic regions of Switzerland 
Quota (%) 
Realized 
interviews (n) 
Realized 
interviews (%) Difference 
Weighting 
factor 
German-speaking 
Male, 15-24 years 5.64 567 4.16 1.48 1.36 
Male, 25-34 years 6.39 802 5.89 0.50 1.09 
Male, 35-44 years 6.97 919 6.75 0.22 1.03 
Male, 45-54 years 7.43 1,114 8.18 -0.75 0.91 
Male, 55-64 years 5.62 861 6.32 -0.70 0.89 
Male, 65-74 years 4.05 517 3.80 0.26 1.07 
Female, 15-24 years 5.42 676 4.96 0.46 1.09 
Female, 25-34 years 6.28 810 5.95 0.33 1.06 
Female, 35-44 years 6.91 971 7.13 -0.22 0.97 
Female, 45-54 years 7.25 1,077 7.91 -0.66 0.92 
Female, 55-64 years 5.66 865 6.35 -0.69 0.89 
Female, 65-74 years 4.49 688 5.05 -0.57 0.89 
French-speaking      
Male, 15-24 years 1.84 154 1.13 0.71 1.63 
Male, 25-34 years 2.07 300 2.20 -0.13 0.94 
Male, 35-44 years 2.26 347 2.55 -0.29 0.89 
Male, 45-54 years 2.41 323 2.37 0.04 1.02 
Male, 55-64 years 1.82 271 1.99 -0.17 0.92 
Male, 65-74 years 1.31 186 1.37 -0.06 0.96 
Female, 15-24 years 1.77 255 1.87 -0.10 0.95 
Female, 25-34 years 2.04 265 1.95 0.10 1.05 
Female, 35-44 years 2.25 294 2.16 0.09 1.04 
Female, 45-54 years 2.35 289 2.12 0.23 1.11 
Female, 55-64 years 1.84 235 1.73 0.12 1.07 
Female, 65-74 years 1.45 196 1.44 0.01 1.01 
Italian-speaking      
Male, 15-24 years 0.31 44 0.32 -0.01 0.96 
Male, 25-34 years 0.33 51 0.37 -0.04 0.88 
Male, 35-44 years 0.44 60 0.44 0.00 1.00 
Male, 45-54 years 0.47 71 0.52 -0.05 0.90 
Male, 55-64 years 0.36 56 0.41 -0.05 0.88 
Male, 65-74 years 0.32 43 0.32 0.01 1.01 
Female, 15-24 years 0.30 42 0.31 -0.01 0.97 
Female, 25-34 years 0.33 46 0.34 -0.01 0.98 
Female, 35-44 years 0.45 66 0.48 -0.04 0.93 
Female, 45-54 years 0.46 67 0.49 -0.03 0.94 
Female, 55-64 years 0.37 51 0.37 -0.01 0.99 
Female, 65-74 years 0.34 40 0.29 0.04 1.16 
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Table S2. Lifetime prevalence of the nonmedical prescription drug use for pharmacological neuroenhancement 
and the use of freely available “soft” enhancers for increased performance at work or for studying among the 
study sample (N = 10,171) 
Nonmedical prescription drug use for increased 
performance at work or for studying  
Use of freely available “soft” enhancers for increased 
performance at work or for studying 
Tranquilizers 1.06% (108) Herbal sedatives 18.8% (1,917) 
Temesta® 0.38% (39)  Zeller-Entspannung® 11.2% (1,137) 
Stilnox® 0.33% (34)  Baldriparan® 7.5% (765) 
Xanax® 0.27% (28)  Jarsin® 2.0% (203) 
Seresta® 0.22% (23)  Zeller Herz-Nerven® 1.4% (139) 
Valium® 0.19% (20)  Remotiv® 1.3% (131) 
Dormicum® 0.17% (17)  Faros® 0.2% (16) 
Remeron® 0.09% (9)  Vitamins and tonics 38.4% (3,910) 
Imovane® 0.07% (7)  Berocca® 18.1% (1,838) 
Halcion® 0.03% (3)  Supradyn® 16.5% (1,675) 
Dalmadorm® 0.02% (2)  Strath® 11.7% (1,192) 
Noctamid® 0  Dynamiasan® 7.2% (731) 
Antidepressants 0.81% (83)  Tonoglutal® 2.6% (263) 
Cipralex® 0.43% (43)  Gincosan® 1.2% (125) 
Seropram® 0.18% (19)  Caffeine 92.8% (9,439) 
Cymbalta® 0.16% (17)  Coffee 87.8% (8,929) 
Fluctine® 0.13% (14)  Caffeine tablets 1.8% (183) 
Efexor® 0.13% (13)  Energy Drinks 47.5% (4,833) 
Zoloft® 0.10% (11)  Nicotine (tobacco) 63.2% (6,424) 
Wellbutrin® 0.05% (5)    
Erdonax® 0.03% (3)    
ADHD medication 0.57% (58)    
Ritalin® 0.48% (49)    
Concerta® 0.12% (12)    
Medikinet® 0.05% (5)    
Focalin® 0.05% (4)    
Strattera® 0.01% (1)    
Beta-blockers 0.14% (14)    
Beloc ZOK® 0.08% (8)    
Meto Zerok® 0.07% (7)    
Modafinil (Modasomil®) 0.07% (7)    
Anti-dementia drugs 0.02% (2)    
Aricept® 0.02% (2)    
Axura® 0    
Exelon® 0    
Reminyl® 0    
Data are % (number) weighted for age, sex, and language region. 
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3.1 Abstract 
Objectives This study sought to examine the relationship between stress, self-efficacy, self-
medication, and pharmacological neuroenhancement (PNE) in the general population. 
 
Methods Using the largest Swiss Internet panel, a sample of 10,171 employees and students 
(unweighted N = 10,084) aged 15 to 74 years was recruited and asked to complete a self-
administered online survey. The data were weighted for age, sex, and language region to 
provide results that were representative of the Swiss population. Multinomial logistic 
regression models were conducted to identify predictors of pharmacological cognitive 
enhancement (PCE) and pharmacological mood enhancement (PME) over the past year. Two 
self-medication models and an overall model were determined. 
 
Results Current medical treatment for a mental disorder was the strongest predictor of both 
PCE and PME use as serious self-medication. The overall model revealed that cannabis use, 
frequent stress, and long-term stress were predictors of both PCE and PME, whereas negative 
stressors and time pressure at work did not remain in the final model. Furthermore, past-year 
PCE was associated with being male, being a student, and using illegal drugs other than 
cannabis, whereas being female and having low self-efficacy predicted past-year PME. 
 
Conclusions Consideration of the predictor variables that were identified in this study may 
help to identify the potential PCE and PME users for whom measures to prevent drug abuse 
and manage stress are most appropriate. More specifically, the use of PCE and PME as self-
medication to enhance performance at work or while studying needs further consideration in 
the neuroenhancement debate. 
 
Keywords: Pharmacological neuroenhancement, cognitive enhancement, self-medication, 
stress, self-efficacy 
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3.2 Introduction 
Pharmacological neuroenhancement (PNE) refers to the nonmedical use of prescription 
drugs, alcohol, and illegal drugs of abuse for the purpose of enhancing cognition, mood, or 
pro-social behavior to improve performance at work or in education (de Jongh et al., 2008; 
Maier & Schaub, 2015). To date, most of the scientific literature has focused on the 
prevalence of PNE and has failed to ask why it is prevalent (Wolff & Brand, 2013). The most 
common explanations for the prevalence of PNE are overwhelming demands and stress at 
work or in education, and the increasing number of media reports on PNE might generate the 
misperception that PNE is an acceptable means of coping with stress (Schleim, 2014b; Wolff 
& Brand, 2013). Lazarus described stress as a feeling that arises when professional or 
academic requirements exceed the personal and social resources that an individual is able to 
mobilize at a given time (Lazarus, 1989). Notwithstanding, responses to stress can vary 
greatly among individuals; the use of prescription drugs and illicit drugs for PNE represents 
only one of many possible pharmacological coping strategies (Maier & Schaub, 2015; Park & 
Iacocca, 2014). Moreover, PNE with stimulants is strongly associated with risky health 
behaviors such as illegal drug use (Arria et al., 2008; McCabe et al., 2005). Insufficient 
coping skills and substance abuse in the face of chronic stress might cause mental health 
problems, and vice versa (Mohr et al., 2014). 
PNE is related to the use of different coping strategies. Young adults who are suppressors 
or employ other-reliant coping strategies show more problematic substance abuse patterns 
than those who use active coping strategies (Wong et al., 2013). Nevertheless, highly stressful 
situations are associated with active coping rather than internal coping, and the mechanisms 
between perceived stress and each coping strategy are situation-specific (Seiffge-Krenke, 
Aunola, & Nurmi, 2009). Individual and situation-specific differences in the perception of 
stress and in coping strategies are also related to decisions about whether to engage in PNE 
(Sattler, Mehlkop, Graeff, & Sauer, 2014).  
Self-efficacy is the ability to initiate and use successful stress coping strategies (Bandura, 
1977) and mediates the path from stress to illness (Sawatzky et al., 2012). In addition, a study 
found that students with high achievement goals and high self-efficacy performed better than 
their counterparts (Cheng & Chiou, 2010). These findings refer to Bandura's (1986) social 
cognitive theory, which states that attainable goals, self-motivation, and controllable 
outcomes are crucial for self-efficacy and personal development. Once the individuals in these 
studies experienced PNE, they showed lower levels of avoidance self-efficacy because they 
could no longer avoid using illicit stimulants in highly stressful situations (Bavarian et al., 
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2013). In other words, they were not confident in their own abilities. Wulf and colleagues 
(2011) argued that the functional use of drugs for enhancement purposes diminishes self-
efficacy because performance is attributed to the drug effects rather than to one’s own 
abilities. This attribution might cause a threat to self-esteem because the absence of negative 
experiences with PNE makes repeated PNE and even addiction more likely to occur (Wulf et 
al., 2011).  
Research on PNE has focused on pharmacological cognitive enhancement (PCE) rather 
than on pharmacological mood enhancement (PME). However, not only effective stress 
management but also well-being is required for good performance at work and in education 
(Sawatzky et al., 2012; Schleim, 2014b). Indeed, in a recent study in which almost half of the 
respondents from the Swiss general population indicated the use of over-the-counter drugs for 
enhancement purposes, PME (3.1%) was more prevalent than PCE (1.4%) (Maier, Schaub, & 
Haug, submitted). Hence, to gain a more comprehensive picture of PNE, PME is a related 
issue that should not be neglected. 
Responsible self-medication with indicated over-the-counter drugs for self-recognized 
conditions is an important element of self-care that reduces the burden on health care systems 
(WHO, 1998). However, Khantzians' (1997) self-medication hypothesis of addictive disorders 
claims that addicts use alcohol or illegal drugs to change the painful affect states that can 
result in addiction. The nonmedical use of prescription drugs or alcohol and illegal drugs for 
PCE or PME to treat an undesired physical or mental condition represents a form of self-
medication that falls in the middle of the range between healthy self-care and addiction. 
However, the terms nonmedical use or misuse are preferred in the scientific literature, and 
definitions that contain the term “enhancement” arise from the bioethical debate (Racine & 
Forlini, 2008). These technical and optimistic terms increase good performers’ fear of 
inadequacy and distract from the issue of serious self-medication among disadvantaged 
individuals who use drugs to diminish the symptoms of a disorder (Earp et al., 2014). 
Consequently, it often remains unclear whether the PCE of an individual with an undiagnosed 
mental disorder, such as ADHD, is self-treatment or misuse (Peterkin et al., 2011; Rabiner et 
al., 2009a). Both PCE and PME might be considered self-medication when healthy 
individuals use drugs to maintain good performance when few resources are available or to 
improve performance from good to excellent or from disadvantaged to normal. Thus, PCE 
and PME are means of achieving specific health or performance goals (Wolff et al., 2014). 
For the most part, studies of academic PCE have focused on PCE as moderate self-medication 
in terms of the self-optimization of healthy individuals who suffer from stress (Singh et al., 
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2014; Wolff & Brand, 2013). Research has often excluded individuals with mental disorders 
to avoid the discussion of where treatment ends and enhancement begins (Barrett et al., 2008; 
Maslen et al., 2014). The use of PCE and PME as serious self-medication to combat 
symptoms of mental disorders or the adverse side effects of medical treatment is prevalent 
(Kasten, 1999) but has not yet been investigated in the neuroenhancement literature. 
Therefore, the current study aimed to investigate factors associated with the use of both 
moderate self-medication and serious self-medication to enhance performance at work or 
while studying. 
The current study is the first to perform an in-depth analysis of the predictors of two 
different forms of neuroenhancement, namely PCE and PME, based on representative 
national-level estimates. Mental disorders and their associated medical treatments as well as 
different forms of stress and self-efficacy were considered as possible predictors of PCE and 
PME. Taking into account the abovementioned theoretical work, stress and insufficient stress 
coping, other illegal drug use and impaired mental health were assumed to predict both PCE 
and PME. Finally, the following hypotheses were made:  
 that past-year PCE and PME are both associated with higher levels of 
 past-year stress and long-term stress (moderate self-medication), 
 that past-year PCE and PME are both associated with illegal drug use in 
 the past year (moderate self-medication), 
 and that past-year PCE and PME are both associated with current 
 medical treatment for underlying mental disorders (serious self-
 medication). 
Moreover, it was assumed that different enhancement intentions are related to different 
predictors. PME with the intention to increase psychological well-being differs from the 
rather competitive intention of PNE (Maier & Schaub, 2015; Schleim, 2014b). Therefore, the 
following hypotheses were made: 
 that past-year PCE is associated with time pressure and other negative 
 professional or academic stressors in the past year (moderate self-
 medication), 
 and that past-year PME is associated with low self-efficacy (moderate 
 self-medication). 
The understanding of the predictors of PCE and PME derived from this cross-sectional 
study has important implications for preventive measures and future longitudinal research that 
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aims to disentangle the relationships among stress, self-efficacy, mental health, and PCE and 
PME. 
3.3 Methods 
3.3.1 Enrollment procedure and study sample 
Participants were recruited through a national Internet panel. The Internet panel of the 
LINK institute for market and social research in Switzerland includes more than 130,000 
people living in Switzerland who consented to be contacted about online public opinion 
surveys during computer-assisted telephone interviews. The panelists were representative of 
the 15- to 74-year-old population in Switzerland that uses the Internet at least once per week 
for private purposes and is able to answer a questionnaire in German, French, or Italian. In 
March 2013, the LINK institute invited 39,996 panelists to participate in a study about health 
and stress at work or in education, and 18,094 panelists took the survey. Following screening 
for exclusion criteria (currently unemployed and not in education = 3,535), quota overflow (n 
= 2,155), and dropouts (n =2,320), the final sample size was 10,084. The data were weighted 
for age, sex and language region (weighted N = 10,171). Informed consent was obtained from 
all of the participants who were included in the study. 
3.3.2 Measures 
A self-administered online survey was used to investigate PCE and PME in Switzerland 
(for details on the survey see Maier et al., submitted). For the present study, only variables 
containing current and past-year indicators of stress, health, and health behaviors were 
considered. 
3.3.3 Outcome variable 
Pharmacological neuroenhancement (PNE). Two principal questions assessed past-year 
PNE. Past-year PNE users indicated either the use of prescription drugs or illicit drugs for 
cognitive enhancement (PCE) at work or while studying in the past 12 months or the use of 
prescription drugs or illicit drugs for mood enhancement (PME) at work or while studying in 
the past 12 months. The following three groups were specified: 1) no PNE in the past 12 
months; 2) past-year PME only; 3) and past-year PCE with and without PME. Because most 
of the previous research has focused mainly on PCE users (Peterkin et al., 2011; Singh et al., 
2014), the third group included all of the participants who indicated past-year PCE with or 
without PME.  
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3.3.4 Stress measures 
Frequency of stress. To determine the participants’ frequency of stress experiences in the 
past 12 months, they were asked the following question: “During the past 12 months, how 
often have you felt stressed – never, rarely, sometimes, often, or very often?” This variable 
was modeled using the original Likert format. 
Long-term stress at work or in education. To determine whether the participants had 
experienced long-term stress at work or in education, they were asked the following question: 
“Have you experienced stress at work or in education that persisted over several months? 
(Eurofound, 2010)” The answer format was dichotomous (yes or no). 
Time pressure and negative aspects at work or in education. The participants 
answered seven questions about current stress at work or in education that were analyzed by 
an exploratory factor analysis. The factor analysis revealed two stress scales, which were used 
as potential predictors of PCE and PME. The first scale included two items (α = .76) asking 
for frequency of working or learning at a fast pace and under tight deadlines (Eurofound, 
2010; Grebner et al., 2010). The items were answered on a 6-point scale (almost never, 
approximately one-quarter of the time, approximately half of the time, approximately three-
quarters of the time, almost always, and always). The second stress scale included five items 
(α = .67) that measured time-independent negative conditions of the participants’ current 
work and education situations that might be related to adverse health outcomes and PNE. 
Those items asked about the frequency of unclear instructions from supervisors and lecturers, 
the occurrence of unnecessary breaks at work or in education, the feeling of a lack of control 
at work or in education, competitive pressure, and the need to show inauthentic feelings at 
work or in education (Eurofound, 2010; Grebner et al., 2010). Each of the five items was 
coded on a 5-point scale (never, rarely, sometimes, often, or very often).  
3.3.5 Other predictor variables 
Socio-demographic characteristics. The following demographic variables were included 
in the analyses: sex, age (15-24, 25-34, 35-44, 45-54, and 55-74 years), professional activity 
(student, employed full-time, and employed part-time), relationship (none/temporary and 
stable), and the presence of children (< 18 years of age) at home (yes or no). 
Mental health and health behavior. The participants indicated their current health status 
in response to the first question of the SF-12 (poor, fair, good, very good, and excellent). The 
survey also contained questions about past and current diagnoses of mental health disorders 
(ADHD, narcolepsy, depression, anxiety disorder, and substance dependence) that are known 
to be treated with medications that the scientific literature often refers to as neuroenhancement 
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drugs (Rabiner et al., 2009b; Sattler et al., 2014). A dichotomous variable was used in the 
analysis to represent the current use of a prescription drug to treat at least one of the 
aforementioned mental disorders (yes or no). Participants who reported undergoing medical 
treatment for a past or current mental disorder were asked whether they had ever used their 
prescribed medication in a manner other than prescribed (e.g., at a higher dose or via a 
different route of administration). 
Past-year psychoactive substance use was assessed dichotomously for tobacco, alcohol, 
cannabis, and other illicit drugs (cocaine, MDMA, amphetamine, ketamine, and GHB/GBL). 
Self-efficacy. The Generalized Self-Efficacy Scale (GSES) was used to assess the strength 
of the participants’ belief in their ability to respond to novel or difficult situations and to cope 
with a variety of stressors (not at all true, barely true, moderately true, and very true). The 
psychometric characteristics of the GSES are satisfactory when implemented online 
(Schwarzer, Mueller, & Greenglass, 1999), and the present study revealed good internal 
consistency (α = .86). 
3.3.6 Logistic Regression Models 
To evaluate each variable’s ability to predict the outcome (PCE or PME), initial separate 
multinomial logistic regression analyses were performed (subsequently termed ‘univariate 
analyses’). Past-year non-users were the reference group for the dependent variable. First, all 
significant univariate socio-demographic predictors were entered in the preliminary 
multivariate model (model 1). Non-significant variables were removed from the overall model 
one at a time. Nagelkerke’s R-square was calculated as a goodness-of-fit measure for the 
multivariate multinomial logistic regression model. In a second model, the demographics, 
stress, and self-efficacy were entered as predictors of PCE and PME (moderate self-
medication, model 2). In model 3 (serious self-medication), the demographics and current 
medical treatment for a mental disorder were entered. Finally, in an overall multivariate 
multinomial logistic regression model all remaining significant predictors were included to 
predict PCE and PME (model 4). All quantitative analyses were conducted using IBM SPSS 
Statistics Version 22 (SPSS, Inc., Chicago, IL, USA), and p < .05 was set as the significance 
level. 
3.4 Results 
Of the study participants, 2.1% (n = 215) reported past-year PNE. Two-thirds of the past-
year PNE users (69.2%) felt frequently or very frequently stressed in the past 12 months, 
  67 Self-Medication 
compared with 35.5% of the non-users. Four out of five past-year PNE users (80.7%) reported 
long-term stress at work or in education, whereas half of the non-users (49.3%) reported such 
long-term stress. Whereas the non-users who said they experienced long-term stress reported 
that they were rarely unable to cope with their stress (7.6%), one-quarter of the PNE users 
(22.9%) were never or almost never able to cope with stress at work or in education. To 
further specify the groups of interest, 1.4% (n = 146) reported past-year PME and 0.7% 
(n·=·69) reported past-year PCE with or without PME.  
The characteristics of the study sample used in the analysis of the two different types of 
past-year PNE are depicted in Table 1. All variables except past-year alcohol use were 
univariate predictors of either past-year PCE or past-year PME (Table 6).  
 
Table 6. Characteristics of the study population with and without current PNE (12 months) and the univariate 
multinomial associations of each variable with PME and PCE (reference group: no PNE during the past 12 
months [no current PNE]) 
No current PNE PME, 12 months PCE, 12 months 
n = 9,956 n = 146 OR (95%CI) n = 69 OR (95%CI) 
Sex  
Male (Ref.) 98.2% (5,335) 1.0% (56) 0.8% (42) 
Female 97.5% (4,621) 1.9% (90) 1.86 (1.33-2.60)** 0.6% (27) 0.74 (0.46-1.21) 
Age in years  
15-24 (Ref.) 96.7% (1,814) 1.8% (33) 1.6% (30) 
25-34  98.1% (2,104) 1.2% (25) 0.66 (0.39-1.12) 0.7% (15) 0.42 (0.23-0.79)** 
35-44  98.0% (2,206) 1.6% (37) 0.92 (0.57-1.47) 0.4% (8) 0.22 (0.10-0.48)** 
45-54  98.2% (2,377) 1.4% (34) 0.79 (0.49-1.28) 0.4% (9) 0.24 (0.12-0.50)** 
55-74  98.4% (1,454) 1.1% (17) 0.64 (0.35-1.15) 0.5% (7) 0.30 (0.13-0.68)** 
Professional 
activity  
Student (Ref.) 96.1% (1,321) 1.8% (25) 2.1% (28) 
Full-time work  
≥ 90% 98.4% (5,456) 1.2% (67) 0.64 (0.41-1.02) 0.4% (21) 0.18 (0.10-0.31)** 
Part-time work  
< 90% 97.7% (3,169) 1.7% (54) 0.90 (0.56-1.45) 0.6% (19) 0.28 (0.16-0.50)** 
Relationship      
None / 
temporary 
(Ref.) 97.0% (2,703) 2.2% (62)  0.8% (23)  
Stable 98.2% (7,252) 1.1% (85) 0.51 (0.37-0.71)** 0.6% (46) 0.75 (0.46-1.25) 
Children in the 
household      
None (Ref.) 97.5% (6,371) 1.6% (105)  0.9% (58)  
At least one 
<18 years old  98.6% (3,585) 1.1% (41) 0.69 (0.48-1.00)* 0.3% (11) 0.32 (0.17-0.62)** 
Drug use past 
12 months      
No tobacco 
(Ref.) 98.4% (6,799) 1.1% (78)  0.4% (30)  
Tobacco 96.7% (3,157) 2.1% (68) 1.89 (1.36-2.62)** 1.2% (39) 2.77 (1.71-4.47)** 
No alcohol 
(Ref.) 97.7% (966) 1.4% (13)  0.9% (9)  
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Alcohol 97.9% (8,990) 1.4% (133) 1.07 (0.61-1.88) 0.6% (59) 0.69 (0.34-1.38) 
No cannabis 
(Ref.) 98.3% (9,248) 1.2% (114)  0.5% (47)  
Cannabis 92.9% (708) 4.2% (32) 3.68 (2.47-5.48)** 2.9% (22) 6.12 (3.66-10.21)** 
No other 
illegal drugs 
(Ref.) 98.0% (9,848) 1.4% (142)  0.5% (54)  
Other illegal 
drugs a 85.1% (108) 3.3% (4) 2.69 (1.00-7.25)** 11.6% (15) 24.84 (13.53-45.60)** 
Stress       
Not long-term 
(Ref.) 99.2% (5,049) 0.5% (26)  0.3% (16)  
Long-term  96.6% (4,907) 2.4% (120) 4.81 (3.14-7.37)** 1.0% (53) 3.45 (1.97-6.06)** 
Frequency 12 
months              
scale 1-5 3.2 (0.9) 4.1 (0.9) 2.89 (2.38-3.51)** 3.9 (1.0) 2.12 (1.63-2.76)** 
Time pressure   
scale 1-6 3.2 (1.2) 3.6 (1.2) 1.30 (1.14-1.48)** 3.5 (1.2) 1.21 (1.00-1.46)* 
Negative 
aspects scale 
1-5 2.4 (0.6) 2.7 (0.7) 2.16 (1.70-2.73)** 2.6 (0.7) 1.90 (1.34-2.69)** 
Self-efficacy        
scale 10-40 30.0 (4.1) 27.0 (0.7) 0.86 (0.83-0.89)** 28.1 (5.9) 0.90 (0.86-0.95)** 
Perceived health  
scale 1-5 3.5 (0.8) 2.8 (0.9) 0.33 (0.27-0.41)** 3.0 (0.9) 0.45 (0.33-0.61)** 
Current medical 
treatment for a 
mental disorder b      
No 98.9% (9,665) 0.7% (65)  0.4% (39)  
Yes 72.4% (291) 20.3% (81) 41.71 (29.49-58.99)** 7.4% (30) 25.06 (15.33-40.96)** 
Note. Data are % (n) or mean (SD). PCE = pharmacological cognitive enhancement; PME = pharmacological 
mood enhancement; PNE = pharmacological neuroenhancement.  
a Cocaine, ecstasy (MDMA), amphetamines (speed), ketamine, GHB/GBL 
b ADHD, narcolepsy, depression, anxiety disorder, dependency 
* p < 0.05; **p < 0.01 
 
Results from models 1 – 3 are depicted in Table 7. The demographic predictors (model 1) 
explained 14% of the variance (Nagelkerke’s R2). The moderate self-medication model, 
which included demographics, stress, and self-efficacy (model 2) explained 19% of the 
variance. Frequent stress in the past 12 months and long-term stress at work or in education 
were good predictors of PCE and PME, but time pressure at work and negative stressors at 
work were excluded from the model. Self-efficacy predicted past-year PME. Finally, the 
serious self-medication model which included both the demographic predictors and current 
medical treatment for a mental health problem (model 3) explained 30%. 
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Table 7. Multiple prediction models for two different purposes of PNE in the past 12 months (reference group: 
no PNE in the past 12 months) 
 
The overall prediction model resulting from the multinomial logistic regression (R2 = .33) 
is presented in Table 8. Current medical treatment was the strongest predictor of both PCE 
and PME. Past-year cannabis use and frequent and long-term stress were also predictors of 
PME, 12 months 
n = 146, OR (95%CI) 
PCE, 12months  
n = 69, OR (95%CI) 
Model 1 (socio-demographic data) 
Sex 
Male (Ref.) 
Female 1.69 (1.17-2.45)** 0.52 (0.30-0.89)* 
Professional activity 
Student (Ref.) 
Full-time work  
≥ 90% 1.15 (0.67-1.97) 0.37 (0.19-0.71)** 
Part-time work  
< 90% 0.99 (0.59-1.64) 0.14 (0.07-0.27)** 
Relationship   
None/temporary (Ref.)   
Stable 0.61 (0.42-0.87)** 1.99 (1.12-3.54)* 
Children in the household   
None (Ref.)   
At least one <18 years old  0.91 (0.61-1.34) 0.41 (0.20-0.83)* 
Drug use past 12 months   
No cannabis (Ref.)   
Cannabis  3.54 (2.28-5.49)** 1.94 (1.02-3.70)* 
No other illegal drugs (Ref.)   
Other illegal drugs a 1.14 (0.40-3.24) 15.47 (7.26-33.00)** 
Perceived health scale 1-5 0.34 (0.28-0.43)** 0.42 (0.31-0.58)** 
Model 2 (moderate self-medication)   
Socio-demographic data (model 1)   
Stress    
Not long-term (Ref.)   
Long-term 2.00 (1.24-3.19)** 1.98 (1.04-3.76)* 
Frequency 12 months, scale 1-5 1.81 (1.45-2.27)** 1.54 (1.13-2.11)** 
Self-efficacy, scale 10-40 0.92 (0.88-0.95)** 0.96 (0.90-1.02) 
Model 3 (serious self-medication)   
Socio-demographic data (model 1)   
Current medical treatment for a mental disorder b   
No   
Yes 32.77 (22.20-48.38)** 24.91 (13.76-45.09)** 
Note. N = 10,171. Model 1: R2 = .03 (Cox & Snell), .14 (Nagelkerke). Model χ2 (16) = 296.898, p < .001; 
Model·2: R2 = .04 (Cox & Snell), .19 (Nagelkerke). Model χ2 (22) = 409.561, p < .001; Model 3: R2 = .06 (Cox 
& Snell), .30 (Nagelkerke). Model χ2 (18) = 656.208, p < .001; PCE = pharmacological cognitive enhancement; 
PME = pharmacological mood enhancement. 
a Cocaine, ecstasy (MDMA), amphetamines (speed), ketamine, GHB/GBL 
b ADHD, narcolepsy, depression, anxiety disorder, dependency 
* p < 0.05; **p < 0.01 
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both PCE and PME. The past-year use of other illegal drugs, being male, being a student, 
being in a relationship, and living without minor children at home were predictors of PCE. 
Being female and having low self-efficacy were predictors of PME. 
 
Table 8. Overall multiple prediction model for two different purposes of PNE in the past 12 months (reference 
group: no PNE in the past 12 months) 
PME, 12 months 
 n = 146, OR (95%CI) 
PCE, 12 months 
n = 69, OR (95%CI) 
Sex 
Male (Ref.) 
Female 1.58 (1.06-2.36)* 0.51 (0.29-0.89)* 
Professional activity 
Student (Ref.) 
Full-time work  
≥ 90% 1.17 (0.68-2.01) 0.16 (0.08-0.32)** 
Part-time work  
< 90% 0.95 (0.53-1.71) 0.28 (0.13-0.57)** 
Relationship   
None/temporary (Ref.)   
Stable 0.71 (0.47-1.05) 2.30 (1.26-4.17)** 
Children in the household   
None (Ref.)   
At least one <18 years old 0.89 (0.58-1.36) 0.38 (0.19-0.78)** 
Drug use 12 months   
No cannabis (Ref.)   
Cannabis  4.73 (2.89-7.23)** 2.86 (1.48-5.52)** 
No other illegal drugs (Ref.)   
Other illegal drugs a 1.01 (0.33-3.12) 11.99 (5.48-26.22)** 
Stress    
Not long-term (Ref.)   
Long-term 2.03 (1.24-3.31)** 2.12 (1.10-4.07)* 
Frequency 12 months, scale 1-5 1.61 (1.28-2.02)** 1.43 (1.06-1.94)* 
Self-efficacy, scale 10-40 0.93 (0.90-0.97)** 0.98 (0.93-1.04) 
Current medical treatment for a mental disorder b   
No   
Yes 27.64 (18.78-40.68)** 23.17 (12.91-41.58)** 
Note. N = 10,171. R2 = .07 (Cox & Snell), .33 (Nagelkerke). Model χ2 (22) = 708.669, p < .001; PCE = 
pharmacological cognitive enhancement; PME = pharmacological mood enhancement; PNE = pharmacological 
neuroenhancement. 
a Cocaine, ecstasy (MDMA), amphetamines (speed), ketamine, GHB/GBL 
b ADHD, narcolepsy, depression, anxiety disorder, dependency 
* p < 0.05; **p < 0.01 
 
Table 9 presents the prevalence of each surveyed mental disorder for non-users, PCE 
users, and PME users. The majority of the PME users reported being diagnosed with 
depression, and half of them reported undergoing current medical treatment for their disorder. 
  71 Self-Medication 
Only a small number of the participants with a mental disorder reported that they had ever 
misused their medication for a purpose other than that for which it was prescribed. 
 
Table 9. Lifetime prevalence of specified mental disorders and associated medical treatment and medication 
misuse across study groups 
No current PNE 
n = 9,956 
PME, 12 months 
n = 146 
PCE, 12 months 
n = 69 
Depression  
Lifetime diagnosis 12.0% (1,194) 72.2% (106) 55.1% (38) 
Received medical treatment 8.0% (796) 70.4% (103) 44.4% (31) 
Current medical treatment 2.2% (221) 51.9% (76) 29.6% (20) 
Ever misused 0.3% (33) 6.2% (9) 10.9% (7) 
ADHD    
Lifetime diagnosis 1.7% (174) 6.0% (9) 28.6% (20) 
Received medical treatment 0.6% (62) 2.6% (4) 19.1% (13) 
Current medical treatment 0.2% (22) 0 15.9% (11) 
Ever misused 0.1% (7) 0.9% (1) 4.4% (3) 
Anxiety disorder    
Lifetime diagnosis 8.3% (822) 42.7% (62) 24.4% (17) 
Received medical treatment 3.4% (338) 31.8% (46) 9.7% (7) 
Current medical treatment 0.8% (82) 20.7% (30) 6.9% (5) 
Ever misused 0.2% (17) 5.3% (8) 2.9% (2) 
Substance use disorder    
Lifetime diagnosis 3.7% (372) 8.3% (12) 19.8% (14) 
Received medical treatment 0.4% (36) 4.0% (6) 5.6% (4) 
Current medical treatment 0.1% (9) 0.8% (1) 1.6% (1) 
Ever misused 0.1% (7) 0.8% (1) 2.9% (2) 
Narcolepsy    
Lifetime diagnosis 1.0% (100) 4.0% (6) 5.2% (4) 
Received medical treatment 0.3% (34) 1.9% (3) 5.2% (4) 
Current medical treatment 0.1% (10) 0.6% (1) 2.0% (1) 
Ever misused 0.03% (3) 0.7% (1) 0 
Note. PCE = pharmacological cognitive enhancement. PME = pharmacological mood enhancement; PNE = 
pharmacological neuroenhancement. 
3.5 Discussion 
This study aimed to identify the predictors of PCE and PME separately to determine 
different user groups using two explanation models that focused on self-medication. The first 
moderate self-medication hypothesis stating that frequent and long-term stress predicts PCE 
and PME was confirmed.  
Consistent with previous studies, the present findings support the second moderate self-
medication hypothesis: that PCE and PME are associated with illegal drug use (Arria et al., 
2008; McCabe et al., 2005). Cannabis users were three times more likely to report PCE and 
five times more likely to report PME. A recent longitudinal study showed the strong link 
between cannabis use and mood disorders and suggested that cannabis was used as self-
medication, similar to the definition of PME in the present study (Feingold, Weiser, Rehm, & 
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Lev-Ran, 2014). The use of illegal drugs other than cannabis was positively associated with 
PCE but not with PME. This finding might be explained by the presence of male participants 
with high levels of sensation seeking in the group (Rabiner et al., 2009a). Additionally, it 
seems reasonable that individuals with a history of illegal drug use are less afraid of the 
unknown effects and side effects of the PCE use because they have learned to deal with the 
uncertainty regarding effects and side effects. 
Furthermore, the serious self-medication hypothesis was confirmed in the analysis, and 
current medical treatment for a mental disorder, particularly depression and/or an anxiety 
disorder, was the strongest predictor of both PCE and PME. However, misuse of the treatment 
medication among patients was rare, and they used illicit substances for PCE or PME in 
addition to the existing medications to cope with stress and other psychological consequences 
of their disorders. Medical treatment might be perceived as helpful and effective for coping 
with the symptoms of the underlying disorder. Hence, the patients might have learned that 
drugs influence their health outcomes in a positive way, consequently engaging in serious 
self-medication to enhance their performance at work or while studying. 
The fourth hypothesis, that time pressure and work-related negative stressors would 
increase the likelihood of PCE, was rejected. Surprisingly, no direct link was found between 
current work- or study-related environmental stressors and PCE. These stressors seemed 
manageable and were not predictors of PCE and PME, whereas frequent and long-term stress 
and mental health impairments were more likely to predict PCE and PME. 
The present findings supported the most specific hypothesis: that low self-efficacy would 
predict PME. Being female and having low self-efficacy were predictors of PME.  
The present findings are in line with Lazarus' (1989) stress theory; PCE and PME are 
suggested to be stress management strategies for coping with high levels of stress. In line with 
previous research, insufficient coping is assumed to be associated with mental health 
problems despite or as a consequence of moderate self-medication in healthy individuals 
(Mohr et al., 2014). Moreover, the fact that PCE and PME were frequently used as serious 
self-medication in addition to current medical treatment provides a new perspective on the 
biomedical ethics debate about PNE. In particular, inequality concerns and questions about 
the possible exacerbation of existing socio-economic inequalities have been raised (Maslen et 
al., 2014). However, what if people with a mental disorder engage in PNE to reduce the stress 
and symptoms associated with their disorder and thus enable themselves to perform at a level 
equal to that of their healthy counterparts? Earp and colleagues (2014) argued that 
diminishment is a form of enhancement. Therefore, diminishing the symptoms of a mental 
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disorder or diminishing the side effects of prescribed medication is classified as PNE serious 
self-medication unless it is recommended by a physician. Inevitably, normative questions 
would need to be used to define a cut-off point on the continuum between health and disease. 
However, such a cut-off point does not exist and would not be able to sufficiently take into 
consideration cultural differences in the concept of health and illness across and even within 
countries (Laungani, 2007). The discussions about specifically designed legal provisions to 
treat PNE are unreasonable given the absence of this clear cut-off point, the individual 
differences in responses to psychoactive substances (de Jongh et al., 2008), and the fact that 
people might obtain the desired prescription or other illegal drug from physicians or friends or 
via the Internet. However, past-year PCE and PME were rare among our sample, and the 
attempt to gain an advantage against competitors is assumed to be of secondary importance in 
the decision to engage in PNE. Maslen et al.'s (2014) proposed solution of an unambiguous 
differentiation between treatment and enhancement cannot solve the issue of self-medication 
with PCE and PME among the two groups. If the bioethical debate is to be moved forward, a 
better understanding of the strong link between mental health and the non-competitive 
interests of PCE and PME users needs to be developed. 
The few healthy PCE users who were identified showed self-efficacy scale values that 
were similar to or even higher than those of non-users. For those users, PCE seems to be a 
lifestyle choice, as Racine and Forlini suggest (2008). PCE users appear to be conscious of 
their abilities and, in line with the drug instrumentalization theory (Wolff & Brand, 2013), 
they use the desirable functionalities of psychoactive substances as an additional resource.  
Returning to the hypothesis that was posed at the beginning of the study, the findings 
revealed that both PCE and PME were associated with stress. An unanticipated finding was 
that time pressure and negative work aspects were not predictors of PCE and PME in the 
overall model. Only long-term stress and frequent stress predicted PCE and PME. 
Furthermore, the high prevalence of past-year cannabis use in the PCE and PME users 
demonstrated that such drug use is likely to be their stress management strategy and a form of 
moderate self-medication. 
3.5.1 Strengths, limitations, and implications for research and policy 
First, this study is one of the largest studies of pharmacological neuroenhancement, and 
the weighting procedures used ensured that the results were representative of the Swiss 
population. Second, participants with a current or past diagnosis of a mental disorder were 
included in the study, whereas many previous studies only focused on healthy individuals 
(Barrett et al., 2008). The important mechanism of self-medication in both healthy and 
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disadvantaged PCE and PME users was unique and progressive. Given that the healthy PCE 
users in most previous studies were almost all students, the present investigation was the first 
to consider deficits in PME users in the general population. Thus, this study is relevant to 
public health. 
The main limitation of the current study is its cross-sectional design, which did not allow 
the causal associations between the predictors to be conclusively examined. However, the 
self-medication hypothesis was supported, which allowed the interpretation of the findings. A 
further limitation is that the PCE users and the participants who reported both PCE and PME 
were modeled within one single group to increase the statistical power and strengthen the 
prediction models. However, the PCE group is the most commonly studied group (Maier & 
Schaub, in press; Maslen et al., 2014); therefore, this grouping seems acceptable. The present 
study assessed stress at work and in education as possible predictors of PNE. Because of the 
length of the questionnaire, only single items (no validated scales) were used to assess stress 
to prevent participant dropouts. Retrospectively, the inclusion of at least one validated stress 
scale may have increased the predictive power of the overall model.  
The understanding of PCE and PME as self-medication and as functional means of 
achieving certain ends related to performance or health, as Wolff et al. (2014) suggest, has 
important implications for future research and policy. The findings of the present study 
indicate a large gap between healthy, self-confident PNE users experiencing temporary stress 
and unconfident, disadvantaged PNE users with consistently low self-efficacy and high stress. 
Consistent with previous Swiss studies of PNE, only a small number of healthy people who 
reported PNE and recreational drug use as a lifestyle choice were found (Maier et al., 2013). 
Thus, future research should focus on complex problems in disadvantaged individuals (e.g., 
those with low self-efficacy, insufficient coping strategies, or mental disorders) who self-
medicate without or beyond an indicated prescription. A careful diagnosis of mental health 
disorders, dialogue about treatment options, and the investigation of social pressure to 
perform (e.g., in accordance with the perceived averages of healthy colleagues) could prevent 
PCE and PME among patients. The communication of risks and medication interactions is 
strongly recommended to achieve beneficial treatment outcomes regarding the absence of 
additional serious self-medication. 
3.5.2 Conclusions 
Various predictor variables for PCE and PME were identified in this study. Consideration 
of these variables may help identifying potential PCE and PME users for whom measures to 
prevent drug abuse and manage stress are most appropriate. Furthermore, causal theories 
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concerning engagement in PCE and PME might be examined in longitudinal studies taking 
into account the identified predictors. Especially serious self-medication but also moderate 
self-medication seem to be suitable candidates for disentangling causal explanations for 
engagement in PCE and PME and thus advancing the neuroenhancement debate. 
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4.1 Abstract 
Background The ongoing bioethical debate on pharmacological cognitive enhancement 
(PCE) in healthy individuals is often legitimated by the assumption that PCE will widely 
spread and become desirable for the general public in the near future. This assumption was 
questioned as PCE is not equally save and effective in everyone. Additionally, it was 
supposed that the willingness to use PCE is strongly personality-dependent likely preventing 
an epidemic distribution of PCE. Thus, we investigated whether the cognitive performance 
and personality of healthy individuals with regular nonmedical methylphenidate (MPH) use 
for PCE differ from stimulant-naïve controls. 
 
Methods Twenty-five healthy individuals using MPH for PCE were compared with 39 age-, 
sex-, and education-matched healthy controls regarding cognitive performance and 
personality assessed by a comprehensive neuropsychological test battery including social 
cognition, prosocial behavior, decision-making, impulsivity, and personality questionnaires. 
Substance use was assessed through self-report and quantitative hair and urine analyses. 
 
Findings Recently abstinent PCE users showed no cognitive impairment but superior 
strategic thinking and decision-making. Furthermore, PCE users displayed higher levels of 
self-reported impulsivity, novelty seeking, and Machiavellianism combined with lower levels 
of social reward dependence and cognitive empathy. Finally, PCE users reported a smaller 
social network and exhibited less prosocial behavior in social interaction tasks. 
 
Interpretation The assumption that PCE use will become epidemic soon is not supported by 
the present findings as PCE users showed a specific personality profile sharing a number of 
features with recreational stimulant users. Moreover, regular MPH use for PCE is not 
necessarily associated with worse cognitive functions.  
 
Funding Swiss National Science Foundation (grants PP00P1-123516/1, PP00P1-146326/1) 
 
  
  79 Personality & Cognition 
4.2 Introduction  
Prescription stimulants such as methylphenidate (MPH) are controversially discussed as 
potential drugs for pharmacological cognitive enhancement (PCE) in healthy individuals 
(Bostrom & Sandberg, 2009; Farah et al., 2004; Greely et al., 2008; McCabe et al., 2005; K. 
Morris, 2008). The increase of MPH prescriptions in the past two decades was supposed to 
coincide with an increased nonmedical use of MPH for PCE and relatively high prevalence 
rates of PCE among college students seemed to confirm the prediction (Bogle & Smith, 2009; 
McCabe et al., 2014). However, many studies failed to clearly define “nonmedical use” and 
considered different substances for PCE impeding the interpretation of the results (Maier & 
Schaub, 2015). Nevertheless, PCE is much more prevalent in the United States compared to 
Europe (Maier & Schaub, 2015), but in both regions, MPH is the most frequently misused 
prescription drug for PCE (Maier et al., 2013; McCabe et al., 2005).  
MPH elevates the neurotransmission of dopamine and noradrenalin by reuptake inhibition 
at the respective monoamine transporters, and was proposed to influence executive functions 
and working memory in healthy individuals (Repantis, 2013; Wood et al., 2014). However, 
potential benefits and risks of PCE are both modulated by individual differences in response 
to drugs further depending on drug dose and task requirements. Consequently, procognitive 
effects of MPH are baseline-dependent (e.g., amelioration at low and impairment at high 
baseline performance) and afflicted with several trade-offs (e.g., improvement in one 
cognitive domain with the cost of impairments in other cognitive domains) as well as 
psychiatric side-effects (Husain & Mehta, 2011; Quednow, 2010; Repantis, 2013; van der 
Schaaf et al., 2013; Wood et al., 2014). 
The use of MPH for the treatment of ADHD is well-established and the potential side-
effects are justified by the proven effectiveness (Rubia et al., 2013). However, this does not 
reclaim the use by healthy individuals without cognitive deficits. So far, it is unclear whether 
regular MPH use for PCE in healthy individuals is related to negative long-term cognitive, 
psychopathological, and neurobiological consequences (Quednow, 2010; Wood et al., 2014). 
Nonetheless, previous studies found a higher prevalence of PCE among students with lower 
grades (Franke et al., 2011; McCabe et al., 2005; Rabiner et al., 2009a). In general, the misuse 
of prescription stimulants might be associated with neuropsychological deficits prior to or as a 
consequence of PCE. Reske and colleagues (2011) found that occasional prescription 
stimulant users showed enhanced verbal fluency but, at the same time, more deficits in verbal 
learning, memory, and cognitive flexibility compared to stimulant-naïve controls. Therefore, 
they suggested that pre-existing cognitive deficits and subtle executive dysfunctions might be 
 80 Chapter 4 
predictors for stimulant use (Reske et al., 2011; Reske, Eidt, Delis, & Paulus, 2010). On the 
other hand, PCE itself might cause drug induced cognitive impairments as shown in a recent 
longitudinal study with recreational cocaine users (Vonmoos et al., 2014). Accordingly, the 
use of MPH might affect neuroplasticity and may, therefore, alter cognitive function, 
behavior, and personality of users (Nyberg, 2014). 
Like amphetamine, MPH is a phenylethylamine derivate but shares the mechanism of 
catecholamine reuptake inhibition with cocaine (Wood et al., 2014). The Zurich Cocaine 
Cognition Study (ZuCo2St) revealed that not only dependent but also recreational cocaine 
users showed significant deficits in the cognitive domains of attention, working and long-term 
memory, and executive functions (Vonmoos, Hulka, Preller, Jenni, Baumgartner, et al., 2013). 
Cocaine users also revealed higher levels of self-reported impulsivity and novelty seeking and 
more ADHD symptoms in general compared to stimulant-naïve controls (Vonmoos, Hulka, 
Preller, Jenni, Baumgartner, et al., 2013; Vonmoos, Hulka, Preller, Jenni, Schulz, et al., 
2013). Moreover, cocaine use was associated with reduced neural sensitivity to social reward 
potentially explaining the users’ deficits in social interactions such as less emotional empathy 
and a smaller social network (Hulka et al., 2014; Preller, Hulka, et al., 2014). Studies 
considering the nonmedical use of MPH in healthy individuals have only addressed acute 
MPH effects on social cognition and behavior (Hysek et al., 2014; Schmid et al., 2014), while 
the effects of chronic MPH use on social behavior are unknown so far.  
The bioethical debate on neuroenhancement is based on the assumption that the use of 
putatively neuroenhancing stimulants already appears to be highly popular and that PCE use 
will further spread in the future. However, these assumptions have been recently disputed 
(Quednow, 2010; Schleim & Quednow, 2015). One argument against a future epidemic of 
PCE is that not everyone is equally interested in cognitive enhancement (Sattler et al., 2014) 
assuming that personality has an essential impact on the willingness to use PCE (Quednow, 
2010). Surprisingly, the influence of personality on the preference of PCE has scarcely been 
investigated yet but Quednow (2010) proposed that in particular narcissistic and ambitious 
people might be more interested in PCE. Preliminary data recently suggested that PCE is 
positively associated with ADHD symptoms, sensation seeking, and impulsivity (Rabiner et 
al., 2009a; Weyandt et al., 2009). As the research on the so-called “dark triad” of personality 
traits revealed that subclinical narcissism is closely related to Machiavellianism and 
subclinical psychopathy (Rauthmann & Kolar, 2012), manipulative, opportunistic, and 
antisocial behaviors might be potential personality features of PCE users as well. 
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The primary goal of the present study was therefore a broad characterization of recently 
abstinent PCE users regarding their cognitive, behavioral, and personality profile. Based on 
previous studies showing a higher prevalence of PCE in students with lower grades (Franke et 
al., 2011; McCabe et al., 2005; Rabiner et al., 2009a) and demonstrating cognitive impairment 
in cocaine and other stimulant drug users (Reske et al., 2011, 2010; Vonmoos et al., 2014; 
Vonmoos, Hulka, Preller, Jenni, Baumgartner, et al., 2013), we hypothesized that MPH 
misuse for PCE is associated with lower cognitive performance. Moreover, in PCE users we 
expected an increase in psychopathological loads and a specific personality structure, which is 
similar to recreational stimulant users (Hulka et al., 2014; Preller, Herdener, et al., 2014; 
Vonmoos, Hulka, Preller, Jenni, Schulz, et al., 2013). Specifically, we expected that PCE 
users show more pronounced narcissistic, opportunistic, Machiavellian, and impulsive facets, 
and less prominent sociable and prosocial behaviors. 
4.3 Methods 
4.3.1 Participants 
Participants were recruited through flyer advertisements at the University of Zurich and 
the Swiss Federal Institute of Technology in Zurich, internet advertisement, and via email 
(study participants from an earlier study on PCE had consented to be contacted again; Maier 
et al., 2013). All participants had to pass an initial telephone screening to assess basic 
eligibility before they were invited for the assessment at the Psychiatric Hospital of the 
University of Zurich. Recently abstinent PCE users had to meet the following inclusion 
criteria: regular MPH use explicitly for PCE during the past 6 months and lifetime use of 
MPH for PCE on at least 25 occasions. Further inclusion criteria for all participants were 20 
to 50 years of age and sufficient knowledge of German language. Exclusion criteria for all 
participants implied the following conditions: 1) severe medical condition, 2) present or prior 
axis-I psychiatric disorder according to DSM-IV, 3) lifetime history of a neurological 
disorder, 4) lifetime history of heroin use, 5) daily use of cannabis, 6) regular use of 
prescription drugs with effects on the central nervous system, and 7) use of other illegal drugs 
not mentioned before on more than 50 occasions. Prior to the testing session, participants had 
to abstain from MPH and illegal drugs for at least 72 hours and from alcohol for 24 hours. 
Adherence with these instructions was assessed by urine testing as described before 
(Vonmoos, Hulka, Preller, Jenni, Baumgartner, et al., 2013). The study was approved by the 
Cantonal Ethics Committee of Zurich. All study participants provided informed consent after 
being fully informed about the study details.  
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4.3.2 Drug use  
Current and past use of illegal substances and prescription drugs was assessed by a 
standardized Interview for Psychotropic Drug Consumption considering the date of last use, 
average quantity (mg, g, tablets, etc.) used weekly, and total lifetime duration of use 
(Quednow, Kühn, Hoenig, Maier, & Wagner, 2004). Moreover, urine and hair testing 
revealed objective quantitative results about recent and past drug use. Urine samples were 
analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) regarding MPH 
and ritalinic acid (Supplementary Methods S1) and by a semi-quantitative enzyme multiplied 
immunoassay method using a Dimension RXL Max (Siemens, Erlangen, Germany) for all 
other drugs (Vonmoos, Hulka, Preller, Jenni, Baumgartner, et al., 2013). MPH and illegal 
drug use during the past 6 months was assessed by 6-cm hair samples analyzed by LC-
MS/MS as described in detail elsewhere (Supplementary Methods S2; Vonmoos, Hulka, 
Preller, Jenni, Baumgartner, et al., 2013). 
4.3.3 Cognition 
For matching reasons, premorbid verbal intelligence was assessed by the Multiple-Choice 
Vocabulary Test (MWT-B). The following classical neuropsychological tests were used to 
assess cognition: four tests of the Cambridge Neuropsychological Test Automated Battery 
(CANTAB) were used to test sustained attention (Rapid Visual Processing, RVP), visuo-
spatial memory (Paired Associates Learning, PAL), Spatial Working Memory (SWM), and 
Intra-Extra-Dimensional Set-Shifting (IED); the Letter-Number-Sequencing Task (LNST) 
was used to test verbal working memory; and the Rey Auditory Verbal Learning Test 
(RAVLT) was applied to test declarative verbal memory functions. Similar to our previous 
studies with cocaine users, four main z-scored cognitive domains (attention, working 
memory, declarative memory, executive functions) were defined and equally integrated in a 
global cognitive index (GCI, for details see Supplementary Methods S3; Vonmoos et al., 
2014; Vonmoos, Hulka, Preller, Jenni, Baumgartner, et al., 2013). Furthermore, the Iowa 
Gambling Task (IGT) was used to measure decision-making. Points gained in the IGT were 
converted into Swiss Francs and disbursed to the participants. 
4.3.4 Social cognition, interaction, and function 
Social cognitive functions such as cognitive and emotional empathy as well as theory-of-
mind (ToM) were assessed with the Multifaceted Empathy Test (MET) and with the Movie 
for the Assessment of Social Cognition (MASC), respectively. Moreover, the Distribution 
Game and the Dictator Game tested social decision-making in an interaction paradigm, while 
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the Social Network Questionnaire (SNQ) provided the number of currently available social 
contacts. Points gained in both interactive games were converted into Swiss Francs and 
disbursed to the participants. All tests have been described in detail before (Hulka et al., 2014; 
Preller, Hulka, et al., 2014).  
4.3.5 Personality and psychiatric symptoms 
Psychiatric symptoms and personality disorders were assessed using the ADHD Self-
Rating scale (ADHS-SR), the Structured Clinical Interview for DSM-IV Axis I (SCID-I 
Interview) and Axis II (SCID-II Questionnaire), and the Beck Depression Inventory (BDI). 
The Barratt Impulsiveness Scale (BIS-11), the Temperament Character Inventory (TCI), and 
the Machiavellianism questionnaire (MACH-IV) were included to assess personality. 
Additionally, the Delay Discounting task (DD) was used to assess delay of 
gratification/reward impulsivity (references to the neuropsychological tasks and all 
questionnaires are given in the Supplementary Table S3). 
4.3.6 Statistical analysis 
PCE users were matched with stimulant-naïve controls on the following variables: age, 
sex, years of education, proportion of students, verbal intelligence, and proportion of smokers. 
Quantitative data were analyzed by independent t-tests in order to compare PCE users with 
controls. For qualitative data, Chi2-tests were applied. Person’s product moment correlations 
were used to evaluate the association between MPH use, cognitive performance, and 
personality scores and to explore intercorrelations between variables with significant group 
differences. All statistical analyses were conducted using SPSS Statistics 22 (Dynelytics, 
Zurich, Switzerland). For group comparisons, p<0·050 was set as the significance level, while 
for correlation analyses the significance threshold was set at p<0·010 in order to avoid an 
accumulation of alpha-error. 
4.3.7 Role of the funding source 
The founder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author has full access to all the data 
in the study and had final responsibility for the decision to submit for publication. 
4.4 Results 
94 PCE users showed interest in study participation, but only 25 regular PCE users met 
the inclusion criteria (Figure 3) and were matched with 39 stimulant-naïve controls.  
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Figure 3. Trial profile.  
ADHD: Attention Deficit Hyperactivity Disorder, ADHD-SR: Attention Deficit Hyperactivity Disorder Self-
Rating scale, BIS-11: Barratt Impulsiveness Scale-11, CANTAB: Cambridge Neuropsychological Test 
Automated Battery, DD: Delay Discounting task, IDPC: standardized Interview for Psychotropic Drug 
Consumption (self-report), IED: Intra-Extra Dimensional Set-Shifting, IGT: Iowa Gambling Task, LNST: Letter 
Number Sequencing Task, MASC: Movie for the Assessment of Social Cognition, MET: Multifaceted Empathy 
Test, MDMA: 3,4-Methylendioxy-N-methylamphetamin, MPH: methylphenidate, PAL: Paired Associates 
Learning, PCE: pharmacological cognitive enhancement, RAVLT: Rey Auditory Verbal Learning Test, RVP: 
Rapid Visual Information Processing, SCID I/II: Structural Clinical Interview for DSM-IV Axis I/II Disorders, 
SWM: Spatial Working Memory, TCI: Temperament and Character Inventory. 
 
The groups did not differ regarding age, sex, student status, years of education, verbal IQ, 
and smoking status, but PCE users reported significantly more ADHD symptoms than 
controls (Table 10). According to the cut-off of the ADHS-SR questionnaire, five PCE users 
potentially met the DSM-IV criteria for ADHD. 
94 responded to the recruitment and underwent 
the obligatory telephone screening 
7 refused to participate 
55 did not meet inclusion criteria 
40 used MPH on <25 occasions 
3 MPH prescribed (ADHD) 
3 ADHD diagnoses without 
MPH prescription 
3 other psychiatric diagnoses 
2 severe medical conditions 
2 regular illegal drug use 
1 regular prescription drug use 
1 other 
32 completed the study assessment 
- Case report form (demography) 
- Mehrfachwahl-Wortschatz-Intelligenztest 
(MWT-B) 
- Drug use (IPDC; quantitative urine and hair 
testing) 
- Neuropsychological assessment (CANTAB 
RVP/PAL/SWM/IED; LNST; RAVLT) 
- Social cognition (MET, MASC) 
- Social decision-making (Distribution Game; 
Dictator Game ) 
- Decision-making (IGT; DD) 
- Impulsivity (BIS) 
- Personality (TCI) 
- Machiavellianism (MACH IV) 
- Psychopathology (ADHD-SR; SKID-I/II; BDI) 
- Social Network Questionnaire (SNQ) 
7 did not meet inclusion criteria 
3 hair analyses revealed 
regular cocaine use  
3 hair analyses revealed 
regular MDMA use 
1 MPH prescribed for ADHD 
25 regular PCE users (MPH) 
  85 Personality & Cognition 
On average, PCE users reported the intake of MPH for PCE since 2·8 years, used 2·5 
tablets with 10mg MPH per week, have taken 486 MPH tablets in their lifetime, and were 
abstinent from MPH since 41 days (Table 10). Six PCE users featured positive urine testing 
for ritalinic acid (mean 248ng/ml, range 3-1312 ng/ml), while only one PCE user revealed 
small traces of MPH (14 ng/ml). Self-reported weekly MPH use was significantly correlated 
with hair concentrations of MPH over the past 6 months (r = 0·640, p < 0·001, n = 25).  
 
Table 10. Demographic characteristics and drug use of stimulant-naïve healthy controls and individuals using 
methylphenidate for the purpose of pharmacological cognitive enhancement (PCE) 
Controls (n = 39) PCE users (n = 25) X2 / t-test df p-value 
Age 26·2 (5·4) 24·0 (3·0) 1·185 62 0·072 
Women 18 (46%) 11 (44%) 0·029 1 0·866 
Smoking status (yes) 24 (46%) 15 (44%) 0·029 1 0·866 
Student status (yes) 26 (67%) 20 (80%) 1·340 1 0·247 
Years of education 11·6 (1·5) 12·0 (1·0) -1·161 62 0·250 
Verbal IQ (MWT-B) 106·0 (8·6) 104·8 (10·5) 0·507 62 0·614 
ADHD-SR (range 0-18) 7·3 (5·1) 12·9 (8·5) -3·303 62 0·002
BDI sum score 3·5 (4·2) 4·8 (5·2) -1·029 62 0·308 
Methylphenidate  
   
Tablets per week (10mg) 0 2·5 (3·2)    
Years of use 0 2·8 (1·5)    
Cumulative dose (tablets) 0 485·6 (1044·4)    
Last consumption (days) NA 40·5 (52·2), n=24    
Hair analysis (pq/mg) 0 84·2 (199·1)    
Alcohol 
Grams per week 90·6 (77·0) 92·8 (76·0) -0·114 62 0·910 
Years of use 8·0 (5·0) 4·2 (2·7) -1·029 62 0·308 
Tobacco   
Cigarettes per day 5·6 (8·0) 4·8 (6·4) 0·456 62 0·650 
Years of use 5·7 (6·4) 2·9 (3·6) 1·998 62 0·050 
Cannabis 
Grams per week 0·2 (0·7) 0·2 (0·4) 0·570 62 0·571 
Years of use 3·4 (4·1) 2·3 (3·5) 1·120 62 0·267 
Cumulative dose (grams) 965·4 (4423·9) 101·3 (164·0) 0·973 62 0·334 
Last consumptions (days) 740·6 (1735·0), n=24 23·5 (24·3), n=13 1·480 35 0·148 
Positive urine testinga 4 (10%) 2 (8%) a 0·064 1 0·801 
Cocaine 
Grams per week 0 0·1 (0·2) -1·566 62 0·122 
Years of use 0 0·7 (2·2) -2·089 62 0·041 
Cumulative dose (grams) 0·2 (0·9) 15·8 (60·4) -1·620 62 0·110 
Last consumptions (days) 1104·8 (947·9), n=3 319·2 (326·4), n=9 2·290 10 0·045
Positive urine testinga 0 0 
Positive hair testinga 0 1 (4%) 1·585 1 0·280
Amphetamine  
Grams per week 0 0·01 (0·02) -1·718 62 0·091 
Years of use 0 0·4 (1·2) -1·832 62 0·072 
Cumulative dose (grams) 0·003 (0·02) 0·6 (2·4) -1·441 62 0·155 
Last consumptions (days) 547·2 (258·0), n=2 346·4 (724·9), n=6 0·367 6 0·726 
Positive urine testinga 0 1 (4%) 1·651 1 0·199 
Positive hair testinga 0 1 (4%) 1·585 1 0·280
MDMA 
Tablets per week 0 0·04 (0·2) -1·399 62 0·167 
Years of use 0 1·6 (1·7) -5·119 29 0·000 
Cumulative dose (tablets) 0·13 (0·4) 3·4 (9·0) -2·256 62 0·028 
Last consumption (days) 3100·8 (1289·8), n=2 31·3 (26·0), n=3 3·976 6 0·007 
Positive hair testinga 0 2 (8%) 3·221 1 0·073
Data are means and standard deviations, or number and percent. Significant p-values are shown in bold. a For 
cut-offs see Supplementary Methods S1 and S2. ADHD-SR: Attention Deficit Hyperactivity Disorder Self-
Rating scale, BDI: Beck Depression Inventory, IQ: intelligence quotient, MWT-B: Mehrfachwahl-Wortschatz-
Test (vocabulary test), PCE: pharmacological cognitive enhancement. 
 
 86 Chapter 4 
PCE users showed no significant differences in the four cognitive domains and the GCI 
compared to controls (Figure 4).  
 
Figure 4. Mean z-scores and standard errors for the global cognitive index (GCI) and four cognitive domains. 
 
 
However, the executive functions showed a moderate effect size (d=0·44) with regard to a 
superior performance of the PCE users, which was mainly explained by a significantly better 
performance in the strategy subscore of the SWM (Table S4).  
In the IGT, PCE users gained more points in a shorter time (Figure 5), showing better 
performance in the second and in the fourth quartile (Figure S1).  
 
Figure 5. Means and standard errors of points gained and of processing time (sec) in the Iowa Gambling Task 
(IGT). **p < 0·010, and *** p < 0·001. 
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PCE users displayed higher levels of novelty seeking (mainly explained by significantly 
higher disorderliness) and revealed lower scores in social reward dependence (primarily due 
to significantly lower sentimentality) compared to controls. No group differences were found 
for delay discounting, but PCE users showed elevated self-reported impulsivity in the BIS-11 
(specifically in the attention subscores), higher negativistic and antisocial personality traits in 
the SCID-II questionnaire, as well as higher Machiavellianism in the MACH-IV (Table 11).  
 
Table 11. Personality traits of stimulant-naïve healthy controls and individuals using methylphenidate for the 
purpose of pharmacological cognitive enhancement (PCE) 
 
Compared to controls, PCE users reported significantly fewer social contacts and their 
decisions in the social interaction tasks were more self-serving as they preferred higher 
monetary payoffs for themselves (Table 12). When assessing mental perspective-taking 
  Controls (n = 39) PCE users (n = 25) t-test df p-value Cohen's d 
BIS-11 sum score 61·6 (8·4) 66·8 (11·0) -2·145 62 0·036 0·53 
BIS-11 Motor impulsiveness 21·7 (3·1) 23·9 (6·0) -1·941 62 0·057 0·49 
BIS-11 Nonplanning impulsiveness 25·4 (4·2) 26·2 (5·1) -0·690 62 0·493 0·18 
BIS-11 Attentional impulsiveness 14·6 (3·2) 16·8 (4·4) -2·293 62 0·025 0·57 
BIS-11 Attention 9·5 (2·3) 11·1 (2·8) -2·428 62 0·018 0·60 
BIS-11 Cognitive Inflexibility 5·1 (1·7) 14·2 (3·3) -1·284 62 0·204 0·33 
TCI Novelty Seeking 21·8 (5·2) 24·6 (5·9) -2·003 62 0·050 0·50 
TCI Exploratory excitability 7·9 (2·0) 8·3 (2·5) -0·804 62 0·425 0·21 
TCI Impulsiveness 4·3 (2·1) 4·6 (2·2) -0·563 62 0·576 0·14 
TCI Extravagance 5·4 (1·8) 5·9 (1·9) -0·946 62 0·348 0·24 
TCI Disorderliness 4·2 (1·8) 5·8 (1·7) -3·566 62 0·001 0·84 
TCI Harm avoidance 14·3 (5·6) 13·2 (6·9) 0·747 62 0·458 0·19 
TCI Reward Dependence 16·9 (4·0) 14·6 (4·2) 2·182 62 0·033 0·54 
TCI Sentimentality 6·5 (1·8) 5·4 (1·8) 2·299 62 0·025 0·57 
TCI Attachment 6·5 (1·9) 5·5 (2·4) 1·850 62 0·069 0·47 
TCI Dependence 4·0 (1·6) 3·7 (1·6) 0·565 62 0·574 0·15 
TCI Persistence 4·3 (2·1) 3·4 (2·1) 1·681 62 0·098 0·42 
TCI Self-Directedness 33·9 (6·0) 31·2 (6·4) 1·704 62 0·093 0·43 
TCI Cooperativeness 33·5 (5·7) 31·5 (5·0) 1·375 62 0·174 0·35 
TCI Self-Transcendence 10·2 (5·2) 9·2 (6·6) 0·695 62 0·490 0·18 
SCID-II Avoidant 1·2 (1·4) 0·7 (1·1) 1·526 62 0·132 0·39 
SCID-II Dependent 1·2 (1·1) 1·2 (1·0) -0·035 62 0·973 0·01 
SCID-II Obsessive-compulsive 3·5 (1·8) 3·6 (1·6) -0·256 62 0·799 0·07 
SCID-II Negativistic 1·2 (1·4) 2·0 (1·4) -2·486 62 0·016 0·61 
SCID-II Depressive 1·1 (1·6) 1·4 (1·7) -0·559 62 0·578 0·14 
SCID-II Paranoid 1·6 (1·8) 1·8 (1·9) -0·359 62 0·721 0·09 
SCID-II Schizotypal 1·3 (1·6) 1·1 (1·0) 0·628 62 0·532 0·16 
SCID-II Schizoid 0·7 (1·1) 1·2 (1·3) -1·699 62 0·094 0·43 
SCID-II Histrionic 1·9 (1·5) 2·5 (1·9) -1·343 62 0·184 0·34 
SCID-II Narcissistic 2·4 (2·5) 3·2 (2·3) -1·241 62 0·219 0·32 
SCID-II Borderline 2·4 (2·1) 2·3 (2·0) 0·303 62 0·763 0·08 
SCID-II Antisocial 1·9 (1·6) 3·0 (2·7) -2·011 62 0·049 0·50 
MACH-IV sum score -10·7 (12·2) -3·0 (10·5) -2·561 61 0·013 0·64 
DD k parameter all 0·012 (0·018) 0·022 (0·032) -1·615 62 0·111 0·41 
Data are means and standard deviations. Significant p-values are shown in bold. BIS: Barratt Impulsiveness 
Scale, DD: Delay Discounting task, MACH-IV: Machiavellianism Scale, PCE: pharmacological cognitive 
enhancement, SCID-II: Structural Clinical Interview for DSM-IV Axis-II Disorders, TCI: Temperament and 
Character Inventory. 
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(ToM), PCE users made somewhat fewer errors in the MASC but the difference was not 
significant. Although PCE users revealed a slightly enhanced mental perspective-taking in the 
MASC, they showed, however, significantly lower cognitive empathy in the MET, indicating 
worse emotion recognition from complex picture material (Table 12). 
 
Table 12. Social cognition (MET, MASC) of stimulant-naïve healthy controls and individuals using 
methylphenidate for the purpose of pharmacological cognitive enhancement (PCE) 
 Controls (n = 39) PCE users (n = 25) t-test df p-value Cohen's d 
MET Direct Empathy 5·1 (1·2) 4·7 (1·2) 1·426 62 0·159 0·36 
MET Indirect Empathy 4·8 (1·2) 4·6 (1·3) 0·420 62 0·676 0·11 
MET Cognitive Empathy 25·4 (3·8) 23·0 (4·9) 2·273 62 0·026 0·56 
MASC Total ToM errors 10·2 (4·6) 8·2 (3·2) 1·905 62 0·061 0·48 
SNQ contacts 21·5 (7·3) 17·8 (5·3) 2·213 62 0·031 0·55 
Distribution game, payoff B 19·0 (8·0) 17·0 (9·6) 0·882 62 0·381 0·23 
Dictator game, payoff B 16·6 (12·2) 10·3 (9·4) 2·196 62 0·032 0·55 
Data are means and standard deviations. Significant p-values are shown in bold. MASC: Movie for the 
Assessment of Social Cognition, MET: Multifaceted Empathy Test, SNQ: Social network questionnaire, 
PCE=pharmacological cognitive enhancement, ToM: Theory-of-Mind. 
 
Neither cognitive performance nor personality scales were correlated with any MPH 
consumption parameters, indicating that the shown abnormalities of PCE users are likely not 
drug-induced. Machiavellianism was positively correlated with the TCI novelty seeking 
subscore disorderliness and the SCID-II negativistic score but negatively correlated with TCI 
social reward dependence and its subscore sentimentality. Not surprisingly, the ADHS-SR 
score was highly correlated with several BIS-11 scores but also with the SCID-II negativistic 
score. TCI disorderliness and the SCID-II antisocial score were positively correlated as well 
(Table S5). These correlations reflect overlapping concepts of impulsivity and sociability as 
measured by the different questionnaires. 
4.5 Discussion 
The aim of the study was to investigate whether regular PCE users show impaired 
cognitive functions and a specific pattern of personality traits. The study revealed two main 
findings: 1) recently abstinent PCE users and stimulant-naïve controls performed equally in 
most of the cognitive tasks but PCE users performed better in strategic thinking and decision-
making, and 2) PCE users showed higher impulsivity, novelty seeking, Machiavellianism, and 
more pronounced antisocial and negativistic personality traits, in combination with lower 
social reward dependence compared to controls. In line with this personality pattern, they 
behaved more opportunistic in social interaction tasks, showed less cognitive empathy, and 
reported a smaller social network. Importantly, these results cannot be explained by 
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withdrawal effects as the mean abstinence duration from MPH was 41 days and only one 
subject has shown very small traces of MPH in the urine testing. 
The finding that regular PCE users showed elevated attentional impulsivity but no 
cognitive impairment might give an indication for their motivation to use MPH for PCE. As it 
was shown that only individuals with low baseline performance show cognitive improvements 
under stimulant drugs (de Jongh et al., 2008), it is unlikely that MPH actually improved 
general cognitive functioning of the present PCE users because they already performed very 
well and sometimes better than controls. However, MPH is effective to treat symptoms of 
ADHD such as attentional impulsivity (Wood et al., 2014). In fact, PCE users in the present 
study showed more ADHD symptoms and a previous study found procognitive effects of 
MPH specifically in healthy individuals with high impulsivity (Clatworthy et al., 2009). Thus, 
MPH might improve impulse control of PCE users, helping them to begin and sustain their 
studies, rather than enhancing cognition directly. Consequently, not everyone benefits from 
MPH use and opposite cognitive effects (improvement and impairment) of the same MPH 
dose can even occur in the same individual depending on task requirements (van der Schaaf et 
al., 2013; Wood et al., 2014). As a specific predisposition such as high impulsivity is needed 
to benefit from MPH use and not everyone is willing to use PCE anyway (Sattler et al., 2014), 
a forthcoming epidemic of MPH for PCE is considered unlikely. 
Although the groups did not significantly differ on the SCID-II narcissistic scale as 
initially hypothesized, PCE users showed more negativistic and antisocial personality traits, 
and higher Machiavellianism compared to controls. Interestingly, the SCID-II narcissistic 
subscale was significantly correlated with Machiavellianism (r = 0·38, p < 0.010) and the 
SCID-II negativistic subscale (r = 0·51, p < 0·001), confirming that narcissism, negativism, 
and Machiavellianism show a considerable phenomenological overlap. Thus, PCE users 
showed a specific pattern of personality traits, which has been conceptualized as the “dark 
triad” (Rauthmann & Kolar, 2012). Moreover, with their increased novelty seeking, higher 
impulsivity, and antisocial tendencies, PCE users share a number of personality features with 
recreational stimulant users (Rounsaville, 2004; Vonmoos, Hulka, Preller, Jenni, Schulz, et 
al., 2013). Additionally, PCE users behaved less prosocial in a money distribution game 
similar to recreational and dependent cocaine users as shown recently (Hulka et al., 2014). As 
intensity of cocaine use was not correlated with social decision-making, Hulka et al. (2014) 
suggested that the opportunistic behavior of stimulant users might be a stable trait and 
possibly a predisposition for the initiation of stimulant use. Furthermore, like cocaine users, 
PCE users also displayed a smaller social network than controls (Preller, Hulka, et al., 2014). 
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This might be explained by the fact that PCE users are less sociable (as their personality 
profile suggests) and, thus, less integrated in social networks. Additionally, the smaller social 
network might mirror an intensified cost-benefit thinking of PCE users, and a more strategic 
selection of friends as supported by the present findings in IGT decision-making and strategic 
thinking. 
This is the first study that broadly characterized individuals regularly using MPH for PCE 
by applying a comprehensive neuropsychological test battery in combination with a thorough 
personality assessment and urine and hair testing. Nevertheless, our findings are subject to 
some limitations. First, the number of PCE users was relatively small. This is obviously a 
threat to the statistical power of the reported analysis but, at the same time, a further implicit 
result of the study. In fact, it was hard to find PCE users who used MPH regularly and 
reported no concurrent regular use of other illegal drugs or no ADHD diagnosis. Second, the 
fact that the data were restricted to PCE users, who used MPH without regular co-use of 
illegal drugs of abuse, is a further limitation as it was shown previously that PCE users show a 
higher prevalence of illegal drug use compared to non-users (Maier et al., 2013; Rabiner et al., 
2009a). Therefore, the question arises, whether we tested only a very unique group within the 
already very specific group of PCE users. Nevertheless, the exclusion of PCE users with 
regular illegal drug use was inevitable in order to explain differences between PCE users and 
controls exclusively by the MPH use. Moreover, previous research revealed that PCE occurs 
most likely during short periods of exam preparation and daily or high dose use of PCE is rare 
(Maier et al., 2013), thus, through our inclusion criteria, we likely skimmed only the most 
intense PCE users. Third, we used a cross-sectional design but a longitudinal design would 
have been most appropriate to investigate cause-effect relationships between PCE drug use 
and changes in cognition and personality. 
In conclusion, our findings indicate that the regular nonmedical MPH use for PCE over 
more than two years was not associated with cognitive deficits. PCE users performed equally 
to controls, or even better in tasks requiring strategic thinking, which disproves the 
assumption that PCE is a compensation for cognitive deficits (Franke et al., 2011; McCabe et 
al., 2005; Rabiner et al., 2009a). As the personality profile of PCE users shared some features 
with recreational illegal stimulant users, such as higher novelty seeking and impulsivity, we 
propose instead that PCE users may aim to improve their impulse control in order to optimize 
their own learning compliance. PCE users were also found to be less prosocial, less emphatic, 
and more Machiavellianism, which is in line with their enhanced strategic thinking and 
planning behavior. Thus, PCE users may instrumentalize MPH as little helpers (Sahakian & 
  91 Personality & Cognition 
Morein-Zamir, 2007), in order to maximize their own benefits. Finally, the overall personality 
profile of PCE users is highly specific disproving the often made assumption that PCE will 
widely spread in society. 
4.5.1 Research in context: systematic review 
We conducted a systematic literature review considering findings on stimulant use for 
cognitive enhancement. We searched the electronic databases Medline, the Cochrane Library, 
PubMed, Scopus, PsychINFO, and article reference lists since 1990. We found studies and 
essays on the bioethical debate and the efficacy of cognitive enhancers in healthy as well as 
studies on the effects of acute stimulant administration on social cognition but no studies 
referred to the cognitive, social, and personality characteristics of chronic stimulant use for 
cognitive enhancement in healthy individuals.  
4.5.2 Research in context: interpretation 
The empirical findings in this study provide a new understanding of cognitive and social 
characteristics of healthy individuals who use methylphenidate for pharmacological cognitive 
enhancement. Consistent with previous research, our study indicates that a specific 
personality profile makes stimulant use for cognitive enhancement more likely to occur. 
Contrary to previous assumptions, we found no cognitive deficits in healthy individuals 
engaged in pharmacological enhancement but differences in cognitive empathy, prosocial 
behavior, and socially-relevant personality traits. According to our study, the nonmedical 
stimulant use for cognitive enhancement is rather performed by strategic long-term planning, 
self-serving, low prosocial, and impulsive individuals who use drugs as instruments and “little 
helpers” to achieve their aims. Because of this specific personality profile, the assumption that 
pharmacological cognitive enhancement will become epidemic is not supported by our data.  
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4.6 Supplementary material 
Methods S1 Urine testing. Concentration of methylphenidate for the calibration ranged 
from 2 ng/mL to 1000 ng/mL and concentrations were equally distributed over the 
concentration range in four calibration solutions. Authentic urine samples were analyzed after 
protein precipitation (PP). Briefly, 300 μL of urine was mixed with 30 μL of the internal 
standard mixture containing methylphenidate d9 at 100 ng/mL and 30 μL of the calibration 
solution. Afterwards it was shaken for 5 min at 1400 rpm. Then, 900 μL of ice cold 
acetonitrile was added, and the mixture was shaken for 10 minutes at 1400 rpm and 
centrifuged for 10 min at 12000 rpm. An aliquot of 600 μL was transferred and evaporated to 
dryness under a gentle stream of nitrogen at 40°C. The residue was dissolved in 50 μL of a 
mixture of eluent A (25 mM NH4+ acetate + 0·1% acetic acid in H2O) and eluent B (0·1% 
acetic acid in acetonitrile). Aliquots of 10 μL of this solution were analysed by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). The acquisition method was 
Sequential Window Acquisition of all Theoretical Ion Spectra (SWATH). Quantification of 
ritalinic acid was done using methylphenidate calibration. For the detection of illegal drug 
use, the following cut-offs (Administration Substance Abuse and Mental Health Services, 
2008) have been applied: Cannabis, 50 ng/ml; cocaine, 150 ng/mg; and amphetamines, 500 
ng/ml. Opioids, benzodiazepines, and barbiturates were not detected in our urine samples. 
 
Methods S2 Hair testing. To characterize drug use over the last six months objectively, 
hair samples were collected and analyzed with LC-MS/MS. If participants’ hair was long 
enough, one sample of six cm hair (from the scalp) was taken and subsequently divided into 
two subsamples of three cm length. The following compounds were assessed: cocaine, 
benzoylecgonine, ethylcocaine, norcocaine, amphetamine, methamphetamine, MDMA, 
MDEA, MDA, morphine, codeine, methadone EDDP (primary methadone metabolite), 
tramadol, and methylphenidate. For our routine protocol for drugs of abuse analysis a three 
step washing procedure with water (2 minutes shaking, 15ml), acetone (2min., 10ml) and 
finally hexane (2min., 10ml) of hair was performed. Then the hair samples were dried at 
ambient temperatures, cut into small snippets and extracted in two steps, first with methanol 
(5ml, 16hours, ultrasonication) and a second step with 3 ml MeOH acidified with 50 µL 
hydrochloric acid 33 % (3 hours, ultrasonication). The extracts were dried and the residue 
reconstituted with 50 µL MeOH and 500 µL 0.2 mM ammonium formate (analytical grade) in 
water. As internal standards deuterated standards of the following compounds were used, 
added as mixture of the following compounds: cocaine-d3, benzoylecgonine-d3, ethylcocaine-
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d3, morphine-d3, MAM-d3, codeine-d3, dihydrocodeine-d3, amphetamine-d6, 
methamphetamine-d9, MDMA-d5. MDEA-d6, MDA-d5, methadone-d9, EDDPd3, 
methylphenidate-d9, tramadol-d3, oxycodone-d3, and ephedrine-d3. All deuterated standards 
were from ReseaChem (Burgdorf, Switzerland), the solvents for washing and extraction were 
of analysis grade and obtained from Merck (Darmstadt, Germany); LC-solvents were of 
HPLC grade and were obtained from Sigma Aldrich (Buchs, Switzerland). The LC-MS/MS 
apparatus was an ABSciex QTrap 3200 (Analyst software Version 1·5, Turbo V ion source 
operated in the ESI mode, gas 1, nitrogen (50 psi); gas 2, nitrogen (60 psi); ion spray voltage, 
3500V; ion source temperature, 450°C; curtain gas, nitrogen (20 psi) collision gas, medium), 
with a Shimadzu Prominence LC-system (Shimadzu CBM 20 A controller, two Shimadzu LC 
20 AD pumps including a degasser, a Shimadzu SIL 20 AC autosampler and a Shimadzu 
CTO 20 AC column oven, Shimadzu, Duisburg, Germany). Gradient elution was 3 performed 
on a separation column (Synergi 4µ POLAR-RP 80A, 150x2·0 with a POLAR-RP 4x2·0 
Security Guard Cartridge, (Phenomenex, Aschaffenburg, Germany). The mobile phase 
consisted of 1mM ammonium formate buffer adjusted to pH 3,5 with formic acid (eluent A) 
and acetonitrile containing 1mM ammonium formate and 1 mM formic acid (eluent B). The 
Analysis was performed in MRM mode with two transitions per analyte and one transition for 
each deuterated internal standard, respectively. According to the Society of Hair Testing, the 
following cut-offs (“Recommendations for hair testing in forensic cases.,” 2004) have been 
applied: cocaine, 500 pg/mg; amphetamine, 200 pg/mg; and MDMA, 200 pg/mg. Opioids and 
other illegal drugs tested above were not detected in our hair samples. 
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Methods S3 Construction of the four cognitive domain scores. 
Attention To assess attention, we primarily focused on sustained attention by including the 
two RVP parameters discrimination performance A’ and total of hits (Jones, Sahakian, Levy, 
Warburton, & Gray, 1992). In order to diversify this domain, we further added the RAVLT 
parameter trial 1, a supraspan measure with a strong attentional component (Lezak, 
Howieson, Loring, Hannay, & Fischer, 2004). 
Working memory The SWM parameter total errors tested the capability to retain spatial 
information and to manipulate remembered items in the working memory (R. G. Morris et al., 
1988). The LNST score measured verbal working memory by summing up the number of 
correct responses (Crowe, 2000). The PAL first trial memory score measured visual working 
memory by counting the number of correctly located patterns after the first presentation 
(Sahakian et al., 1988). 
Declarative memory Three RAVLT parameters were included to assess the verbal 
declarative memory performance: ∑trials 1-5, delayed recall trial 7, and adjusted recognition 
performance p(A). Furthermore, the two PAL parameters (adjusted total of errors and 
adjusted total of trials) were used to capture visual declarative memory (Sahakian et al., 
1988). 
Executive functions First, the SWM strategy score assessed the applied heuristic 
strategies, (R. G. Morris et al., 1988) a typical feature of the executive functions. Second, the 
RAVLT recall consistency score is a parameter typically impaired in patients with prefrontal 
lesions (Benedict et al., 2005; Jokeit et al., 1997), and related with measures of executive 
functions.(Beebe, Ris, & Dietrich, 2000) Third, the IED was used to assess visual 
discrimination, attentional set formation, maintenance, shifting, and flexibility (Downes et al., 
1989). The considered test parameters were the total of errors and trials adjusted to the 
amount of completed stages. 
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Table S3. References to neuropsychological tasks, interviews, and questionnaires used 
Test abbreviation Test name Reference 
Drug use   
IPDC Interview for Psychotropic Drug Consumption Quednow et al. (2004) 
Cognition 
MWT-B Mehrfach-Wortwahl-Intelligenztest Lehrl (1989) 
CANTAB Cambridge Neuropsychological Test Automated Battery Strauss, Sherman, & Spreen (2006) 
RVP Rapid Visual Processing Jones et al. (1992) 
PAL Paired Associates Learning Sahakian et al. (1988) 
SWM Spatial Working Memory Morris et al. (1988) 
IED Intra-Extra-Dimensional Set Shifting Downes et al. (1989) 
LNST Letter Number Sequencing Task Wechsler (1997) 
RAVLT Rey Auditory Verbal Learning Test Rey (1964); Helmstaedter, Lendt, & Lux (2001) 
IGT Iowa Gambling Task Bechara, Dolan, & Hindes (2002) 
Social cognition, interaction, and function 
MET Multifaceted Empathy Test Dziobek et al. (2008) 
MASC Movie for the Assessment of Social Cognition Dziobek et al. (2006) 
SNQ Social Network Questionnaire Linden, Lischka, Popien, & Golombek (2007) 
Distribution Game Distribution Game Engelmann & Strobel (2004) 
Dictator Game Dictator Game Charness & Rabin (2002) 
Personality and psychiatric symptoms 
ADHS-SR ADHD Self-Rating scale Rösler et al. (2004) 
SCID-I Structured Clinical Interview for DSM-IV Axis I Wittchen, Wunderlich, Gruschwitz, & Zaudig (1997a) 
SCID-II Structured Clinical Interview for DSM-IV Axis II Wittchen, Wunderlich, Gruschwitz, & Zaudig (1997b) 
BDI Beck Depression Inventory Beck, Steer, & Carbin (1988) 
BIS-11 Barratt Impulsiveness Scale Patton, Stanford, & Barratt (1995) 
TCI Temperament Character Inventory Cloninger, Przybeck, Svrakic, & Wetzel (1994) Berth, Cloninger, Przybeck, Svrakic, & Wetzel (2001) 
MACH-IV Machiavellianism Test Christie & Geis (1970) 
DD Delay Discounting Task Kirby & Petry (2004) 
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Table S4. Global cognitive index (GCI), the four cognitive domain z-scores, and neuropsychological test scores 
of stimulant-naïve healthy controls and individuals using methylphenidate for the purpose of pharmacological 
cognitive enhancement (PCE) 
 Controls (n·= 39) 
PCE users 
(n·=25) t-test df p-value Cohen’s d 
Global Cognitive Index (GCI) 0 (0·5) 0·1 (0·6) 0·564 62 0·456 0·19 
Neurocognitive domain scores       
Attention 0 (0·8) 0·2 (0·8) 0·931 62 0·338 0·25 
Working memory 0 (0·7) -0·04 (0·7) 0·039 62 0·844 0·05 
Declarative memory 0 (0·8) -0·01 (0·9) 0·004 62 0·953 0·02 
Executive functions 0 (0·7) 0·3 (0·5) 3·090 62 0·084 0·44 
Neuropsychological test scores       
Attention       
RVP Discrimination performance A' 0·9 (0·04) 0·9 (0·04) -0·484 62 0·630 0·12 
RVP Total hits 19·2 (4·5) 19·7 (3·9) -0·469 62 0·641 0·12 
RAVLT Supraspan trial 1 9·9 (2·1) 10·7 (2·5) -1·347 62 0·183 0·34 
Working memory       
LNST Score 16·9 (2·7) 16·4(3·1) 0·631 62 0·530 0·16 
SWM Total errors 18·0 (16·6) 12·4 (13·1) 1·402 62 0·166 0·36 
PAL First trial memory score 16·7 (3·4) 15·8 (3·7) 1·017 62 0·313 0·26 
Declarative memory       
RAVLT Learning performance (∑ trials 1-5) 65·2 (5·1) 65·8 (7·1) -0·371 62 0·712 0·10 
RAVLT Adjusted recognition performance p(A) 0·9 (0·1) 0·9 (0·1) 0·499 62 0·619 0·13 
RAVLT Delayed recall trial 7 13·8 (1·6) 14·0 (1·4) -0·704 62 0·484 0·18 
PAL Total errors adjusted 7·8 (9·6) 9·3 (9·2) -0·641 62 0·524 0·16 
PAL Total trials adjusted 7·9 (2·7) 8·0 (2·7) -0·187 62 0·852 0·05 
Executive functions       
IED Total errors adjusted 30·0 (38·4) 19·4 (17·9) 1·278 62 0·206 0·33 
IED Total trials adjusted 104·0 (68·7) 86·4 (32·1) 1·196 62 0·236 0·31 
SWM Strategy score 31·5 (5·9) 28·1 (5·2) 2·363 62 0·021 0·58 
RAVLT Recall consistency in % 94·3 (5·0) 94·4 (5·6) -0·068 62 0·946 0·02 
Data are means and standard deviations. Significant p-values are shown in bold. IED: Intra-Extra 
Dimensional Set-Shifting, LNST: Letter Number Sequencing Task, PAL: Paired Associates Learning, PCE: 
pharmacological cognitive enhancement, RAVLT: Rey Auditory Verbal Learning Test, RVP: Rapid Visual 
Information Processing, SWM: Spatial Working Memory. 
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Table S5. Pearson’s product-moment correlations between test outcomes and clinical measures of social functioning with significant group differences between stimulant-naïve 
healthy controls (n = 39) and pharmacological cognitive enhancement users (n = 25) 
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SWM strategy score, 
high performance = 
low score        
0·33**          
Iowa Gambling Task 
sum score        -0·34**          
Iowa Gambling Task 
time    -0·49***  -0·41***   -0·33**   -0·39*** -0·32**     
Machiavellianism 0·39** -0·43*** -0·39** 0·46***  
TCI novelty seeking 
(NS) sum score      0·73***      0·62***      
TCI NS4 
Disorderliness          0·46***  0·52***      
TCI reward 
dependence (RD) 
sum score        
0·70*** -0·34**         
TCI RD1 
sentimentality                  
SCID II negativistic  0·40*** 0·38** 
SCID II antisocial  
ADHD-SR sum score 0·39***  0·56*** 0·73*** 0·63*** 
BIS-11 sum score  0·65*** 0·64*** 
BIS-11 attentional 
impulsiveness              0·90***    
BIS-11 attention  
Dictator game, 
payoff B                  
Significant partial correlations with a p-level below 1% are shown and marked as: **p < 0·010, ***p < 0·001. ADHD-SR: ADHD Self-Rating Scale, BIS: Barratt 
Impulsiveness Scale, MET: Multifaceted Empathy Test, NS: Novelty Seeking, PCE: pharmacological cognitive enhancement, RD: Reward Dependence, SCID I/II: 
Structural Clinical Interview for DSM-IV Axis I/II Disorders, SNQ: Social Network Questionnaire, SWM: Spatial Working Memory, TCI: Temperament and Character 
Inventory. 
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Figure S1. Means and standard errors for quartiles (Q1-Q4) and the net score (good minus bad cards) in the Iowa 
Gambling Task (IGT); *p < 0·050. 
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5   General Discussion 
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5.1 Overview of the general discussion 
The aim of the present thesis was to determine the prevalence of pharmacological 
neuroenhancement in Switzerland, considering different motives for use, and to identify 
predictors and correlates of pharmacological neuroenhancement. The nonmedical use of 
prescription drugs and the use of alcohol and illegal drugs for the purpose of cognitive and 
mood enhancement to perform better at work and in education are associated with several 
risks for physical and mental health. Therefore, this thesis aimed to address various ethical, 
social, and legal questions related to pharmacological neuroenhancement to make a 
noteworthy contribution to the current neuroenhancement debate. Additionally, the cognitive, 
social, and personality characteristics of individuals with regular methylphenidate use for 
cognitive enhancement were compared to stimulant-naïve controls. Accordingly, directions of 
further development of pharmacological neuroenhancement in Switzerland were investigated. 
This final chapter aims to summarize the main findings, strengths, and limitations of the three 
studies conducted in the present thesis. Because of the findings’ relevance for public health 
issues, important implications for policy, prevention and future research will be discussed. 
5.2 Prevalence of and motives for pharmacological neuroenhancement 
By using the largest Swiss Internet panel and weighting procedures, the lifetime 
prevalence of pharmacological neuroenhancement among Swiss employees and students 
could be determined to be 4.0%, and the 12-month prevalence was found to be 2.1%. 
Pharmacological mood enhancement was more prevalent than cognitive enhancement or both. 
Having been diagnosed with a mental disorder, perceived poor health, stress, and illegal drug 
use were the strongest predictors of pharmacological neuroenhancement. The nonmedical use 
of tranquilizers and antidepressants to improve mood and relaxation in order to cope with 
stress at work or in education was more prevalent than the nonmedical use of ADHD 
medications or other prescription drugs for direct cognitive enhancement. Most individuals 
using tranquilizers and antidepressants were satisfied with the drug’s effect while only a small 
minority of stimulant users reported that their expectations had been fulfilled. However, the 
majority of respondents considered the use of prescription drugs and illegal drugs for 
neuroenhancement as not justifiable, risky, and potentially harmful. Only a small number of 
the respondents would be willing to use available hypothetically effective neuroenhancement 
drugs, however, students showed a greater interest in testing such drugs. Illegal drugs were 
rather used for recreational purposes than for cognitive enhancement at work or in education. 
  101 General Discussion 
Nevertheless, the use of alcohol and cannabis to reduce stress associated with work or 
education was prevalent. If this stress coping strategy is functional to improve performance at 
work or while studying the next day, this use might be classified as neuroenhancement (Maier 
& Schaub, 2015; Wolff et al., 2014).  
In our previous study on pharmacological neuroenhancement among Swiss students, we 
found that every seventh student had already used prescription drugs, illegal drugs, or alcohol 
at least once explicitly to enhance cognitive performance while studying (Maier et al., 2013). 
Consistent with studies among U.S. and European college students, methylphenidate was the 
prescription drug most frequently misused for pharmacological cognitive enhancement. 
Nevertheless, alcohol was the substance most often used for enhanced studying performance 
among Swiss students. For many, it may seem implausible that alcohol, a substance with 
sedating effects, is used to improve cognitive function as a study aid. However, while alcohol 
in large doses is rather known to impair memory and cognitive function, low doses have been 
found to reduce stress-induced impairment of spatial working memory (Gomez, Lewis, & 
Luine, 2012) and might, therefore, enhance concentration while studying. Moreover, alcohol 
might be used as a motivational aid to overcome procrastination and start with adverse 
perceived tasks. 
One might claim that the Bologna reform is the reason for the high pressure and large 
amount of work at universities, and that one cannot cope without using prescription and 
recreational drugs. Even if the harmonization process of higher educational systems in Europe 
(Bologna Process; Cumming, 2010) brings new challenges and appears rigorous from the 
outside, the way to complete a degree has remained similar. What has changed, in particular, 
is the social expectation in other areas of life. Students do not longer want to spend their 
whole time in libraries, but they also want to have a satisfied social life (Hildt et al., 2014). In 
addition, the development of media and the Internet has enabled novel ways of learning and 
novel options for research. Given the abundance of information and irrelevant distraction, 
students need to learn to focus on the essential. This uncertainty regarding the required 
knowledge in combination with high time pressure might create a certain helplessness, which 
some students might try to counteract by using neuroenhancement. Creating a realistic 
timetable that considers all examination contents and breaks in between (Dunlosky, Rawson, 
Marsh, Nathan, & Willingham, 2013), would probably be more effective than using 
pharmacological neuroenhancement during exam preparation. 
Consistent with previous studies, a positive relationship between recreational drug use and 
the misuse of prescription drugs or illegal drugs for the purpose of neuroenhancement was 
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found (McCabe et al., 2005; Weyandt et al., 2009). Individuals who used psychoactive 
substances to achieve better cognitive performance reported more experience with illegal drug 
use than non-users. This finding was also strengthened by the third study of the present thesis 
which found that individuals with regular methylphenidate use for cognitive enhancement 
were likely to be also occasional recreational drug users. To date, there is a lack of studies 
regarding the direction of the relationship between neuroenhancement and the use of illegal 
drugs of abuse for recreational purposes. Recreational drug users may be more likely to 
misuse prescription drugs because they are less afraid of potential side effects of 
neuroenhancement, since they have experience with side effects of recreational drugs. This 
hypothesis might be tested in further prospective studies together with a detailed assessment 
of recurring periods of use and duration of specific substances used for both pharmacological 
neuroenhancement and recreational use. Since pharmacological neuroenhancement was found 
to be most prevalent among students, it is of great interest whether the duration of use is 
limited to student life or whether a transition to working life is likely.  
5.3 Predictors of pharmacological neuroenhancement 
The second study tested two explanatory models of pharmacological neuroenhancement 
and found that the serious self-medication model explained far more variance than the 
moderate self-medication model including stress and self-efficacy. The current medical 
treatment for a mental disorder was the best predictor of pharmacological neuroenhancement 
and it was assumed that patients self-medicate beyond their actual prescription in order to 
perform better at work or while studying. The additional use of prescription and illegal drugs 
to enhance cognitive performance or mood might aim to increase the effect of prescribed 
medication, to treat additional symptoms of mental disorders, or to reduce the side effects of 
indicated medication (Kasten, 1999). When stress and self-efficacy were added to the serious 
self-medication model, only a little more variance was explained in the overall model. This 
finding shows the close relationship between stress, self-efficacy, and mental disorders, 
indicating that most of the stress, which has potentially led to the decision to use 
pharmacological neuroenhancement, might be explained by the current mental disorder and 
associated symptoms. The majority of past-year pharmacological mood enhancement users 
reported having a depression and half of them used prescription drugs to reduce depressive 
symptoms. Drugs indicated to treat mental disorders were rarely misused. However, other 
illicit substance use was common, especially among pharmacological cognitive enhancement 
users. In contrast to former studies that named mostly stress as the result of high workloads 
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and overwhelming demands as cause for neuroenhancement (Wolff & Brand, 2013), we 
examined further predictors. Hence we could show that more complex systems underlie 
pharmacological neuroenhancement and that the prediction of neuroenhancement was best 
modeled when using a model of serious self-medication. 
5.4 Pharmacological cognitive enhancement is a question of personality 
In the third study, we found recently abstinent pharmacological cognitive enhancement 
users and stimulant-naïve controls to perform equally well in most of the cognitive tasks. In 
addition, cognitive enhancement users performed better in strategic thinking and decision-
making. This finding was in contrast to previous research findings which suggested that 
pharmacological cognitive enhancement aims to compensate deficits such as low grade point 
average (Franke et al., 2011; McCabe et al., 2005; Rabiner et al., 2009a). We also found a 
very specific personality profile of individuals with regular methylphenidate use for cognitive 
enhancement. Previous research has suggested that healthy cognitive enhancement users 
might be more ambitious and narcissistic than non-users (Quednow, 2010). Cognitive 
enhancement users were found to show the dark triad of personality traits (Rauthmann & 
Kolar, 2012). They exhibit more antisocial and negativistic personality traits, more 
Machiavellianism and an overlap with narcissism although no significant group differences 
for narcissism could be found. However, these traits have all beneficial and detrimental 
trajectories (Rauthmann & Kolar, 2012). Strategic planning and self-serving and less 
prosocial behavior might be beneficial and sometimes required to succeed in academia. Thus, 
cognitive enhancement might be perceived as a functional means to achieve good grades or 
good positions for healthy individuals (Wolff et al., 2014). Despite recent concerns about 
individualization and a rather narcissistic development in the Western society, no evidence for 
changes in narcissism and self-enhancement were found when comparing students between 
1980 to 2007 (Trzesniewski, Donnellan, & Robins, 2008). This relatively stable proportion of 
narcissism among students over the years would further dispute the assumption that 
neuroenhancement will spread in the near future.  
5.5 Strengths 
The three studies presented in this thesis were unique in their composition and have 
several strengths worth mentioning. Generally, the studies and their findings would not have 
achieved the same quality without the continuous review of the rapidly growing literature on 
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pharmacological neuroenhancement during the time of the thesis. Therefore, the literature 
body and the careful reflection of its contents is an important strength of this thesis.  
The two initial original research articles of this thesis are based on data from one of the 
largest studies of pharmacological neuroenhancement, and applied weighting procedures used 
ensured that the results were representative of the Swiss population. No other study in Europe 
included a representative sample of the general population in their survey to create a national-
level estimate of the prevalence of pharmacological neuroenhancement. Instead, previous 
studies focused on specific groups, such as college students, therefore reporting high 
prevalence rates of stimulant use for cognitive enhancement based on non-representative 
survey data. A further strength of the study is that participants with current and past diagnosis 
of a mental disorder were included in the study, whereas many previous studies only focused 
on healthy individuals (Barrett et al., 2008).  
Addressing the important mechanism of self-medication in both healthy and 
disadvantaged neuroenhancement users in the second study was unique and progressive. 
Every substance use following a certain intention to improve a desirable mental or physical 
state, without being advised by a doctor, is considered self-medication. Pharmacological 
neuroenhancement, as self-medication, is a functional means to change a current state which 
is perceived as unpleasant or insufficient (Wolff et al., 2014). Another important strength of 
the second study was the discussion of the national data with regard to the non-existent cut-off 
point on the continuum between health and disease (Laungani, 2007). Specifically designed 
legal provisions to treat pharmacological neuroenhancement are unreasonable given the 
absence of this clear cut-off point. Prevention of pharmacological neuroenhancement has to 
start with the question “why” (Wolff et al., 2014) instead of the prohibiting “no”. 
The third study presented in the present thesis was the first that broadly characterized 
individuals regularly using methylphenidate for cognitive enhancement by applying an 
extensive neuropsychological test battery. Previous studies addressed single personality traits 
and demographic characteristics of cognitive enhancement users without differentiating 
between those who used pharmacological cognitive enhancement on trial and those who used 
psychoactive substances repeatedly as study aid. The comparison with stimulant-naïve 
controls and, in a broader sense, also the comparison of personality features with recreational 
stimulant users, was progressive and may enlighten the neuroenhancement debate. 
A further important strength was the urine and hair testing to verify self-report data on 
psychoactive substance use and to ensure that cognitive task outcomes were unbiased by 
substance use.  
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5.6 Limitations 
A number of limitations need to be considered. The first and main limitation of the studies 
presented in this thesis is their cross-sectional design. Therefore, no causal relations can be 
drawn from the results and only associations could be established. Nevertheless, the use of 
theoretical models provides evidence about plausible relationships which could be 
investigated in further studies. The personality characteristics used to differentiate between 
pharmacological cognitive enhancement users and stimulant-naïve controls have been shown 
to be antecedent causes of individual differences in psychopathology and personality 
disorders. These limitations warrant further work on pharmacological cognitive and mood 
enhancement in longitudinal studies. 
A second limitation of the conducted study is the use of the LINK Internet panel to 
estimate the prevalence of neuroenhancement in Switzerland because this leads to a double 
self-selection bias. The first bias might have occurred during the computer-assisted telephone 
recruitment interviews for the Internet panel. Even if this panel is representative for the Swiss 
population, not every individual will be equally willing to participate in public opinion 
surveys. Therefore, the prevalence of neuroenhancement in Switzerland might be 
underestimated if employees and students experiencing high stress would deny participation, 
as this is a predictor of pharmacological neuroenhancement. The second self-selection bias 
might have occurred as a consequence of the survey topic since we invited the panelists to 
participate in a survey about stress and stress management strategies at work and in education. 
Although it was a topic appealing to anyone who met the inclusion criteria (employed or 
being a student), it is possible that those affected by stress and associated problems were more 
likely to talk about stress and coping strategies. Contrarily, those with high stress might not 
have had time to respond to this large-scale survey. However, the frequency of stress in the 
past 12 months was slightly higher than in the stress study among Swiss employees, so this 
might confirm the continuously increase of perceived stress among Swiss employees over the 
years (Grebner et al., 2010).  
Thirdly, the current research was limited by the use of self-reported data, which might be 
subject to perceptual bias and socially desired responses. However, we addressed this issue in 
all studies to minimize its influence as far as possible and informed potential respondents that 
participation was voluntary and all survey procedures provided full anonymity. Moreover, 
web-based self-administered questionnaires lead to higher reporting rates of substance use 
(Wang et al., 2005) and the use of a national Internet panel to assess the prevalence of 
nonmedical drug use has shown to be a good strategy (Novak et al., 2007). We controlled for 
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random answering behavior by presenting two fictitious medications and only a negligible 
small number of participants reported the use of those drugs. Confidence in our findings is 
supported by the low prevalence of self-reported pharmacological neuroenhancement and the 
reasonable prevalence for alcohol, nicotine, and illegal drug use which are comparable to the 
prevalence rates reported by the Swiss Addiction Monitoring (Gmel et al., 2013). Especially 
students showed a considerably openness to report nonmedical prescription drug and illegal 
drug use in Internet surveys and misreporting seemed to be unlikely (Maier et al., 2013; Ott & 
Biller-Andorno, 2014). However, the self-reported drug use of healthy cognitive enhancement 
users and stimulant-naïve controls in the third study were verified by urine and hair testing 
which was an important strength. The potential perceptual bias when answering the 
personality questionnaires (Cloninger & Zohar, 2011) was equal for cognitive enhancement 
users and not problematic in previous studies among cocaine users (Preller, Herdener, et al., 
2014; Vonmoos, Hulka, Preller, Jenni, Schulz, et al., 2013) 
A further limitation was the small sample size in the third study that compared only 25 
healthy individuals with regular methylphenidate use for cognitive enhancement with 39 
stimulant-naïve controls. Despite the possibility of contacting individuals who reported 
cognitive enhancement in previous studies (Maier et al., 2013; Maier & Schaub, 2014) and 
additional advertisement it was exceptionally difficult to find regular nonmedical 
methylphenidate users without both ADHD diagnosis and concurrent illegal drug use. The 
personal interviews with potential study participants revealed that most of them had used 
methylphenidate only on an experimental basis or sporadically. In combination with the low 
prevalence of pharmacological cognitive enhancement in the general population survey and 
the finding that pharmacological cognitive enhancement among students is often limited to 
exam preparation (Maier et al., 2013), it can be concluded that the group of healthy cognitive 
enhancement users is only a very small one. The recruitment of healthy individuals with 
regular methylphenidate use for cognitive enhancement took more than one year and, 
therefore, did not conflict or generally overlap with academic exam periods. 
5.7 Implications 
5.7.1 Implications for policy and prevention 
Taken together, the findings of the present thesis do not support the often raised 
assumption that neuroenhancement might spread in the near future (Greely et al., 2008). 
Several prescription drugs are potentially effective to enhance cognition in healthy individuals 
but their effectiveness cannot be generalized. The same drug can have different effects in 
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different individuals as well as different outcomes on performance within the same individual, 
depending on dose, task, brain plasticity, current physical and mental condition, and 
personality (de Jongh et al., 2008; Wood et al., 2014). This list of factors that may influence 
the effectiveness of a drug off beyond its actual mechanism of action is not conclusive and 
shows the complexity of the debate.  
Occupational health has to consider new challenges in the near future irrespective of 
whether or not pharmacological neuroenhancement will spread. Therefore, prevention of 
tobacco, alcohol, and illegal drug use at work has to be extended to include prescription drug 
misuse. Especially big companies with high competitive pressure should be vigilant 
concerning employee’s psychoactive substance use to enhance performance at work. 
Furthermore, illicit substance use prevention for pharmacological neuroenhancement should 
directly or indirectly be fostered even though this behavior might maximize the economic 
benefit of a company in the short-term. Mohamed (2014) claimed that increased economic 
benefit, however, is not equal to greater well-being and happiness for society. Thus, the 
dialogue between management and employees to account for employee’s well-being is 
strongly recommended.  
An open dialogue might also help those individuals with current medical treatment for a 
mental disorder to reflect their additional self-medication and to become aware of associated 
risks (Ruiz, 2010). Pharmacological neuroenhancement as serious self-medication to cope 
with symptoms of a mental disorder and associated stress was identified as an important 
public health issue that has, to date, achieved minor attention. The assumption that cognitive 
enhancement among healthy individuals will widely spread and become a desirable means to 
improve work and study performance in the general public was not supported by the present 
findings. 
Prevention of pharmacological neuroenhancement is probably more difficult to address at 
universities. Students know exactly which tests they have to pass and which diplomas they 
would like to achieve in a specific time. Due to the limited time as a student, which is only a 
transit to “real” employment life, it is easy to self-legitimate the use of pharmacological 
neuroenhancement only for one or more exam periods. The findings in the present thesis 
confirm that students are more willing to use prescription drugs or illegal drugs to improve 
their academic performance compared to employees. This might be a generation effect that 
will disappear in the future because similar to the normalization of recreational drug use 
(Sznitman et al., 2013), it might indeed become normal for a certain group of students to test 
pharmacological neuroenhancement during their studies. If policy considered regulations to 
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prevent pharmacological neuroenhancement by healthy individuals, a case-by-case regulation 
of drugs which are off-label-used for enhancement purposes is recommended (Dubljević, 
2013). Even different regulations of the same substance based on different release forms 
(instant vs. extended) might be considered (Dubljević, 2013). Moreover, regulations should 
aim at minimizing the risks and harms of pharmacological neuroenhancement while 
maximizing the benefits (Ragan et al., 2013). Recently, the Swiss Federal Council has 
announced that there is no need for additional regulations among ADHD medications because 
the misuse of these drugs in Switzerland is rather low (Eckhardt, 2014).  
As long as no prescription drug is developed specifically for neuroenhancement, 
neuroenhancement with prescription drugs will remain an off-label use. Physician’s are not 
obliged to respond on neuroenhancement requests but they are allowed to prescribe adult 
patients drugs for neuroenhancement following guidelines of off-label drug prescription 
(Larriviere, Williams, Rizzo, & Bonnie, 2009). Swiss practitioners show a considerable 
openness regarding the prescription for medication for neuroenhancement as long as the level 
of an individual’s suffering was perceived as high and no therapeutic alternatives were 
available (Ott et al., 2012). Practitioners are not familiar with the term neuroenhancement but 
they are generally willing to improve the well-being of their patients in the absence of disease 
as well to improve their quality of life (Ott et al., 2012; Ragan et al., 2013). Moreover, our 
findings revealed that physicians were the most common source of supply for drugs used for 
pharmacological mood enhancement. Thus, it is hypothesized that prescriptions for 
pharmacological mood enhancement are already common practice in Switzerland while more 
concerns are raised at pharmacological cognitive enhancement. 
However, there are many non-pharmacological means for cognitive enhancement which 
have received relatively little attention in the neuroenhancement debate such as sleep, 
nutrition, cognitive training, or physical exercise, all of which should be promoted more 
strongly (Dresler et al., 2013; Maier & Schaub, 2015). It is important to address the question 
whether all available non-pharmacological alternatives have been fully utilized, especially for 
scenarios in which pharmacological neuroenhancement might seem to be the best solution 
(Russo, 2007).  
Finally, moderate and serious self-medication and associated mental health issues first 
have to be acknowledged as worthy of dealing with by policy and practitioners. A campaign 
to objectively inform the public about prescription drug use, associated indications, and 
misuse potential, as suggested by Eckhardt (2014), seems to be a good preventive instrument. 
Objective information about potentials and risks and the diminishment of public fear and 
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stigma regarding prescription drugs and disorders will be an important step to take. Moreover, 
it is important to provide the public with essential evidence-based information about 
pharmacological neuroenhancement and the associated risks and safety concerns. We should 
not be afraid of informing about both, positive and negative implications of pharmacological 
neuroenhancement in healthy individuals. Consistent with other European studies, our 
findings indicate that the willingness to use prescription drugs or illegal drugs for 
neuroenhancement is rather low (Sattler et al., 2014).  
5.7.2 Implications for future research 
The findings of the three studies have important implications for future research and the 
understanding of pharmacological neuroenhancement in its different forms. Underlying 
motives for neuroenhancement substance use are not limited to cognitive enhancement only 
and warrant more detailed investigation due to their complexity. A reasonable approach to 
better understand consumption motives could be to investigate the causality of relationships in 
longitudinal studies. Therefore a welfarist approach (Earp et al., 2014) which focuses on an 
individual’s mental health that can, but not necessarily has to be associated with improved 
cognitive performance, is recommended. Nevertheless, communicating recent research 
findings is crucial to dispel popular myths regarding pharmacological neuroenhancement 
(Arria & DuPont, 2010). As our study findings indicate, there is only a very specific group 
that might benefit from pharmacological neuroenhancement, while the expectations of the 
drug’s effect are often not met. Hence, further studies should address the point prevalence of 
pharmacological neuroenhancement more strongly to avoid reporting a high lifetime 
prevalence that is likely to be based on several curious experimental users.  
Monitoring the development of pharmacological neuroenhancement in Switzerland is 
essential in order to develop effective policy responses. Nevertheless, future research should 
transfer from first-world problems with self-optimization of already good functioning to the 
preservation and recovery of health of vulnerable groups in the public. Moreover, while 
regular prescription drug misuse for cognitive and mood enhancement in Switzerland is rare, 
regular use of alcohol and cannabis to relieve stress or to improve academic performance is 
more common and affects physical and mental health. Future research on pharmacological 
neuroenhancement considering the complexity of psychoactive substance use for improved 
performance at work and in education is therefore recommended. Building on the present 
findings, future studies should not be limited to healthy individuals and use longitudinal 
designs. 
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